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EDOXABAN IN VENOUS THROMBOEMBOLISM
ASSOCIATED WITH CANCER
Investigator’s Signature:
I have fully discussed the objectives of this study and the contents of this protocol with 
the Sponsor’s representative.
I understand that information contained in or pertaining to this protocol is confidential 
and should not be disclosed, other than to those directly involved in the execution or the 
ethical review of the study, without written authorization from the Sponsor.  It is, 
however, permissible to provide information to a subject in order to obtain consent.
I agree to conduct this study according to this protocol and to comply with its 
requirements, subject to ethical and safety considerations and guidelines, and to conduct 
the study in accordance with the Declaration of Helsinki, International Conference on 
Harmonisation guidelines on Good Clinical Practice (ICH E6), and applicable regional 
regulatory requirements.
I agree to make available to Sponsor personnel, their representatives and relevant 
regulatory authorities, my subjects’ study records in order to verify the data that I have 
entered into the case report forms.  I am aware of my responsibilities as a Principal 
Investigator as provided by the Sponsor.
I understand that the Sponsor may decide to suspend or prematurely terminate the study
at any time for whatever reason; such a decision will be communicated to me in writing.  
Conversely, should I decide to withdraw from execution of the study, I will communicate 
my intention immediately in writing to the Sponsor.
Print Name Signature
Title Date (DD MMM YYYY)
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Study Title: A Phase 3b, prospective, randomized, open-label, blind 
evaluator (PROBE) study evaluating the efficacy and safety 
of (LMW) heparin/edoxaban versus dalteparin in venous 
thromboembolism associated with cancer
Short Title: Edoxaban in Venous Thromboembolism Associated with 
Cancer (Hokusai VTE Cancer)
Study Phase: Phase 3b trial
Indication Under 
Investigation:
Venous thromboembolism associated with cancer
Study Objectives: Primary Objectives: The primary objective is to 
demonstrate the non-inferiority of a 12-month course of 
low molecular weight heparin (LMWH)/edoxaban 
compared with dalteparin for the prevention of the 
combined outcome of recurrent venous thromboembolism 
(VTE) or major bleeding in subjects with VTE associated 
with cancer.  If non-inferiority is established, edoxaban will 
be compared with dalteparin for superiority.
Secondary Objectives: To compare LMWH/edoxaban with 
dalteparin with regards to rates of:
1. Recurrent VTE;
2. Major bleeding;
3. Clinically relevant non-major (CRNM) bleeding;
4. Major + CRNM bleeding;
5. Event-free survival, defined as the proportion of 
subjects over time free of recurrent VTE, major 
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bleeding events, and death;
6. VTE-related death;
7. Mortality from all causes;
8. Recurrent deep vein thrombosis (DVT);
9. Recurrent pulmonary embolism (PE);
10. Healthcare resource utilization for potential 
recurrent VTE and bleed events.
Exploratory Objectives: To compare LMWH/edoxaban 
with dalteparin with regards to:
1. Cardiovascular events (myocardial infarction [MI], 
stroke, systemic embolic events [SEE; see 
Appendix 17.5.1]);
2. Thrombotic events at other locations (see Appendix
17.5.2)
3. Reason for permanent early discontinuation of study 
drug.
Study Design: This is a multinational, prospective, randomized, open-
label, blind-evaluator (PROBE), non-inferiority study
comparing edoxaban with dalteparin for prevention of the 
combined outcome of recurrent VTE or major bleeding in 
patients with VTE associated with cancer. One thousand 
subjects (1000) will be equally randomized to 1 of the 2 
treatment groups.
After a subject’s eligibility is confirmed, the subject will be 
stratified by 1) bleeding risk, and 2) the need for dose 
adjustment, and then randomly assigned via interactive 
voice/web response system (IXRS) in a 1:1 ratio to 
treatment with either LMWH/edoxaban or dalteparin (see 
details in Section 3.1.2.
LMWH/Edoxaban group: Therapeutic doses of LMWH 
(subcutaneous [SC]) will be administered for at least 5 
days; this 5 day period may include the pre-randomization 
LMWH (if applicable). The choice of this parenteral 
LMWH is up to the treating physician. Thereafter, 
edoxaban will be started orally at 60 mg once daily [QD] (2 
× 30 mg tablets) (30 mg QD for subjects requiring dose 
adjustment) for the remainder of the treatment period.
Dalteparin group: After randomization, dalteparin will be 
administered at a dose of 200 IU/kg SC (maximum daily 
dose 18,000 IU) for 30 days.  The 30 day period may 
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include the pre-randomization anticoagulant treatment if 
dalteparin was used in therapeutic doses.  Thereafter 
(approximately Day 31 forward), dalteparin will be 
administered at a dose of 150 IU/kg SC (~ 75% - 83% of 
the initial dose) for the remainder of the treatment period.
The intended treatment duration and follow-up for all 
subjects is 12 months, except for the final subject(s) 
randomized to the study.  Once 1000 subjects are 
randomized, a global End-of-Treatment (EOT) date will be 
established that ensures a minimum of 6 months of study 
treatment and follow-up for the final subject(s) randomized.
All subjects will permanently discontinue study treatment 
on or before the EOT date.
After randomization subjects will be assessed at Month 1, 
Month 3, and quarterly thereafter for up to 12 months until 
they complete the study.
Subjects requiring additional anti-coagulation therapy who 
complete their treatment and full 12-month post 
randomization follow-up or whose treatment is truncated 
due to the global End of Treatment date will be managed 
according to local practice.
Guidance for switching from edoxaban to other 
anticoagulants is provided in Appendix 17.2.
Additional guidance for long-term management of cancer 
subjects with VTE is provided by Lyman, et al.
1
Study Duration: The expected study duration is approximately 30 months 
from the time the first subject is enrolled (planned for 
March 2015) to the time of the last subject’s last follow-up 
visit (expected September 2017).
Study Sites and Location: Approximately 130 study sites in North America, Europe, 
and Australia/New Zealand are planned to enroll subjects in 
this study.
Planned Sample Size: Assuming a hazard ratio of 1, a total of 191 overall primary 
events is projected to accrue in the modified intention-to-
treat (mITT) analysis set which will ensure at least 80% 
power for the primary analysis at a non- inferiority margin 
for the hazard ratio of 1.5 and a Type I error of 0.05 (two-
sided).
Assuming a primary combined outcome rate (recurrent 
VTE or major bleed) of 20.0%, a total of 1000 subjects are 
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expected to be randomized to study treatment in order to 
accrue 191 overall primary events in the mITT analysis.
Subject Eligibility Criteria: Adult male or female subjects who present with VTE
associated with cancer (other than basal-cell or squamous-
cell carcinoma of the skin) for whom long-term treatment 
with LMWH is indicated, are eligible to participate in this 
study.
Key eligibility criteria include:
Inclusion Criteria:
1. Male or female subjects with age ≥ 18 years or the 
otherwise legal lower age according to the country 
of residence;
2. Confirmed symptomatic or unsuspected lower 
extremity proximal DVT (ie, popliteal, femoral, 
iliac or inferior vena cava vein thrombosis), or 
confirmed symptomatic PE, or unsuspected PE of a 
segmental or larger pulmonary artery;
3. Cancer, other than basal-cell or squamous-cell 
carcinoma of the skin.  Cancer should be active (see 
Section 6.1) or diagnosed within 2 years prior to 
randomization.  The diagnosis/history of cancer 
must be objectively documented;
4. Intention for long-term treatment (at least 6 months) 
with parenteral LMWH;
5. Able to provide written informed consent.
Exclusion Criteria:
1. Thrombectomy, insertion of a caval filter, or use of 
a fibrinolytic agent to treat the current (index) 
episode of DVT and/or PE;
2. More than 72 hours pre-treatment with therapeutic 
dosages of anticoagulant treatment (LMWH, 
unfractionated heparin, and fondaparinux per local 
labeling), oral direct anticoagulants or vitamin K 
antagonist (VKA) prior to randomization to treat the 
current (index) episode;
3. Treatment with therapeutic doses of an 
anticoagulant other than that used for pre-treatment 
of the current (index) VTE episode prior to 
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4. Active bleeding or any contraindication for
treatment with LMWH/dalteparin or edoxaban;
5. Indication for dalteparin other than DVT and/or PE;
6. An Eastern Cooperative Oncology Group (ECOG) 
Performance Status of 3 or 4 at the time of 
randomization (see Appendix 17.6);
7. Calculated creatinine clearance (CrCL) < 30 
mL/min;
8. History of heparin associated thrombocytopenia;
9. Acute hepatitis, chronic active hepatitis, liver 
cirrhosis;
10. Hepatocellular injury with concurrent transaminase 
(alanine transaminase [ALT]/aspartate transaminase
[AST] > 3 x upper limit of normal [ULN]) and 
bilirubin (> 2 x ULN) elevations in the absence of 
a clinical explanation;
11. Life expectancy < 3 months;
12. Platelet count < 50,000/mL;
13. Uncontrolled hypertension as judged by the 
Investigator (eg, systolic blood pressure > 170 
mmHg or diastolic blood pressure > 100 mmHg 
despite antihypertensive treatment);
14. Women of childbearing potential without proper 
contraceptive measures, and women who are 
pregnant or breast feeding;
15. Chronic treatment with non-aspirin non-steroidal 
anti-inflammatory drugs (NSAIDs) including both 
cyclooxygenase-1 (COX-1) and cyclooxygenase-2 
(COX-2) inhibitors for ≥ 4 days/week anticipated to 
continue during the study;
16. Treatment with aspirin in a dosage of more than 100 
mg/per day or dual antiplatelet therapy (any 2
antiplatelet agents including aspirin plus any other 
oral or intravenous antiplatelet drug) anticipated to 
continue during the study;
17. Treatment with the P-gp inhibitors ritonavir, 
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nelfinavir, indinavir, or saquinavir anticipated to 
continue during the study;
18. Systemic use of the P-gp inhibitors ketoconazole, 
itraconazole, erythromycin, azithromycin or 
clarithromycin at the time of randomization; 
subsequent use is permitted;
19. Subjects with any condition that as judged by the 
Investigator would place the subject at increased 
risk of harm if he/she participated in the study.
Dosage Form, Dose and 
Route of Administration:
Edoxaban (30 mg) will be supplied by the Sponsor as 
yellow film-coated tablets and administered per oral (PO).
LMWH for the edoxaban lead-in will be as prescribed by 
the Principal Investigator (see Study Design, above).
Dalteparin will be supplied by the Sponsor as single-use
pre-filled syringes and administered by SC injection.
Study Outcomes: The primary study outcome is the composite of recurrent 
VTE, and major bleeding.
Recurrent VTE is either:
 symptomatic confirmed (new) DVT or (new) PE;
 unsuspected (new) proximal DVT of the legs or 
unsuspected (new) PE located in segmental or more 
proximal arteries:
 Unsuspected DVT or PE are thrombi that 
are detected during imaging testing 
performed for other reasons (eg, computed 
tomography (CT) for cancer staging) and not 
for suspicion of DVT or PE.
 fatal PE (including unexplained death for which PE 





 Major + CRNM bleeding;
 Event-free survival, defined as the proportion of 
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subjects over time free of recurrent VTE, major 
bleeding events, and death;
 VTE-related death;
 Mortality from all causes; 
 Recurrent DVT;
 Recurrent PE;
 Healthcare resource utilization for potential 
recurrent VTE and bleed events.
Other outcomes include:
 Cardiovascular events (MI, stroke, SEE [see 
Appendix 17.5.1]);
 Thrombotic events at other locations (see 
Appendix 17.5.2);
 Reason for permanent early discontinuation of 
study drug.
Statistical Analyses: Analysis of the Primary Study Outcome
The primary analysis will be based on the mITT Analysis 
Set (which includes all randomized subjects who receive at 
least 1 dose of study drug) using all primary outcome 
events (ie, recurrent VTE or major bleeding) occurring 
from randomization through the end of the 12 month study 
period or up to the global EOT visit when the study has 
been stopped, regardless of whether the subject is taking 
study drug. In this analysis, the time to the first event of 
the composite outcome will be analyzed using a Cox’s 
proportional hazards model including treatment and the 
stratification factors as covariates.  The LMWH/edoxaban
to comparator hazard ratio will be computed along with a 
95% confidence interval [CI] (two-sided) based on this 
model.  The LMWH/edoxaban will be considered non-
inferior to the comparator if the upper limit of the CI is 
< 1.5.
The following sensitivity analyses will be performed for the 
Primary Outcome:
 On-Treatment events based on the per-protocol 
(PP) Analysis Set will be analyzed using the 
counting process approach of the Cox 
proportional hazards regression model including 
treatment group, and the stratification factors as 
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covariates.    An On-Treatment event is defined 
as the event occurring during the time period the 
subject is taking study drug up to 3 days after 
their last dose for that time period.  Only events
occurring prior to or on Day 365 will be 
included into this analysis. Subjects who do not 
experience an On-Treatment event will be 
censored at Day 365, or the time study drug is 
permanently discontinued plus 3 days or on the 
last day the subject had a complete assessment 
(in-person visit or by telephone) for study 
outcomes, or the day of global end of treatment, 
whichever comes first.
 Events occurring during the first 6 months (180 
days) based on the mITT Analysis Set will be 
analyzed using the same statistical model as the 
primary analysis of the primary outcome. The 
time to event is defined as the time (days) from 
the randomization to the first event during the 
first 6 months after randomization.  Subjects 
who do not experience an event until Day 180
will be censored at Day 180, or the time study 
drug is permanently discontinued or on the last 
day the subject had a complete assessment (in-
person visit or by telephone) for study 
outcomes, whichever comes first.
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1. INTRODUCTION AND BACKGROUND INFORMATION
Venous thromboembolism (VTE) is a common and clinically important disease in cancer 
patients and current standard treatment consists of long-term low-molecular weight 
heparin (LMWH).
1, 2, 3, 4
Although subcutaneous (SC) injections with LMWH are 
effective they are often difficult to tolerate and inconvenient for long-term use by cancer 
patients. Therefore, if oral medications, such as the current direct oral anticoagulants 
(DOACs) are effective and safe without the need for SC punctures, they are potentially 
an attractive alternative in this population.  The Hokusai VTE study has shown that 
edoxaban, an oral direct Factor Xa (FXa) inhibitor, was effective and safe in the 
treatment of VTE.
5
In a subgroup analysis among 771 cancer patient randomized to the 
Hokusai VTE study, edoxaban was non-inferior in terms of efficacy and associated with a 
relative risk reduction of 19% in clinically relevant bleeding compared to warfarin.
6
  In 
view of these results, a clinical study with edoxaban versus LMWH in cancer-associated 
VTE is proposed.
1.1. Data Summary
The efficacy and safety of edoxaban for the treatment of VTE, including deep vein 
thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent VTE 
was demonstrated in the Phase 3 Hokusai VTE study. A large pivotal Phase 3 study in 
non-valvular atrial fibrillation (NVAF) (ENGAGE AF-TIMI 48) has also been completed 
and provides important information regarding the safety of long-term edoxaban 
treatment. Features of the Hokusai VTE and ENGAGE AF-TIMI 48 studies are 
summarized in Table 1.1.































Edoxaban 60 mg 4118 0.7 years Recurrent 
VTE












Edoxaban 60 mg 7012 2.5 years Stroke and 
SEE





HR (95% CI) 
0.80 (0.71, 
0.91)
Edoxaban 30 mg 7002
Warfarin 7012
VTE – venous thromboembolism; HR – Hazard Ratio; CI – confidence interval; CRNM – clinically relevant non-major; 
NVAF – non-valvular atrial fibrillation; SEE – systemic embolic event
Other completed studies include Phase 1 clinical pharmacology studies, Phase 2 
dose-ranging studies in subjects with NVAF and subjects undergoing lower-extremity 
orthopedic surgery, and Phase 3 studies in subjects undergoing lower-extremity 
orthopedic surgery. In the edoxaban program, a combined total of 18,132 subjects were 
treated with edoxaban (7002 with edoxaban 30 mg and 11,130 with edoxaban 60 mg) 
encompassing over a total exposure of > 34,048 subjects years for edoxaban.
7
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Name of Investigational Product: Edoxaban tosylate (DU-176b)
Edoxaban (INN), anhydrous free base (DU-176)
Active Ingredient: N-(5-Chloropyridin-2-yl)-N -[(1S,2R,4S)-4-(N,N-
dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-
carboxamido)cyclohexyl] oxamide mono(4-methylbenzenesulfonate) monohydrate
1.1.1.2. Description
Edoxaban tosylate is an antithrombotic agent, an orally active, selective, direct, and 
reversible inhibitor of FXa, manufactured by Daiichi Sankyo Co., Ltd., Japan.  Inhibition 
of FXa in the coagulation cascade prolongs clotting time and potentially reduces the risk 
of spontaneous or induced thrombus formation.
Edoxaban refers to the anhydrous free base of edoxaban tosylate.  Subjects are given 
edoxaban tosylate (a monohydrate salt) but all doses and plasma concentrations are 
expressed in terms of edoxaban, the anhydrous free base.
For simplicity, this protocol uses the term “edoxaban” to refer to either or both forms.
1.1.1.3. Nonclinical Studies
In nonclinical studies, edoxaban showed excellent potential as an antithrombotic agent.  
Nonclinical data indicate no evidence of liver function abnormalities in study animals 




The global clinical experience with edoxaban includes 43 completed Phase 1 studies, 12 
completed Phase 2 studies and 8 completed Phase 3 studies.
Edoxaban has been evaluated in the treatment of VTE in a large pivotal Phase 3 study, 
the Hokusai VTE study.
5
In this study, 8292 patients were enrolled: 4921 with DVT and 
3319 with PE.  Patients were randomized to an initial course of LMWH followed by 
edoxaban or LMWH/warfarin followed by warfarin alone.  The primary efficacy analysis 
of non-inferiority versus the current standard of care (ie, heparin overlapped with 
warfarin until the international normalized ratio (INR) reaches ≥ 2.0) was demonstrated 
with a high degree of confidence (hazard ratio [HR]: 0.89; 95% confidence interval [CI]: 
0.703, 1.128; p<0.0001).  The efficacy was consistent across analysis populations, 
individual components of the primary endpoint and subgroups of subjects including older 
individuals, those with renal impairment and subjects with lower body weight.  For the 
primary safety outcome (adjudicated major/clinically relevant non-major (CRNM)
bleeding, Safety Analysis Set, On-Treatment Study Period), edoxaban was superior to 
warfarin (HR: 0.81; 95% CI: 0.71, 0.94; p=0.0040) for a relative risk reduction of 19%.  
The benefit was most apparent for more serious bleeding including intracerebral 
hemorrhage. There was an increase in gastrointestinal (GI) bleeding, in line with other 
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  There was also an increase in vaginal bleeding, where the majority of 
cases were menses-related, but few cases were serious or led to discontinuation of 
treatment.  
It was concluded that once daily edoxaban after heparin was equally efficacious and 
caused significantly less bleeding compared with high-quality standard therapy with 
warfarin in a broad spectrum of VTE patients, including those with severe PE.
Additional details are available in the edoxaban Investigators’ Brochure.
7
1.2. Study Rationale
Venous thromboembolism (comprising DVT and PE) is a serious and frequently 
occurring comorbidity in cancer patients. It is the second most common cause of death in 
these patients
9
and compared with healthy persons cancer patients have a 4- to 7-fold 
increased risk for developing VTE.
10, 11
The association between thrombotic disease and 
cancer can be explained by pathophysiological mechanisms, while chemotherapy and 
central venous catheters (CVCs) often used in this population further increase the risk of 
VTE. 
In addition to a higher risk for developing VTE, patients with a malignancy when treated 
with anticoagulants also have an increased risk of bleeding, with major bleeding rates that 
are in the same range as the rate of recurrent VTE (ie, 8% - 12% per year as shown in 
contemporary studies).
12, 13, 14
Given these findings, clinical studies evaluating effective and safe VTE treatment are 
considered a priority for cancer patients. Since the principal problem in cancer patients 
with VTE is the underlying cancer, VTE management should preferably not interfere 
with the cancer therapy and have minimal impact on the patient’s already compromised 
quality of life (QOL). In this respect, VTE treatment in cancer patients is more 
challenging and different than VTE treatment in non-cancer patients. Current standard 
therapy for cancer-associated VTE is daily SC injected LMWH-dalteparin for at least 6 
months.
1, 2 ,3, 4
  Although SC injections are effective they are often difficult to tolerate and 
inconvenient for long-term use by cancer patients.  Therefore, if oral medications such as 
the current direct oral anticoagulants are effective and safe without the need for SC 
punctures then they are potentially an attractive alternative for patients with cancer and 
VTE. The Hokusai VTE study has shown that edoxaban, an oral direct FXa inhibitor 
(DOAC), was effective and safe in treatment of venous thromboembolism.
5
Additionally, among 771 patients with cancer randomized in the study, the recurrence 
rate over the 12-month study period in the edoxaban group was 3.7% compared with 
7.1% in the warfarin group (HR: 0.53; 95% CI: 0.28, 1.00). In these same patients, the 
clinically significant bleeding rates were 12.4% versus 18.8% (HR: 0.64; 95% CI: 0.45, 
0.92) in the edoxaban and warfarin treatment groups, respectively.
6
Interestingly, in the 
subgroup of patients classified by the treating physician as having cancer active at entry 
in the study (n=208), the risk of VTE recurrence was 3.7% in the edoxaban group and 
7.1% in the warfarin group (HR, 0.55; 95% CI, 0.16, 1.85), showing virtually identical 
results between patients with a history of cancer and the subset of those considered by the 
physician to have “active” cancer. This novel observation illustrates that the risk with 
respect to recurrent VTE is more the history of cancer than the more narrow definition of 
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cancer that is “active.” This conclusion was reached also in another recent study in a 
subgroup of cancer patients with VTE.
15
In view of these results, a comparative clinical study between standard treatment 
consisting of long-term SC LMWH-dalteparin and the new oral direct FXa inhibitor, 
edoxaban, is proposed. 
In a clinical study evaluating new anticoagulant therapy in the cancer patient population 
several design aspects require consideration. 
• Both recurrent VTE and major bleeding are potential life-threatening complications 
occurring at a comparable rate and with a significant and similar impact on the patient’s 
clinical status. The VTE-treatment should therefore aim to prevent both recurrent VTE 
and major bleed and in a study evaluating a new treatment option and the 2 outcomes will 
need to be equally considered. Therefore, in this novel design it is proposed that the 
primary outcome of the study will be a combined outcome consisting of recurrent VTE 
and major bleeding.
• In cancer patients, VTE-symptoms often are not obvious and erroneously attributed to 
the cancer or its treatment.  This unsuspected VTE occurs frequently
16, 17, 18
and the 
prognosis of these unexpected VTEs in terms of recurrent VTE and mortality are similar
to those with symptomatic disease. 
1,19, 20, 21, 22
As a consequence, current guidelines 
advise a similar treatment strategy for unsuspected PE and DVT as for clinically apparent 
VTE.
1
Therefore, unsuspected PE and DVT will be considered as an inclusion criterion 
and also as a component of the primary outcome.
• In non-cancer patients the duration of VTE-treatment is at least 3 months and 
prolonged up to 12 months or indefinitely depending on the clinical judgment balancing 
risk and benefit.  In cancer patients the recommended treatment duration is at least 6 
months.  Consistent with guideline recommendations prolonging treatment needs to be 
strongly considered especially in patients in whom cancer is still present.
1 ,2 ,3
However, 
after 6 months physicians are faced with a dilemma since data from studies beyond 6 
months are absent.
1, 2, 3
In evaluating a new anticoagulant treatment it is desirable to 
document the effects of treatment over a longer period of time.  Therefore, the intent in 
the present study is to treat all subjects for 12 months, and to follow all subjects for 12 
months after randomization whether or not they complete 12 months of treatment.  This 
is important because bleeding, including CRNM bleeding events, may lead to 
discontinuation or interruption of anticoagulant therapy, which then increases the risk of 
subsequent recurrent VTE events, with such events not captured using traditional On-
Treatment analyses.
1.3. Risks and Benefits for Study Subjects
Edoxaban is a selective FXa inhibitor with rapid onset of action and predictable 
antithrombotic properties.  Edoxaban appears to be well tolerated up to a dose of 90 mg 
QD, with expected transient and manageable bleeding adverse events (AEs) and transient 
and reversible liver enzyme and bilirubin elevations.
In the edoxaban program, a combined total of 18,132 subjects were treated with 
edoxaban (7002 with edoxaban 30 mg and 11,130 with edoxaban 60 mg) encompassing 
Protocol DU176b-D-U311
Version 1.0, 15 Dec 2014
Proprietary & Confidential
Page 26
over a total exposure of > 34,048 subjects years for edoxaban.
7
  This exceptionally large 
database allowed the overall safety of edoxaban to be adequately characterized in terms 
of adverse reactions with rare frequency and those occurring after a long latency period.  
The program also conducted a large number of specific studies to allow characterization 
of the pharmacokinetic (PK) and safety profile of edoxaban in subjects with hepatic 
dysfunction, severe renal impairment, and concomitant medications.  These specific 
studies together with the large clinical database allowed for the safety of edoxaban to be 
assessed in a large number of subject subgroups of intrinsic and extrinsic factors.  
Edoxaban demonstrated a consistent safety profile across subgroups.  An effective oral 
and parenteral transition scheme from edoxaban to other anticoagulants has also been 
demonstrated.
The completed Phase 3 clinical trials in AF and VTE have demonstrated efficacy and 
safety of edoxaban 60-mg dose (with a 30-mg dose reduction in subjects with 1 or more 
of the following: moderate to severe renal impairment, weight ≤ 60 kg, or concomitant 
use of specified P-gp inhibitors) in the prevention of stroke and systemic embolism in 
adult subjects with NVAF and in the treatment of VTE including DVT and PE, and 
prevention of recurrent VTE.
For VTE in particular, the primary efficacy analysis of non-inferiority versus the current 
standard of care (ie, heparin overlapped to warfarin until the INR reaches ≥2.0) was 
demonstrated with a high degree of confidence. In the primary efficacy modified 
intention-to-treat (mITT) overall analysis, the edoxaban regimen demonstrated non-
inferiority versus warfarin (HR: 0.89; 95% CI: 0.703, 1.128; p<0.0001).  The efficacy was 
consistent across analysis populations, individual components of the primary endpoints 
and subgroups of subjects including older individuals, those with renal impairment, and 
lighter subjects. 
Edoxaban 60 mg showed a clear benefit in terms of reduced bleeding when compared 
with well-controlled warfarin treatment.  In the Hokusai VTE study, the primary safety 
endpoint (adjudicated major/CRNM bleeding, Safety Analysis Set, On-Treatment Study 
Period), edoxaban was superior to warfarin (HR: 0.81; 95% CI: 0.71, 0.94; p=0.0040) for a 
relative risk reduction of 19%. The benefit was most apparent for more serious bleeding 
including ICH, and intra-articular and intra-ocular bleeds.  There was an edoxaban 
associated increase in GI bleeding, in line with other FXa inhibitors. There was also an 
increase in vaginal bleeding, where the majority of cases were menses-related, but few 
cases were serious or led to discontinuation of treatment.  
Bringing together quantitatively the benefits and risks as a net clinical outcome, Table 1.2
summarizes the benefit-risk outcomes.  For each indication, the net clinical outcome 
covers the principal efficacy and safety outcomes, and includes all-cause mortality.
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Table 1.2: Quantitative Benefit Risk
Composite Endpoint HR (95% CI) for Edoxaban 60 mg versus 
Warfarin
NVAF: Net Clinical Outcome mITT, Overall 0.89 (0.83 to 0.96)
VTE: Net Clinical Outcome PP, On-Treatment 0.87 (0.70 to 1.10)
HR – Hazard Ratio; CI – confidence interval; NVAF – non-valvular atrial fibrillation; mITT – modified 
intention-to-treat; VTE – venous thromboembolism; PP – per protocol
For NVAF, net clinical outcome is a composite of stroke, systemic embolic event, major bleeding, and 
all-cause mortality. 
For VTE, net clinical outcome is a composite of symptomatic recurrent deep vein thrombosis, non-fatal 
symptomatic recurrent pulmonary embolism, fatal pulmonary embolism, and major bleeding, 
and all-cause mortality.
Overall, edoxaban has an adequately characterized positive benefit-risk ratio in large and 
representative populations globally in patients with NVAF and VTE, demonstrating 
efficacy in the overall populations and subgroups (with dose reduction as required) in 
conjunction with a favorable bleed profile as well as demonstrating its effectiveness in a 
dose-dependent manner for VTE prevention after orthopedic surgery such as hip or knee 
replacement.  Additional advantages of edoxaban are its once daily (QD) dosing, 
dose-reduction strategies to minimize the risk of bleeding with preserved efficacy and no 
necessity for constant monitoring of therapy.
Dalteparin is the only licensed anticoagulant for the extended treatment and prevention of 
recurrence of VTE in cancer patients and thus is considered the “gold” standard 
treatment.  Six months of dalteparin was found to be more effective than, and as safe as, 
vitamin K antagonists [VKAs] (ie, warfarin/coumarin) for patients with cancer and acute 
VTE, without significantly increasing the risk of major bleeding.  The authors concluded 
that “longer term” dalteparin is safe in cancer patients.
23
References and information on dalteparin (Fragmin
®
) is available in the Summary of 
product Characteristics/Product Monograph and the package inserts.
24
Complete prescribing information for dalteparin can be found in Appendix 17.1.1.
1.4. Population, Route, Dosage, Dosage Regimen, Treatment Period
Adult subjects who present with VTE associated with cancer (other than basal-cell or 
squamous-cell carcinoma of the skin) for whom long-term treatment with LMWH is
intended are eligible to participate in this study. Section 4 lists all eligibility 
requirements necessary to qualify for the study. 
Eligible subjects will be stratified by 1) bleeding risk, and 2) the need for dose 
adjustment, and then randomized to receive either LMWH/edoxaban or dalteparin (see 
full details below; Section 3 provides complete treatment details).  
 Edoxaban group: Therapeutic doses of LMWH (SC) for at least 5 days will be 
administered; this 5 day period may include the pre-randomization LMWH
treatment (if applicable). The choice of parenteral LMWH is up to the 
treating physician.  Thereafter, edoxaban will be started orally at 60 mg QD (2 
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× 30 mg tablets; 30 mg QD for subjects requiring dose adjustment) for the 
remainder of the treatment period.
 Dalteparin group: After randomization, dalteparin will be administered at a 
dose of 200 IU/kg SC (maximum daily dose 18,000 IU) for 30 days.  The 30 
day period may include the pre-randomization anticoagulant treatment if 
dalteparin was used in therapeutic doses. Thereafter (approximately Day 31 
forward), dalteparin will be administered at a dose of 150 IU/kg SC (~ 75% -
83% of the initial dose) for the remainder of the treatment period.
1.5. Compliance Statement, Ethics and Regulatory Compliance
This study will be conducted in compliance with the protocol, the ethical principles that 
have their origin in the Declaration of Helsinki, the International Conference on
Harmonisation (ICH) consolidated Guideline E6 for Good Clinical Practice (GCP) 
(CPMP/ICH/135/95), and applicable regulatory requirement(s).
 European Commission Directive (2001/20/EC Apr 2001) and/or
 European Commission Directive (2005/28/EC Apr 2005) and/or
 Food and Drug Administration (FDA) GCP Regulations: Code of Federal 
Regulations (CFR) Title 21, Parts 11, 50, 54, 56 and 312 as appropriate and/or
 Other applicable local regulations.
1.5.1. Subject Confidentiality
The Investigators and the Sponsor will preserve the confidentiality of all subjects taking 
part in the study, in accordance with GCP and local regulations.
For European Union (EU) sites, the Sponsor will observe the rules laid down in the 
European Data Protection Directive 95/46/EC on the protection of individuals with 
regard to the processing of personal data and the free movement of such data.
The Investigator must ensure that the subject’s anonymity is maintained.  On the Case 
Report Forms (CRFs/electronic CRF [eCRF]) or other documents submitted to the 
Sponsor and/or its designated representatives, subjects should be identified by a unique 
subject identifier as designated by the sponsor.  Documents that are not for submission to 
Sponsor and/or it’s designated representatives (eg, signed Informed Consent Forms 
[ICFs]) should be kept in strict confidence by the Investigator.
In compliance with Federal regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the 
regulatory agency(s), and the Independent Ethics Committee (IEC) or Institutional 
Review Board (IRB) direct access to review the subject’s original medical records for 
verification of study-related procedures and data.  The Investigator is obligated to inform 
the subject that his/her study-related records will be reviewed by the above named 
representatives without violating the confidentiality of the subject.
Protocol DU176b-D-U311
Version 1.0, 15 Dec 2014
Proprietary & Confidential
Page 29
1.5.2. Informed Consent Procedure
Before a subject’s participation in the study, it is the Investigator’s responsibility to 
obtain freely given consent, in writing, from the subject or legally acceptable 
representative after adequate explanation of the aims, methods, anticipated benefits, and 
potential hazards of the study and before any protocol-specific screening procedures or 
any study drugs are administered (see Section 6.1 Study Qualification).  A legally 
acceptable representative is an individual or other body authorized under applicable law 
to consent, on behalf of a prospective subject, to the subject’s participation in the clinical 
study.  The written ICF should be prepared in the local language(s) of the potential 
subject population.
In obtaining and documenting informed consent, the Investigator should comply with the 
applicable regulatory requirements, and should adhere to GCP and to the ethical 
principles that have their origin in the Declaration of Helsinki.  The consent form and any 
revision(s) should be approved by the IEC or IRB prior to being provided to potential 
subjects.
The subject’s written informed consent should be obtained prior to his/her participation in 
the study, and should be documented in the subject’s medical records, as required by 21 
CFR Part 312.62.  The ICF should be signed and personally dated by the subject or a 
legally acceptable representative, and by the appropriate qualified person who conducted 
the informed consent discussion (not necessarily the Investigator but delegated by the 
Investigator).  The original signed ICF should be retained in accordance with institutional 
policy, and a copy of the signed consent form should be provided to the subject or legal 
representative.  The date that informed consent was given should be recorded on the 
CRF.
If the subject or legally acceptable representative cannot read, then according to ICH 
GCP Guideline, Section 4.8.9, an impartial witness should be present during the entire 
informed consent discussion.  This witness should sign the ICF after the subject or the 
legally acceptable representative has orally consented to the subject’s participation and, if 
possible, signed the ICF.  By signing the ICF, the witness attests that the information in 
the ICF and any other written information was adequately explained to and apparently 
understood by the subject or the legally acceptable representative and that informed 
consent was freely given by the subject or the legally acceptable representative.
Suggested model text for the ICF for the study and any applicable subparts (genomic, 
pharmacokinetic, etc) are provided in the Sponsor ICF template for the Investigator to 
prepare the documents to be used at his or her site.  Updates to applicable forms will be 
communicated via letter from the Clinical Study Manager.
This study will be conducted in the United States (US), therefore, additional consent is 
required for the Health Insurance Portability and Accountability Act (HIPAA).  
1.5.3. Regulatory Compliance
The study protocol, subject information and consent form, the Investigator brochure, any 
subject diary card or written instructions to be given to the subject, available safety 
information, subject recruitment procedures (eg, advertisements), information about 
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payments and compensation available to the subjects and documentation evidencing the 
Investigator’s qualifications should be submitted to the IEC or IRB for ethical review and 
approval according to local regulations, prior to the study start.  The written approval 
should identify all documents reviewed by name and version.
Changes in the conduct of the study or planned analysis will be documented in a protocol 
amendment and/or the Statistical Analysis Plan (SAP).
The Investigator must submit and, where necessary, obtain approval from the IEC or IRB 
and/or Sponsor for all subsequent protocol amendments and changes to the informed 
consent document or changes of the site, facilities or personnel.  The Investigator should 
notify the IEC or IRB of deviations from the protocol or serious adverse events occurring 
at the site and other adverse event reports received from Sponsor/contract research 
organization (CRO), in accordance with local procedures.
As required by local regulations, the Sponsor’s local Regulatory Affairs group will 
ensure all legal aspects are covered, and approval of the appropriate regulatory bodies 
obtained, prior to study initiation, and that implementation of changes to the initial 
protocol and other relevant study documents happen only after the appropriate 
notification of or approval by the relevant regulatory bodies.
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2. STUDY OBJECTIVES AND HYPOTHESES
2.1. Study Objectives
2.1.1. Primary Objective
The primary objective is to demonstrate the non-inferiority of a 12-month course of 
LMWH/edoxaban compared with dalteparin for the prevention of the combined outcome 
of recurrent VTE or major bleeding in subjects with VTE associated with cancer.  If non-
inferiority is established, edoxaban will be compared with dalteparin for superiority.
2.1.2. Secondary Objectives





4. Major + CRNM bleeding;
5. Event-free survival, defined as the proportion of subjects over time free of 
recurrent VTE, major bleeding events, and death;
6. VTE-related death;
7. Mortality from all causes;
8. Recurrent DVT;
9. Recurrent PE;
10. Healthcare resource utilization for potential recurrent VTE and bleed events.
2.1.3. Exploratory Objectives
Exploratory objectives include comparing LMWH/edoxaban with dalteparin with regards 
to:
1. Cardiovascular events (myocardial infarction (MI), stroke, SEE [see Appendix
17.5.1]);
2. Thrombotic events at other locations (see Appendix 17.5.2);
3. Reason for permanent early discontinuation of study drug.
2.2. Study Hypothesis
Edoxaban will be non-inferior to dalteparin with respect to the occurrence of recurrent 
VTE or major bleeding in the treatment of VTE associated with cancer. 
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The study treatment (edoxaban) will be considered non-inferior to the standard therapy 
(dalteparin) if the upper limit of the two-sided 95% CI for the hazard ratio 
(edoxaban/standard therapy) is < 1.5.
Protocol DU176b-D-U311






This is a multinational, prospective, randomized, open-label, blind-evaluator (PROBE), 
non-inferiority study comparing edoxaban with dalteparin for prevention of the combined 
outcome of recurrent VTE or major bleeding in patients with VTE associated with 
cancer. Adult subjects with VTE associated with cancer (other than basal-cell or 
squamous-cell carcinoma of the skin; cancer should be active (see Section 6.1) or 
diagnosed within the previous 2 years), and who present with confirmed acute 
symptomatic or unsuspected lower extremity proximal DVT, confirmed symptomatic PE, 
or unsuspected PE in a segmental or larger pulmonary artery for whom long-term 
treatment (at least 6 months) with LMWH is indicated are eligible to participate in this 
study. One thousand subjects (1000) will be equally randomized to 1 of the 2 treatment 
groups.  
After a subject’s eligibility is confirmed, the subject will be stratified by 1) bleeding risk,
and 2) the need for dose adjustment, and then randomly assigned via interactive 
voice/web response system (IXRS) in a 1:1 ratio to treatment with either 
LMWH/edoxaban or dalteparin (see Section 5.1.1 for complete details).
After randomization subjects will be assessed at Month 1, Month 3, and then quarterly 
thereafter for up to 12 months until they complete the study.
Approximately 130 study sites in North America, Europe, and Australia/New Zealand are
planned to enroll subjects in this study.
3.1.2. Treatment Groups and Dosing
Figure 3.1 depicts the study design and treatment plan.  The detailed Schedule of Events 
is provided in Appendix 17.7 and the protocol-required study procedures are provided in 
Section 6.   
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Figure 3.1: Study Design
Eligible subjects will be stratified by 1) bleeding risk, and 2) the need for dose 
adjustment: 
1. Bleeding risk (assessed at time of randomization)
 surgery within 2 weeks prior to randomization
 use of antiplatelet agents (eg, aspirin ≤ 100 mg/day) that will continue during 
the study
 brain tumor or brain metastases present at the time of randomization
 metastatic disease present at the time of randomization
 regionally advanced cancer present at the time of randomization
 gastrointestinal cancer at randomization or diagnosed within a 6-month period 
prior to randomization
 urothelial cancer at randomization or diagnosed within a 6-month period prior 
to randomization
 Avastin (bevacizumab) use at randomization or given within the 6-week 
period prior to randomization
2. The need for dose adjustment
 body weight ≤ 60 kg, or
 creatinine clearance (CrCL) between 30 and 50 mL/min inclusive
 concomitant use of P-gp inhibitors
After stratification, subjects will be assigned randomly via IXRS in a 1:1 ratio to 1 of the 
2 following treatment groups:
 LMWH/Edoxaban group: Therapeutic doses of LMWH (SC) will be 
administered for at least 5 days; this 5-day period may include the pre-
randomization LMWH (if applicable). The choice of this parenteral LMWH
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is up to the treating physician. Thereafter, edoxaban will be started orally at 
60 mg QD (2 × 30 mg tablets; 30 mg QD for subjects requiring dose 
adjustment) for the remainder of the treatment period.
The first dose of edoxaban should be taken: 
 12 (±3) hours after the last injection of the initial LMWH if this was a twice 
daily regimen, 
 24 (±3) hours after the last injection of the initial LMWH if this was a once 
daily regimen.
The edoxaban daily dose should be decreased to 30 mg QD for:
 body weight ≤ 60 kg; or
 creatinine clearance [CrCL] between 30 and 50 mL/min inclusive;
 concomitant use of P-gp inhibitors (eg, hormonal agents: tamoxifen, 
enzalutamide, abiraterone).
Dose reduction of edoxaban to 30 mg QD is intended only during concomitant use of P-
gp inhibitors.  When use of these inhibitors is discontinued/intermittent (eg, between 
chemotherapy cycles) the full 60 mg edoxaban dose should be used.
After randomization, if the subject’s CrCL becomes ≤ 50 mL/min and ≥ 30 mL/min and 
the decrease in CrCL is > 20% from the subject’s baseline CrCL value, repeat the 
measurement in 1 week. If the repeat measurement confirms this decrease, the edoxaban 
dosage regimen will be reduced permanently, even if the subject subsequently 
experiences improved CrCL to > 50 mL/min at a later measurement.
After randomization, if the subject’s body weight drops to ≤ 60 kg (confirmed by repeat 
measurement at least 1 week apart) and the body weight change is > 10% of the subject’s 
baseline body weight, the edoxaban dosage regimen will be reduced permanently, even if 
the subject subsequently re-gains weight to > 60 kg.
More details are provided in Appendix 17.3.7.
 Dalteparin group: After randomization, dalteparin will be administered at a 
dose of 200 IU/kg SC (maximum daily dose 18,000 IU) for 30 days.  The 30 
day period may include the pre-randomization anticoagulant treatment if 
dalteparin was used in therapeutic doses. Thereafter (approximately Day 31 
forward), dalteparin will be administered at a dose of 150 IU/kg SC (~ 75% -
83% of the initial dose) for the remainder of the treatment period.  
Dalteparin doses by weight and precautions for dose modifications are listed in Appendix
17.4 .
3.1.2.1. Treatment Duration
The intention is to treat patients for 12 months with the allocated study treatment. 
Continuation of anticoagulant treatment beyond 6 months will be based on the 
risk-benefit evaluation by the treating physician.  
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Continue anticoagulation treatment if the benefit of doing so outweighs the risk and/or 
cancer is still “active”.  In this case ongoing anticoagulation with the allocated treatment 
regimen is preferred (if this is considered appropriate by the Investigator).  If however the 
Investigator decides to switch to another treatment regimen (eg, in the dalteparin arm the 
decision can be made to stop the parenteral administration and switch to oral therapy), it 
is recommended to switch to VKA and strongly discouraged to switch to a DOAC. 
Note: All subjects, including those in whom study medication is stopped or those who 
switch to VKA, will be followed up to 12 months with the following exception:
Once 1000 subjects are randomized in the study, a global end-of-treatment (EOT) date 
will be established that ensures a minimum of 6 months of study treatment and follow-up 
for the final subject(s) randomized. All subjects will permanently discontinue study 
treatment on or before the EOT date.
3.1.3. Study Governance
3.1.3.1. Steering Committees
The study oversight will be managed by a Steering Management Coordinating 
Committee (SMCC) whose members are country coordinators, as well as, non-voting 
representatives of the Sponsor and Academic Research Organization (ARO). In this 
study, International Trial Expertise Advisory and Services (ITREAS) will function as the 
ARO.
An Executive Committee to the SMCC will have a scientific advisory function and will 
not be involved in operational matters.
Ongoing study oversight and management will be the responsibility of a joint supervisory 
committee.  The members of this committee are the chairman and co-chair of the SMCC 
and designated representatives from the Sponsor, CRO and ARO.  
3.1.3.2. Data Monitoring Committee
An independent Data Monitoring Committee (DMC) will monitor safety during the study 
and give recommendations to the Executive Committee.  The DMC will periodically 
review and examine the safety and efficacy data (mortality and events, bleeding events, 
serious adverse events [SAEs], systemic embolic event [SEE]) and alert the Chairman of 
the Executive Committee in case of any clinically concerning safety issues.
3.1.3.3. Clinical Events Committee
An independent Clinical Events Committee (CEC) will be established to objectively 
adjudicate and categorize the presenting index diagnosis, VTE outcomes, cardiovascular 
events, bleeding events, selected hepatic events, and death.  Adjudicators will be blinded 
as to subject treatment allocation.  
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The primary outcome is the composite of recurrent VTE, and major bleeding.
All suspected recurrent VTE and bleeding events will be adjudicated by the CEC.  
Adjudicated results will be the basis for the final analyses. 





 CRNM bleeding; 
 Major + CRNM bleeding;
 Event-free survival, defined as the proportion of subjects over time free of 
recurrent VTE, major bleeding events, and death;
 VTE -related death;
 Mortality from all causes;
 Recurrent DVT;
 Recurrent PE;
 Healthcare resource utilization for potential recurrent VTE and bleed events.
All suspected VTE events, deaths, and bleeding events will be adjudicated by the CEC.  
Adjudicated results will be the basis for the final analyses.
3.1.4.3. Other Outcomes
Other outcomes include:
 Cardiovascular events (MI, stroke, SEE[see Appendix 17.5.1]);
 Thrombotic events at other locations (see Appendix 17.5.2);
 Reason for permanent early discontinuation of study drug.
All suspected cardiovascular events and other thrombotic events will be adjudicated by 
the CEC.  Adjudicated results will be the basis for the final analyses.
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3.2. Selection of Doses
3.2.1. Experimental Treatments
In the current guidelines extended LMWH therapy is the first choice for long-term 
treatment of VTE in cancer patients.
1, 2, 3
Dalteparin is the only approved anticoagulant 
specifically indicated for the extended treatment and prevention of recurrent VTE in 
cancer patients; thus, it is considered the standard of care.  The dalteparin regimen to be 
used in this study is based on the CLOT study which showed that 6 months of dalteparin 
was more effective than and as safe as VKAs (ie, warfarin/coumarin) for patients with 
cancer and acute VTE, without significantly increasing the risk of major bleeding.
23
The edoxaban regimen (60 mg QD with dose reduction for specific risk factors) was 
selected for this study based on the Hokusai VTE study results.  In the Hokusai VTE 
study, edoxaban produced a 47% relative reduction in risk for recurrent VTE in subjects 
with a history of cancer compared with warfarin.  Additionally, edoxaban resulted in a 
36% relative reduction for risk of clinically significant bleeding in these same subjects.
25
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Subjects must sign and date the ICF provided by the site before any study-specific 
qualification procedures are performed, except as noted in Section 6.1 Study 
Qualification/Pre-randomization.  
4.1.1. Inclusion Criteria
Adult subjects presenting with VTE associated with cancer (other than basal-cell or 
squamous-cell carcinoma of the skin) for whom long-term treatment with LMWH is 
intended are eligible to participate in the study. 
Subjects must satisfy all of the following criteria to be included in the study:
1. Male or female subjects with age ≥ 18 years or the otherwise legal lower age 
according to the country of residence;
2. Confirmed symptomatic or unsuspected lower extremity proximal DVT (ie, 
popliteal, femoral, iliac or inferior vena cava (IVC) vein thrombosis), or 
confirmed symptomatic PE, or unsuspected PE of a segmental or larger 
pulmonary artery;
3. Cancer (other than basal-cell or squamous-cell carcinoma of the skin), either 
active or diagnosed within 2 years prior to randomization.  [Note: Diagnosis of 
cancer must be objectively documented];
4. Intention for long-term treatment (at least 6 months) with parenteral LMWH;
5. Able to provide written informed consent.
4.1.2. Exclusion Criteria
Subjects who meet any of the following criteria are not eligible for enrollment:
1. Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the 
current (index) episode of DVT and/or PE;
2. More than 72 hours pre-treatment with therapeutic dosages of anticoagulant 
treatment (LMWH, unfractionated heparin, and fondaparinux per local labeling), 
oral direct anticoagulants or VKA prior to randomization to treat the current 
(index) episode;
3. Treatment with therapeutic doses of an anticoagulant other than that used for pre-
treatment of the current (index) VTE episode prior to randomization;
4. Active bleeding or any contraindication for treatment with LMWH/dalteparin or 
edoxaban;
5. Indication for dalteparin other than DVT and/or PE;
6. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 3 or 4 at 
the time of randomization (Appendix 17.6);
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7. Calculated CrCL < 30 mL/min;
8. History of heparin associated thrombocytopenia;
9. Acute hepatitis, chronic active hepatitis, liver cirrhosis;
10. Hepatocelullar injury with concurrent transaminase (ALT/AST > 3 x ULN) and 
bilirubin (> 2 x ULN) elevations in the absence of a clinical explanation;
11. Life expectancy < 3 months;
12. Platelet count < 50,000/mL;
13. Uncontrolled hypertension as judged by the Investigator (eg, systolic blood 
pressure (BP) > 170 mmHg or diastolic blood pressure > 100 mmHg despite 
antihypertensive treatment);
14. Women of childbearing potential without proper contraceptive measures, and 
women who are pregnant or breast feeding;
Note: Childbearing potential without proper contraceptive measures (ie, a method 
of contraception with a failure rate < 1 % during the course of the study including 
the observational period). These methods of contraception according to the note 
for guidance on nonclinical safety studies for the conduct of human trials for 
pharmaceuticals (CPMP/ICH/286/95, modification) include consistent and correct 
use of hormone containing implants and injectables, combined oral 
contraceptives, hormone containing intrauterine devices, surgical sterilization, 
sexual abstinence, and vasectomy for the male partner).
15. Chronic treatment with non-aspirin non-steroidal anti-inflammatory drugs 
(NSAIDs) including both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 
(COX-2) inhibitors for ≥ 4 days/week anticipated to continue during the study;
16. Treatment with aspirin in a dosage of more than 100 mg/per day or dual 
antiplatelet therapy (any 2 antiplatelet agents including aspirin plus any other oral 
or intravenous [IV] antiplatelet drug) anticipated to continue during the study;
17. Treatment with the P-gp inhibitors ritonavir, nelfinavir, indinavir, or saquinavir 
anticipated to continue during the study;
18. Systemic use of the P-gp inhibitors ketoconazole, itraconazole, erythromycin, 
azithromycin or clarithromycin at the time of randomization; subsequent use is 
permitted;
19. Subjects with any condition that as judged by the Investigator would place the 
subject at increased risk of harm if he/she participated in the study.
4.2. Removal of Subjects From Therapy
4.2.1. Reasons for Withdrawal/Early Discontinuation
A subject may discontinue or interrupt study drug for a number of reasons including, but 
not limited to, those listed below: 
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 Withdraw of consent as defined in Section 4.2.1.2;
 Lost to follow-up as defined in Section 4.2.1.3 (every attempt will be made by 
the Investigator not to have subjects "lost to follow-up");
 CrCL decrease to < 30 mL/min, confirmed by repeat testing at least 1 week 
later or need for kidney dialysis;  
 Investigator judgment due to:
o SAE or other safety concern eg,
 Major life-threatening bleeding 
 Onset clinical jaundice or other overt signs of liver toxicity 
o Unfavorable benefit-to-risk evaluation for continuing anticoagulant 
treatment 
 Subject decision (refusal for intake or administration of study drugs). It is 
important to distinguish between withdrawal of consent with regards to 
continuing on study medication but continuing to be followed on study;
 Termination of all or part of the study by the SMCC acting in concert with the 
Sponsor.
4.2.1.1. Temporary Interruption
Temporary interruptions of edoxaban and dalteparin for 4 or more consecutive days will 
be recorded in the eCRF.  Interruptions of edoxaban and dalteparin for less than 4 
consecutive days will not be recorded in the eCRF. Potential reasons may include:
 Short-term use of prohibited concomitant medications;
 Surgical procedures;
 Any medical condition where continuing study drug may expose the subject to 
an increased hazard;
 New onset of elevated liver enzymes in the absence of a known cause:
o ALT > 8 × ULN 
o AST or ALT > 5 x ULN for more than two weeks
o ALT or AST > 3 x ULN, but not reaching the limits in the above criteria, 
in combination with clinical symptoms suggestive of hepatitis 
o ALT or AST > 3 x ULN with TBL > 2 x ULN 
During a study drug interruption or after study drug discontinuation, a subject can be 
placed on antithrombotic therapy per local guidelines and the Investigator's discretion. It 
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is, however, discouraged to switch to another DOAC. Guidance for switching from 
edoxaban to other anticoagulants is provided in Appendix 17.2.
Post-randomization changes (other than CrCL decreased to < 30 mL/min or need for 
kidney dialysis) in health status related to study exclusion criteria should not 
automatically lead to study drug interruption or discontinuation unless continuing study 
drug places the subject at undue hazard as determined by the Investigator. Such 
situations should be handled on a case-by-case basis.  It is strongly recommended that the 
Investigator consults with ITREAS (Medical Support Line:  +32 495 54 74 51) if a 
subject has a post randomization change in health status that is associated with an 
exclusion criterion.
Also, a decision to stop prematurely the overall recruitment in the study and/or intake of 
study drug can be taken by the Executive Committee /Sponsor following advice on safety 
aspects of the study by the DMC.  The IECs/IRBs will be informed of this decision. The 
DMC stopping guidelines will be defined prior to the start of the study.  The Sponsor has 
the right to close this study and the right to close a center, at any time, although this 
should occur only after consultation between involved parties and the Executive 
Committee. The IECs/IRBs must be informed.  Should the site be closed prematurely, all 
study materials (except documentation that has to remain stored at site) must be returned 
to the Sponsor. The Investigator will retain all other documents until notification by 
Sponsor for destruction
If the subject is withdrawn due to an adverse event, the Investigator will follow the 
subject until the adverse event has resolved or stabilized.
4.2.1.2. Withdrawal of Consent from Study Participation
In accordance with the Declaration of Helsinki and other applicable regulations, a subject 
has the right to withdraw consent from study participation at any time and for any reason 
without prejudice to his or her future medical care by the physician or at the institution.
However, it is important to distinguish between withdrawal of consent with regards to 
continuing on study medication (but continuing to be followed on study) versus 
withdrawal of consent with regards to discontinuing the study all together (ie, withdrawal 
of consent with regards to continuing on study medication and any further study follow-
up).
Only subjects who refuse all 4 of the following methods of follow-up will be considered 
to have withdrawn consent from study participation:
 Participation in the trial follow-up visits per protocol, either in clinic or by 
telephone;
 Contact by trial personnel even if only by telephone (quarterly, bi-annually, 
annually, End of Treatment visit only);
 Permission for trial personnel to contact an alternative person (eg, family
member, spouse, partner, legal representative, physician, the anticoagulation 
clinic, or another healthcare provider) even if only by telephone;
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 Permission for trial personnel to access and review their medical information 
from alternative sources (eg, doctor’s notes, hospital records).
If the subject refuses all 4 of the above methods of follow-up, the Investigator should 
personally speak to the subject to ensure the subject understands all of the potential 
methods of follow-up.  If the subject continues to refuse all potential methods of 
follow-up, the Investigator will document this as a withdrawal of consent in the medical 
record.
All subjects should be followed for the full duration of the trial using any or all of the 
above methods, unless there is written documentation by the Investigator of the subject's 
withdrawal of consent to ALL of the above methods of follow-up.
If a subject is withdrawn entirely from the study, the IXRS will be called by the site to 
register the subject as permanently discontinued from the study (and study treatment if 
not done previously).
The site will complete and report the observations as thoroughly as possible up to the 
date of consent withdrawal and including the date of the final dose of study drug. The 
reason(s) for limited follow-up/data collection will be clearly documented in the medical 
record and eCRF.
Public databases and subject finder services may be used to determine subject status and 
to locate potential lost to follow-up patients.
4.2.1.3. Subjects Lost to Follow-Up
The Investigator will make every effort not to have any subjects lost to follow-up.  If a 
subject is potentially lost to follow-up (eg, missed study visits, unable to be contacted by 
phone), the Investigator will make every effort to contact the subject before the subject is 
declared lost to follow-up.  These efforts may include but are not limited to:
 Calling all telephone numbers for the subject and their contacts (including 
during the evening and on weekends);
 Calling primary care physician, referring specialist and/or other listed 
physicians for more recent locator information, date of last office visit, or to 
determine mortality status;
 Sending email and follow with mailing certified letters (return receipt 
requested) to all known subject addresses and all listed contacts (eg, relatives, 
friends, neighbors);
 Reviewing subject’s records and medical notes for any details of a 
hospitalization, doctor’s visit, or other procedure that may indicate status of 
subject;
 Using the Internet to search for possible contact information for subject
 Try reverse directory for phone numbers to get possible addresses
 Utilize social networking sites (eg, Facebook); 
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 Checking local, regional, and national public records to locate subject or 
search for mortality status in accordance with local law;
 Possible home visit.
Once the site has exhausted and documented these actions, the Clinical Research 
Associate or monitor should be contacted for additional guidance and alternative options.
Public databases and subject finder services may be used to determine subject status and 
to locate potential lost to follow-up patients.
4.2.2. Withdrawal Procedures
4.2.2.1. Follow-Up of Subjects with Study Drug Discontinuations
The Investigator may contact ITREAS (Medical Support Line:  +32 495 54 74 51) or
email) in case of any questions regarding how to handle a study drug discontinuation or 
interruption.
All randomized subjects, including those who temporarily interrupted or discontinued 
study drug, will be followed for a 12-month period after randomization, except when the 
study is truncated as noted in Section 3.1.2.1.
In case of premature discontinuation of treatment, study outcomes can be collected by 
telephone contact until 12 months after the first dose of study drug. If the subject has an 
on-site visit at any time after study drug discontinuation, it is expected that a clinical 
status will be obtained along with any laboratory assessments deemed appropriate by the 
Investigator.
If the subject and Investigator agree that study drug can be resumed without increased 
hazard to the subject, study medication may be resumed at any time, regardless of the 
duration of study drug interruption.
Any subject who temporarily interrupts or discontinues study drug due to confirmed liver 
enzyme abnormalities or jaundice in the absence of a known cause, must have an 
evaluation to determine the cause of the event. Evaluation may include the following 
depending on the clinical situation:
 Abdominal ultrasound;
 Hepatitis A, B, C, and E screening (anti-HAV IgM, HbsAg, anti-HCV plus 
viral titer, and evaluation for Hep E), Antinuclear antibody (ANA) and anti-
SmAb, Cytomegalovirus (CMV), Epstein Barr virus (EBV);
 Additional evaluations as deemed appropriate by the Investigator to exclude 
other causes of liver enzyme and bilirubin elevations.
Follow-up of liver enzymes and bilirubin (total and direct) should be performed on a 
weekly basis until the values return to baseline.
All laboratory results, including local laboratory reference ranges are to be recorded in 
the eCRF.
If the subject and Investigator agree that study drug can be resumed without increased
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hazard to the subject, blinded study drug may be resumed at any time, regardless of the
duration of study drug interruption.
All clinically significant hepatic enzyme abnormalities and/or hepatic events are to be 
documented in the eCRF and prompt submission of the adjudication dossier should also 
occur when indicated/directed (see Section 9.3.1).
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The Investigator must ensure that the investigational products will be used only in 
accordance with the protocol.
 Edoxaban (30 mg) will be supplied by the sponsor as yellow film-coated 
tablets and administered orally (PO).
 LMWH for the edoxaban lead-in will be as prescribed by the Principal 
Investigator (PI).
 Dalteparin will be supplied by the Sponsor as single-use pre-filled syringes 
and administered by SC injection.
The Investigator or designee will be responsible for dispensing study drugs. 
The Investigators/study coordinators must ensure that the appropriate fields on the label 
are completed, including subject number and date of dispensing.  
Subjects must be supplied with sufficient study drug to last until the next scheduled 
dispensing visit.  
Subjects may take edoxaban with or with or without food, in the AM or PM, but at 
approximately the same time every day.  Dalteparin should also be consistently 
administered at approximately the same time every day as well.
5.1.1. Method of Assigning Subjects to Treatments and Dispensing of Study 
Drug
Eligible subjects will be stratified by 1) bleeding risk, and 2) the need for dose 
adjustment.  After confirmation of eligibility, the Investigator will provide the IXRS with 
the study center number, appropriate demographic information consistent with local 
regulations, bleeding risk profile, CrCL, body weight category (≤ 60 kg or > 60 kg), and 
whether the subject’s currently using any P-gp inhibitors.
The IXRS will assign the unique subject identification number, stratify the subject by 
bleeding risk and need for dose adjustment, then allocate the treatment group assignment 
for the subject.  A fax or email will be sent by the IXRS to the study site noting the 
treatment group and dosage strength of the assigned medication.  The fax or e-mail will 
also provide a calendar of subsequent dispensing dates.  Study drug will be dispensed at 
randomization, approximately Day 31, Month 2 then at least once every 3 months (more 
frequent dispensing of study drug is allowed if necessary), thereafter while the subject 
remains on treatment.
This study has an open-label, blind-evaluator design with LMWH/edoxaban and 
dalteparin.  The subjects, Investigators, Sponsor, CRO, and ITREAS staff involved in the 
treatment or clinical evaluation of the subjects will be aware of the treatments received.  
There will be an independent DMC to monitor the efficacy and safety data on a periodic 
basis. All study outcome events will be adjudicated by the CEC using blinded evaluators.
Protocol DU176b-D-U311
Version 1.0, 15 Dec 2014
Proprietary & Confidential
Page 47
The specifications for generation of the randomization schedule will be prepared by the 
study biostatistician and the CRO in charge of the IXRS.  For this study, the 
randomization schedule refers to a list that includes the randomization number, 
randomization block number, and treatment.
5.1.2. Method of Assessing Treatment Compliance
Dosing compliance will be assessed by means of edoxaban tablet and dalteparin syringe
counts.  
5.1.3. Labeling and Packaging
Edoxaban 30 mg tablets for oral use will be supplied by the Sponsor in PVC/foil blister 
packs.  
Dalteparin will be supplied in pre-filled syringes.




Edoxaban must be stored by the site at 20°C to 25°C (68°F to 77°F) as measured by a 
thermometer in a secure, limited access storage area under the recommended storage 
conditions.  Temperature measurements will be recorded on a temperature log excluding 
weekends and holidays.
Excursions from 15°C to 30°C (59°F to 86°F) are permitted.  The Sponsor must be 
contacted in the event of a temperature excursion outside this range.
5.1.4.2. Dalteparin 
Dalteparin must be stored at controlled room temperature below 25°C (77°F).
5.1.5. Drug Accountability
The IXRS will contain a Drug Accountability Module for any medications provided by 
the Sponsor (eg, edoxaban, dalteparin).  The Investigator or designee will enter the 
required information (see IXRS user manual) in the IXRS drug accountability module. In 
addition, the Investigator or designee shall contact Sponsor as soon as possible if there is 
a problem with the shipment.
A Drug Accountability Record will be provided for the investigational products.  The 
record must be kept current and should contain, the dates and quantities of drug received, 
subject’s (identification number and/or initials or supply number as applicable), for 
whom the investigational product was dispensed, the date and quantity of investigational 
product dispensed and remaining, if from individual subject drug units as well as the 
initials of the dispenser.
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At the end of the study, or as directed, all medications supplied by the Sponsor, including 
any unused, partially used, and empty blisters and syringes will be destroyed at the site 
according to the site’s drug handling and disposition standard operating procedures 
(SOPs).  A copy of these SOPs must be available onsite.  The certificate of destruction 
must be provided to Daiichi Sankyo documenting the drug, the quantity (in tablets or 
syringes), method of destruction, and date of destruction. 
If sites are unable to destroy drug, the monitor will make arrangements to return drug to a 
designated depot for destruction.  
Medications provided by the Sponsor will be destroyed (or returned) only after the study 
monitor has completed an inventory to verify the quantity to be destroyed (or returned).  
The destruction (or return) of medications provided by the sponsor must be documented 
and the documentation filed (and if returned, included in the shipment).
5.2. Concomitant Medications
Pre-specified medications that the subject has taken within 30 days before randomization 
or during the study will be recorded in the “targeted concomitant medications” eCRF.  
These pre-specified medications taken by the subjects upon entry to the study or at any 
time during the study are regarded as targeted concomitant medications and must be 
documented on the appropriate pages of the eCRF.  If the subject has an endpoint event 
or an SAE, then information on targeted and non-targeted concomitant medications taken 
within the past 30 days must be documented on the appropriate eCRF pages.  
Concomitant therapy will be captured until the subjects completes the 12-month study 
period.
A list of specifically excluded medications is provided in Appendix 17.3.  The list reflects 
the list at the beginning of the study.  If there are changes to this list during the study, the 
changes will not be considered a protocol amendment but updated information.  It is 
strongly encouraged to restrict the dose of aspirin (if indicated) to ≤ 100 mg daily, 
although higher doses are permitted for strong clinical indication (eg, development of an 
acute MI).
5.3. Therapeutic Management of Subjects in Emergency Situations
5.3.1. Bleeding
There is no specific antidote to reverse the effect of edoxaban.  The following steps are 
recommended for subjects with ongoing life-threatening bleeding (bleeding resulting in 
hemodynamic compromise requiring intervention or any intracranial hemorrhage):
 Withhold study drug and all antiplatelets/anticoagulants;
 Institute standard of care for life-threatening bleeding (large bore IV or central 
venous line, type and crossmatch blood, admit to the intensive care unit, 
provide hemodynamic and respiratory support);
 Administer antidotes if applicable (eg, administer protamine if the subject had 
recently received heparin);
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 Administer packed red blood cells (or whole blood) as needed.
If life-threatening bleeding persists, it is recommended to contact the ITREAS Medical 
Support Line (+32 495 54 74 51) to discuss subject management.  Use of prothrombin 
complex concentrates (PCCs), recombinant Factor VIIa, other factor procoagulants, or 
antifibrinolytics (depending upon the clinical situation and local availability) should be 
considered in consultation with an expert and the ITREAS Medical Support Line.
5.3.2. Emergency Surgery
If an urgent surgical intervention is needed, anticoagulant therapy should be discontinued 
and the surgery should be deferred, if possible, until at least 12 hours and ideally 24 hours
after the last administration of anticoagulant therapy. There is no reversal agent for 
edoxaban. Protamine can be used to (partially) reverse the effect of LMWH. Depending 
upon the clinical situation and local availability, the use of factor procoagulants or other 
measures can be considered in case of the recent intake of edoxaban prior to the surgical 
procedure. It is recommended to consult the ITREAS Medical Support Line (+32 495 54 
74 51) in case of urgent surgery.
5.3.3. Suspected Recurrent VTE
In case of suspected recurrent VTE, the Investigator may decide to treat the subject 
according to the standard of care.
5.4. Therapeutic Management of Subjects for Planned Interventions
Given the half-life of both study medications and the interval of dosing (ie, once a day) it 
is advised to withhold the study medications at least 24 hours prior to the planned 
intervention. Study drug can be resumed upon complete hemostasis and after the 
assessment of the bleeding risk, ie, after 6 to 24 hours for most minor procedures and 
after 2-3 days for most surgical procedures that carry a bleeding risk. Antithrombotic 
therapy other than the study drug can be initiated, eg, a (prophylactic) dose of LMWH, 
according to the institutional best practice, until re-initiating dosing of the study drug is 
considered to be appropriate.
It is recommended to consult the ITREAS Medical Support Line (+32 495 54 74 51) in 
case of any further questions on the management of subjects who need a planned 
intervention.
5.5. Therapeutic Management of Subjects in Other Critical Situations
Other critical situations could be admission to hospital for acute medical illness or active 
periods of chemotherapy.  In these circumstances gastrointestinal disorders might 
preclude intake of oral therapy with edoxaban and bridging to LMWH is allowed 
according to the guidance in Appendix 17.2.  In case of doubt it is recommended to 
contact the ITREAS Medical Support Line (+32 495 54 74 51).
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5.6. Therapeutic Management of Subjects Beyond Month 12 and at Global 
End-of-Treatment
Subjects requiring additional anti-coagulation therapy who complete their treatment and 
full 12-month post randomization follow-up or whose treatment is truncated due to the 
global End of Treatment date will be managed according to local practice.
Guidance for switching from edoxaban to other anticoagulants is provided in Appendix 
17.2.
Additional guidance for long-term management of cancer subjects with VTE is provided 
by Lyman, et al.
1
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The Schedule of Study Procedures for this study is provided in Appendix 17.7.
6.1. Study Qualification/Pre-randomization
It is expected that most subjects will have had some or all of the study qualification 
procedures done as part of routine care outside the auspices of this study (for example, 
diagnostic work-up and associated care for VTE).  If these procedures are done prior to
randomization, they may be used to randomize the subject to study and begin completion 
of the eCRF, once the subject has signed the ICF.  The subject does not need to repeat 
recently completed procedures/tests for study qualification.  For such subjects it may be 
possible to combine the study qualification and randomization visits into a single visit.
Any protocol-specified study qualification procedures/tests not already done as part of 
routine care will be conducted only after the subject signs the ICF and before 
randomization.  Prior to signing the ICF, potential subjects will have the study risks and 
benefits explained to them, the associated ICF will be reviewed, and all questions 
answered for them.
The following study qualification procedures must be completed to ensure that the 
subject is eligible for the study.
 Sign ICF;
 Review inclusion/exclusion criteria, and ensure that the subject qualifies with 
regard to the clinical laboratory tests for exclusion criteria:
 Calculated CrCL < 30 mL/min;
 Platelet count < 50,000/mL
 Review concomitant medications for assessment of exclusion criteria;
 Ensure that the subject has a diagnosis of VTE confirmed by appropriate 
imaging methods;
The following imaging methods are typically considered part of routine hospital work-up 
for the management of VTE and/or cancer, and as such, will normally be obtained prior 
to informed consent as part of the subject’s normal standard-of-care.
o For a suspected symptomatic DVT:  compression ultrasonography (CUS), 
venography, or specific computerized tomography (CT) venography. 
o For unsuspected DVT:  a thrombus detected in the IVC or iliac veins on a 
(staging) abdominal or pelvic CT will be considered diagnostic. Because 
of potential flow artifacts and layering of contrast, a suspected thrombus 
detected in the common femoral vein or more distal can only be
considered if confirmatory CUS or (CT) contrast venography diagnostic 
criteria are also met.
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o For suspected symptomatic PE: Computerized tomographic pulmonary 
angiography (CTPA; also called spiral CT angiography [spiral CT]), 
ventilation perfusion scan (V/Q scan; if perfusion scan only is done a 
confirmatory test for leg DVT is required), or catheter pulmonary 
angiography. 
Note: A perfusion scan (without ventilation scan) does not qualify for the diagnoses of 
PE, unless concomitant DVT is documented.
o For an unsuspected PE: found during a staging-CT a repeat test is not 
recommended in order to limit radiation and contrast exposure. This 
incidental finding will only be considered diagnostic if the clot is in a 
segmental or greater artery, whereas clots in sub-segmental or more 
peripheral arteries will not be accepted due to risk of a false positive 
result.
 Record demographic information;
 Record medical/surgical history, including co-morbidities;
 Record description of cancer (date of diagnosis, type, (ie, histologically or 
cytologically diagnosed solid tumor), location or hematological malignancy, 
stage (eg, early, regionally advanced, metastatic), details on therapeutic 
management);
 Based on data completed in the eCRF it will be assessed whether subject 
meets the criteria for active cancer which will be defined as:
 Diagnosed with cancer within the past 6 months; or
 Recurrent, regionally advanced or metastatic disease; 
 Currently receiving treatment or have received any treatment for cancer 
during the 6 months prior to randomization; or
 A hematologic malignancy not in complete remission
Note:  Subjects not meeting these criteria will be categorized as history of cancer and 
then cancer should have been diagnosed within the 2 years preceding randomization.
 Perform physical examination including vital signs (sitting BP and heart rate) 
and record height and body weight (may be performed by an Investigator or 
other healthcare provider designated by the Investigator);
 Assess the subject for active bleeding, high risk for bleeding, and any other 
contraindications for treatment with LMWH or edoxaban.
Samples obtained as part of routine care outside study auspices may be analyzed by local 
laboratories and the results used to qualify the subject provided the tests were performed 
within 72 hours of randomization.  
Full documentation for the above study qualification procedures and related results are 
required, including local laboratory results used to qualify the subject.  Therefore, the
eCRF must be completed for every subject with a signed ICF.
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An index event dossier must be compiled, which includes copies of the diagnostic tests 
done to confirm the index VTE. The dossier will be reviewed by the CEC. Instructions 
for completing the dossier package will be provided in the outcome reporting manual. 
Due to logistical constraints, adjudication of index events will be performed after 
randomization; hence, the adjudicated result will not be used to qualify the subject for the 
study, but rather to subsequently define the outcome analyses sets.
The index event package must also contain copies of test reports confirming the subject’s 
cancer diagnosis.  The investigational site should ensure that any personal subject 
identification other than subject number and initials are removed from the index event 
dossier.
Based on the inclusion criterion that long term treatment with LMWH is intended to be 
given, it is expected that a large proportion of subjects will meet the criteria for active 
cancer.  Nevertheless, the percent of subjects with active cancer will be monitored during 
the study by a medical monitor who will report to the SMCC chair.  If necessary, the 
SMCC will take appropriate actions to ensure that the proportion of subjects with active 
cancer is sufficient (ie, > 75%) to draw valid conclusions in the active-cancer population
6.2. Day 1/Randomization
Before randomization, the Investigator will ensure that all protocol-specified 
pre-randomization requirements and procedures are met and/or completed.  For subjects 
who meet all the inclusion criteria and none of the exclusion criteria, the following will 
be performed on the day of randomization, prior to actual randomization.  
 Complete the IXRS Randomization Visit worksheet including review of 
subject’s age, bleeding risk profile, body weight, calculated CrCL, and 
concomitant medications;
 Record vital signs (sitting BP and heart rate) and weight;
 Assess and record ECOG Performance Status (see Appendix 17.6 for the 
ECOG performance scale);
 Collect serum sample for archiving by QLabs for later testing if necessary.  
Use the QLabs pre-dose Day 1 kit and ship the sample to QLabs;
 Record the following local laboratory results in the eCRF:
 Serum chemistry
 Total bilirubin (direct and indirect)
 Alanine transaminase (ALT)
 Aspartate transaminase (AST)
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 Hematology and platelet count
 Hematocrit  White blood cell (WBC) count with 
differential
 Hemoglobin  Platelet count
If all procedures and tests done before randomization confirm the subject's eligibility for 
the study, access the IXRS, register the subject for study qualification, and obtain the 
subject identification number.  
The following activities and/or assessments will be performed at/during randomization:
 Record AEs and treatments (drug and non-drug) given for AEs;
 Record prior medications taken within 30 days before randomization;
 Record date and time for Day 1 dose of study drug;
 Dispense study drug (dalteparin or edoxaban) and record amount (number of 
tablets and syringes) dispensed;
 Explain the study medications and the proper daily dosing to the subject using 
the study medication dosing calendar, and confirm that the subject 
understands the proper daily dosing of study medication, including when to 
stop LMWH and begin edoxaban dosing;
 Instruct subject to bring all medications including study drugs to each study 
visit;
 Provide subjects with a patient information booklet, which will contain the 
following information:
 The study outline in layman’s terms;
 The local medical contact person and emergency telephone number;
 The visit schedule provided by the IXRS (fax or email with dates of 
telephone and/or hospital visits);
 How to recognize and report signs and symptoms of possible recurrent 
symptomatic PE/DVT or bleeding;
 Instructions to keep empty medication packages;
 How to use the study medication.
 Provide subjects with a subject identification safety card and a prohibited 
medication card.
Investigators will maintain a confidential subject identification code list of names of all 
the subjects randomized to study to allow the Investigator to reveal the identity of any 
subject when necessary.
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The treatment period begins with the first dose of LMWH (dalteparin or other LMWH 
depending on randomized treatment assignment) after randomization and ends with the 
last dose of study drug at the time of permanent discontinuation of study drug.  During 
the treatment period, the subject will be instructed to bring all study drug supplies to each 
scheduled (every 3 months) study assessment.  Outcome and other event reporting (eg, 
VTE, bleeding, AEs) will be done throughout the study as soon as site personnel learn of 
the event.  Recording of AEs and treatments (drug and non-drug) given for AEs will be 
done throughout the study.
Subjects who permanently discontinue study drug will be followed for efficacy and safety 
outcomes and SAEs by visit or telephone contact at least once every 3 months until 
Month 12, except as noted in Section 3.1.2.1.  If the subject has an on-site visit, obtain 
vital signs and any laboratory assessments deemed appropriate by the Investigator.  
Ideally, all subjects should have their final EOT post-randomization visit completed in 
person either in-clinic or home visit.
6.3.1. Day 31 (± 3) Visit
At Day 31 following randomization, all subjects should be seen by qualified medical 
personnel for the following procedures:
 Record concomitant medications and any interruptions in chemotherapy 
treatment due to a VTE or bleed event;
 Assess study drug dosing compliance;
 Record any interruptions of edoxaban or dalteparin with the date of last dose 
and the date of the first dose of resumption of drug;
 Assess for AEs and outcome events;
 Capture healthcare resource utilization as appropriate;
 Assess ECOG performance status;
 Monitor and record hemoglobin/hematocrit, platelet counts, weight, serum 
creatinine, creatinine clearance, and P-gp inhibitor use and determine if a 
study drug dose adjustment is necessary;
 Dispense study medications and down-titrate dalteparin subjects to 
maintenance dose.
6.3.2. Months 3, 6, and 9 (± 7 days)
All subjects should be seen by qualified medical personnel for the following procedures:
 Record concomitant medications and any interruptions in chemotherapy 
treatment due to a VTE or bleed event;
 Assess study drug dosing compliance;
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 Record any interruptions of edoxaban or dalteparin with the date of last dose 
and the date of the first dose of resumption of drug;
 Assess for AEs and outcome events;
 Capture healthcare resource utilization as appropriate;
 Assess ECOG performance status;
 Monitor and record hemoglobin/hematocrit, platelet counts, weight, serum 
creatinine, creatinine clearance, and P-gp inhibitor use and determine if a 
study drug dose adjustment is necessary;
 Liver function test monitoring:
 Record (or collect a serum sample for) transaminase (ALT/AST), alkaline 
phosphatase, and bilirubin levels
 Dispense study medications.
6.4. End of Treatment/Month 12 (± 7 days)
All subjects should be seen by qualified medical personnel for the following procedures
at Month 12 or whenever study treatment is permanently discontinued.  Subjects 
permanently discontinuing study treatment before Month 12 will still be followed until 
Month 12 or the global EOT date whichever occurs first.
 Record concomitant medications and any interruptions in chemotherapy 
treatment due to a VTE or bleed event;
 Collect all unused study drug and review the dosing calendar, if one was used;
 Assess study drug dosing compliance;
 Record any interruptions of edoxaban or dalteparin with the date of last dose 
and the date of the first dose of resumption of drug;
 Count unused edoxaban tablets and dalteparin syringes and record in the 
IXRS drug accountability module;
 Assess for AEs and outcome events;
 Capture healthcare resource utilization as appropriate;
 Assess ECOG Performance Status;
 Update cancer status/stage;
 Liver Function Test monitoring:
 Record (or collect a serum sample for) transaminase (ALT/AST), alkaline 
phosphatase and bilirubin.
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The Investigator should conduct the study in compliance with the protocol agreed to by 
Sponsor and, if required, by the regulatory authority(ies), and which was given 
approval/favorable opinion by the IRB/IEC.
A deviation to any key protocol procedures, or waiver to any stated eligibility criteria will 
not be allowed except as noted below and where necessary to eliminate immediate 
hazard(s) to the subject.  
Subjects for whom experimental anticancer treatment is instituted after randomization to 
the cancer VTE trial will remain in the study and followed for 12 months or the global 
EOT date, whichever occurs first. The decision whether to discontinue the VTE study 
treatment will be at PI discretion according to local regulations.
Sponsor must be notified of any unintended deviations to the protocol (eg, 
inclusion/exclusion criteria, dosing, missed study visits).
The Investigator, or person designated by the Investigator, should document and explain 
any deviation from the approved protocol.
If a subject was ineligible or received the incorrect dose or investigational treatment, and 
had at least 1 administration of investigational product, data should be collected for safety 
purposes.
The Investigator should notify the IECs/IRBs of deviations from the protocol in 
accordance with local procedures.
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Subjects with suspected recurrent PE/DVT will undergo objective testing to assess 
the recurrent episode.  In subjects with bleeding additional examinations will be done 
if deemed necessary by the investigator (eg, hematology blood sample, diagnostic 
imaging/scoping). In subjects with other suspected outcomes such as death, 
cardiovascular events, or other thrombotic events the diagnostic work-up will be 
conducted according to the hospital routine.
For all suspected events an adjudication dossier must be prepared for shipment to the 
CEC. This dossier will contain the following documentation:  
 copies of all diagnostic imaging;
 the relevant adjudication worksheets;
 other clinically relevant notes/hospital letters/ laboratory reports/medical 
records.
Details regarding the definitions of the study outcomes and how they will be assessed are 
provided in the CEC Charter.  The requirements for testing and reporting are provided in 
the Outcome Reporting Manual and will be provided to all sites.
7.1. Primary Outcome Variable(s)
The primary study outcome is the composite of recurrent VTE and major bleeding.
Recurrent VTE is either: 
 symptomatic confirmed (new) DVT or (new) PE;
 unsuspected (new) proximal DVT
 Unsuspected DVT is a DVT coincidentally detected during other 
investigations (eg, abdominal or pelvic CT for cancer staging).  This DVT 
will only be included as an outcome if it concerns a (new) clot located in 
the popliteal or more proximal leg veins.  A thrombus detected in the IVC 
or iliac veins on an abdominal or pelvic CT does not require additional 
confirmation. A thrombus detected in the common femoral vein or more 
distal veins can only be confirmed if CUS (or venography) diagnostic 
criteria are also met.
 unsuspected (new) PE;
 unsuspected PE is an embolism coincidentally detected during other 
investigations (eg, CT for cancer staging), that involves segmental or more 
proximal pulmonary arteries.
 fatal PE (including unexplained death for which PE cannot be ruled out).
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Major bleeding is defined as overt bleeding and:
 associated with a decrease in hemoglobin of ≥ 2 g/dL, or
 leading to a transfusion of ≥ 2 units of packed red blood cells or whole blood,
or 
 occurring in a critical site: intracranial, intraspinal, intraocular, pericardial, 
intra-articular, intramuscular with compartment syndrome, retroperitoneal, or
 contributing to death.
7.2. Secondary Outcome Variable(s)
Secondary outcome variables include:
 Recurrent VTE;
 Major bleeding;
 CRNM bleeding; 
 Major + CRNM bleeding;
 Event-free survival, defined as the proportion of subjects over time free of 
recurrent VTE, major bleeding events, and death;
 VTE -related death;
 Mortality from all causes;
 Recurrent DVT;
 Recurrent PE;
 Healthcare resource utilization for potential recurrent VTE and bleed events.
7.3. Other Outcome Variable(s)
Other outcome variables include:
 Cardiovascular events (myocardial infarction, stroke, SEE [see 
Appendix 17.5.1]);
 Thrombotic events at other locations (see Appendix 17.5.2);
 Reason for permanent early discontinuation of study drug.
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8.1. Pharmacokinetic (PK) Variable(s)
Not applicable.
8.2. Pharmacodynamic (PD) Variable(s)
Not applicable.
8.3. Biomarker and Exploratory Variable(s)
Not applicable.
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This study will follow a targeted approach to AE and SAE reporting.  All AEs occurring 
after the subject signs the ICF and through Month 12 or the global EOT date, whichever 
occurs first (see Sections 4.2.2.1 and Section 6.4 ), whether observed by the Investigator 
or reported by the subject, will be recorded on the Master Event/AE page of the CRF if 
they fulfill 1 of the following criteria: 1) meet seriousness criteria (see Section 9.4.2); 2) 
result in interruption or discontinuation of study drug (edoxaban or dalteparin); 3) meet 
criteria as a study outcome (see Section 3.1.4); or 4) an event of special interest (see 
Section 9.3).
All laboratory, vital sign, or electrocardiogram (ECG) values should be evaluated by the 
Investigator regarding clinical significance.  Isolated abnormal laboratory results or vital 
sign findings or ECG findings should be reported as AEs if they are symptomatic, result 
in study drug discontinuation, require corrective treatment, or are otherwise defined as an 
AE of special interest (AESI).  Clinically significant abnormal laboratory findings 
associated with the subject’s cancer or other pre-existing conditions will not be reported
as AEs or SAEs unless judged by the Investigator as more severe than expected for the 
subject’s condition and meet the criteria for targeted AE and SAE reporting.  Medical 
conditions (including laboratory values/vital signs that are out of range) that were 
diagnosed or known to exist prior to informed consent will be recorded as part of medical 
history.  All SAEs are to be reported according to the procedures in Section 9.5 Serious 
Adverse Event Reporting-Procedure for Investigators.  
All SAEs occurring after informed consent for general study participation is obtained are 
to be reported according to the procedures in Section 9.5.  Always report the diagnosis as 
an AE or SAE term.  When a diagnosis is unavailable, report the primary sign or 
symptom as the AE or SAE term with additional details included in the narrative until the 
diagnosis becomes available.  If the signs and symptoms are distinct and do not suggest a 
common diagnosis, report them as individual entries of AE or SAE.  For events that are 
serious due to hospitalization, the reason for hospitalization must be reported as the 
serious adverse event (diagnosis or symptom requiring hospitalization).  A procedure is 
not an AE or SAE, but the reason for the procedure may be an AE or SAE.  A pre-
planned (prior to signing the Informed Consent Form) procedure or treatment requiring 
hospitalization for pre-existing conditions which do not worsen in severity should not be 
reported as SAEs (see Section 9.4.2 for Definitions).  For deaths, the underlying or 
immediate cause of death should always be reported as an SAE. When a subject dies 
from disease progression of pre-existing cancer with no other immediate causes, “disease
progression” should be reported as an SAE.  In addition, any serious, untoward event that 
may occur subsequent to the reporting period that the Investigator assesses as related to 
study drug should also be reported and managed as an SAE.
At each visit, the Investigator or appropriately qualified designee will determine whether 
any AEs have occurred by evaluating the subject.  Adverse events may be directly 
observed, reported spontaneously by the subject or by questioning the subject at each 
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study visit.  Subjects should be questioned in a general way, without asking about the 
occurrence of any specific symptoms.  The Investigator must assess all AEs to determine 
seriousness, severity, and causality, in accordance with the definitions in Section 9.4. 
The Investigator’s assessment must be clearly documented in the site’s source 
documentation with the Investigator’s signature.  
Investigator should follow subjects with AEs until the event has resolved or the condition 
has stabilized.  In case of unresolved AEs including significant abnormal laboratory 
values at the end of study assessment, these events will be followed up until resolution or 
until they become clinically not relevant.
9.2. Safety Outcomes
9.2.1. Bleeding Outcomes
All suspected bleeding events, irrespective of the clinical relevance assessed by the 
Investigator, must be reported and will be reviewed and classified by the CEC as major, 
clinically relevant non major, nuisance or no bleeding event.  
Details regarding the classification of bleeding events and how these events will be 
assessed are provided in the CEC Charter.  The requirements for reporting bleeding 
events are provided in the Outcome Reporting Manual and will be provided to all study 
sites.  
9.3. Events of Special Interest
9.3.1. Combined Elevations of Aminotransferase and Bilirubin
There was no clinically concerning signal of drug-induced liver injury associated with 
edoxaban based on the extensive global Phase 3 experience involving over 34,100 
edoxaban subject-years exposure (with median drug exposure of ~2.5 years among 
~14,000 edoxaban subjects). However, there will be ongoing monitoring of hepatic 
events, including combined elevations of aminotransferases and bilirubin (ALT or AST >
3 x ULN with simultaneous TBL > 2 x ULN), particularly without evidence of 
cholestasis (ALP > 2 x ULN is considered evidence of possible cholestasis) and without 
alternative etiology for hepatocellular damage. 
Combined elevations of aminotransferases and bilirubin, either serious or non-serious and 
whether or not causally related, should always be reported to the Sponsor as soon as 
possible following the procedures outlined in Section 9.5 for SAE reporting.
In cases of liver laboratory abnormalities, or evidence of liver dysfunction, it is important 
to ensure that the nature and the extent of liver injury is identified and study subjects are 
monitored until the liver laboratory assessments return to normal. (Please refer to Section 
4.2.2.1).
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9.4.1. Adverse Event (AE)
Any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a 
causal relationship with this treatment.  An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding, for example), symptom, or 
disease temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product (ICH E2A Guideline.  Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting, Oct 1994).
It is the responsibility of Investigators, based on their knowledge and experience, to 
determine, those circumstances or abnormal laboratory findings which should be 
considered adverse events.
9.4.2. Serious Adverse Event (SAE)
Any untoward medical occurrence that at any dose:
 Results in death;
 Is life-threatening;
 Requires inpatient hospitalization or prolongation of existing hospitalization;
 Results in persistent or significant disability/incapacity;
 Is a congenital anomaly/birth defect; or
 Is an important medical event.
Note: The term “life-threatening” in the definition of “serious” refers to an event in 
which the subject was at risk of death at the time of the event; it does not refer to an event 
which hypothetically might have caused death if it were more severe (ICH E2A 
Guideline.  Clinical Safety Data Management: Definitions and Standards for Expedited 
Reporting, Oct 1994).
Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is appropriate in other situations, such as important medical events that may not 
be immediately life-threatening or result in death or hospitalization but may jeopardize 
the subject or may require intervention to prevent one of the other outcomes listed in the 
definition above.  Examples include allergic bronchospasm, convulsions, and blood 
dyscrasias or development of drug dependency or drug abuse.
Note:
The following are not considered AEs or SAEs:
 Hospitalization for a pre-planned procedure or diagnostic tests (including for 
cancer staging, eg, CT scan, Magnetic Resonance Imaging, gastroscopy, 
cystoscopy, bronchoscopy, etc) or treatment for pre-existing conditions (eg, 
chemotherapy, radiation therapy) should NOT be reported as SAEs;
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 Hospitalization for diagnostic work-up or treatment of worsening underlying 
cancer or complications of cancer treatment (eg, work-up for febrile 
neutropenia, transfusion for anemia, MUGA scan to rule out cardiomyopathy) 
should NOT be reported as SAEs.
9.4.3. Adverse Event Severity
The following definitions should be used to assess intensity of AEs per the NCI CTCAE 
criteria:
 Grade 1 Mild AE
 Grade 2 Moderate AE
 Grade 3 Severe AE
 Grade 4 Life-threatening consequences; urgent intervention indicated
 Grade 5 Death related to AE
9.4.4. Causality Assessment
The Investigator should assess causal relationship between an adverse event and the study 
product LMWH/edoxaban on the basis or his/her clinical judgment and the following 
definitions.  The causality assessment should be made based on the available information 
and can be updated as new information becomes available.
 1 = Related:
 The AE follows a reasonable temporal sequence from study drug 
administration, and cannot be reasonably explained by the subject’s 
clinical state or other factors (eg, disease under study, concurrent diseases, 
and concomitant medications).
 The AE follows a reasonable temporal sequence from study drug 
administration, and is a known reaction to the drug under study or its 
chemical group, or is predicted by known pharmacology.
 2 = Not Related:
 The AE does not follow a reasonable sequence from study product 
administration, or can be reasonably explained by the subject’s clinical 
state or other factors (eg, disease under study, concurrent diseases, and 
concomitant medications).
9.4.5. Action Taken Regarding the Study Product
 1 = Dose Not Changed: No change in study drug dosage was made.
 2 = Drug Withdrawn: The study product was permanently stopped.
 3 = Dose Reduced: The dosage of study product was reduced.
 4 = Drug Interrupted: The study product was temporarily stopped.
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 5 = Dose Increased: The dosage of study product was increased.
9.4.6. Adverse Event Outcome
 1 = Recovered/Resolved
 The subject fully recovered from the adverse event with no residual effect 
observed.
 2 = Recovered/Resolved with Sequelae
 The residual effects of the adverse event are still present and observable.
 Include sequelae/residual effects.
 3 = Not Recovered/Not Resolved
 The adverse event itself is still present and observable.
 4 = Fatal
 5 = Unknown
9.4.7. Other Action Taken for Event
 1 = None.
 No treatment was required.
 2 = Medication required.
 Prescription and/or over-the-counter medication was required to treat the 
adverse event.
 3 = Other.
9.5. Serious Adverse Event Reporting–Procedure For Investigators
All AEs, SAEs, AESIs, and study outcomes will be captured in the eCRF. 
Study outcomes are clinically anticipated events and will be periodically reviewed by the 
DMC to ensure prompt identification of any clinically concerning safety issues. Study 
outcomes (suspected recurrent DVT or PE, bleeding, MI, stroke, SEE [see Appendix
17.5.1], and thrombotic events at other locations [see Appendix 17.5.2]) will be exempted 
from expedited safety reports of suspected unexpected serious adverse reactions
(SUSARs) to regulatory authorities, Investigators, IECs, and IRBs.  All SAEs resulting in 
death, regardless of whether they are waived endpoint events, will be captured in the 
Sponsor’s global safety database.
The following types of events should be reported by the Investigator in eCRF within 24 
hours of awareness to support expedited safety reporting:
 SAEs (see Section 9.4.2 for definition)
 Liver enzyme abnormalities/liver dysfunction events [ALT or AST > 3x ULN 
with simultaneous TBL > 2 x ULN] without evidence of cholestasis (ALP > 2 
Protocol DU176b-D-U311
Version 1.0, 15 Dec 2014
Proprietary & Confidential
Page 66
x ULN) and without alternative etiology for hepatocellular damage (both 
serious and non-serious).
Call Quintiles (telephone number will be provided per country, per region; please refer to 
Study Manual for an appropriate phone number) for any questions on SAE reporting. 
Urgent safety queries must be followed up and addressed promptly.  Follow-up 
information and response to non-urgent safety queries should be combined for reporting 
to provide the most complete data possible within each follow-up.
In the event that eCRF is unavailable, report SAEs by faxing the paper Daiichi Sankyo 
Serious Adverse Event Report (SAVER) Form to Quintiles using the provided fax cover 
sheet and the appropriate fax number provided for your country (please refer to Study 
Manual for an appropriate fax number).  Once eCRF becomes available, please enter 
SAEs reported on the SAVER Form into eCRF as soon as possible.
9.5.1. Notifying Regulatory Authorities, Investigators, and IRB/IEC
Daiichi Sankyo and/or Quintiles will inform Investigators, IRBs (Institutional Review 
Board)/ECs, and regulatory authorities of any Suspected Unexpected Serious Adverse 
Event Reactions (SUSARs) occurring in other study centers or other Daiichi Sankyo 
studies of the investigational product (excluding waived study outcomes per Section 9.5), 
as appropriate per local reporting requirements.
In the US, upon receipt of the Sponsor’s notification of SUSARs that occurred with the 
investigational product, unless delegated to the Sponsor, it is the Investigator’s 
responsibility to inform the IRB per Sponsor’s instruction.
In the European Economic Area (EEA) states, it is the Sponsor’s responsibility to report
SUSARs to all ECs.
9.6. Exposure In Utero During Clinical Studies
Daiichi Sankyo must be notified of any subject who becomes pregnant while receiving 
investigational product and through Month 12 or the global EOT date, whichever occurs 
first, or, within 30 days of last dose if it occurred less than 30 days of the global EOT 
date. 
Although pregnancy is not technically an adverse event, all pregnancies must be followed 
to conclusion to determine their outcome.  This information is important for both drug 
safety and public health concerns.  It is the responsibility of the Investigator, or designee, 
to report any pregnancy in a female subject using the Exposure In Utero (EIU) Reporting 
form.  Please contact your study monitor to receive the EIU Reporting form upon
learning of a pregnancy.  The Investigator should make every effort to follow the subject 
until completion of the pregnancy.  If the outcome of the pregnancy meets the criteria for 
immediate classification as a SAE (ie, post-partum complications, spontaneous abortion, 
stillbirth, neonatal death, or congenital anomaly, including that in an aborted fetus), the 
Investigator should follow the procedures for reporting SAEs outlined in Section 9.5.  
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9.7. Clinical Laboratory Evaluations
Local laboratory results and reference ranges for the analytes outlined in Sections 6.2, 
6.3.1, 6.3.2, and 6.4 will be recorded in the eCRF.
9.8. Vital Signs
Vital sign data will consist of heart rate, BP, and height.  Weight will also be recorded in 
order to make determinations regarding study drug dose adjustments.
9.9. Electrocardiograms
Routine ECGs are not required but will be recorded in the eCRF when appropriate.
9.10. Physical Findings
A physical examination, conducted prior to or at the time of randomization by the 
Investigator or other qualified health care provider designated by the Investigator, will 
consist of assessment of each of the relevant major body systems.
9.11. Other Safety Assessments
Other safety assessments will be conducted as necessary.
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11.1.1. Randomized Analysis Set
The randomized analysis set includes all subjects randomized to treatment.
11.1.2. Modified Intention-to-Treat Analysis Set




11.1.3. Per-Protocol Analysis Set
The Per-Protocol (PP) Analysis Set includes all randomized subjects who receive at least 
1 dose of study drug, who have not experienced treatment misallocation, and for whom 
the index DVT or PE event at baseline was confirmed by the CEC.  Treatment 
misallocation is defined as a subject taking incorrect treatment during the entire study 
period.
11.1.4. Safety Analysis Set
The Safety Analysis Set includes all randomized subjects who receive at least 1 dose of 
randomized study drug.  Analyses will be based on the randomized treatment, unless a 
subject inadvertently receives the incorrect drug during the entire study, in which case, 
the subject will be grouped according to the treatment actually received.
11.2. General Statistical Considerations
The efficacy analyses will be based on the mITT and PP Analysis sets.
The safety analyses will be based on the Safety Analysis Set.
The data analysis will be performed by a CRO under the guidance of the study 
biostatistician.  Data analyses will be performed using software SAS Version 8.0 or 
higher.
11.3. Study Population Data
The number of subjects in each analysis set will be presented by treatment group.  
Subjects excluded from the analysis sets will be listed and summarized by treatment 
group and reason for exclusion.  The number and percentage of randomized subjects who 
discontinued treatment prematurely will be tabulated by main reason for discontinuation 
and treatment group.  Demographic and baseline characteristics (including risk factors) 
will be summarized by treatment group using descriptive statistics.  No statistical tests 
will be performed.
                                                
1
Study drugs include the LMWH prescribed by the PI as the edoxaban lead-in, edoxaban, and dalteparin.
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11.4.1. Primary Outcome Analyses
The primary outcome analysis will be based on the mITT Analysis Set.  In this analysis,
the time to the first event of the composite primary outcome (recurrent VTE
[symptomatic recurrent DVT, non-fatal symptomatic recurrent PE, unsuspected PE, fatal-
PE] or major bleed) will be analyzed using a Cox’s proportional hazard model including 
treatment group, and the stratification factors as covariates.  The time to first event is 
defined as the time (days) from the day of randomization to the first event experienced by 
a subject during the 12-month study period.  Subjects who do not have a primary 
outcome during the 12-month study period will be censored at Day 365, or the last day 
the subject had a complete assessment for study outcomes, or the global EOT date, 
whichever comes first.  Subjects lost to follow-up, subjects who died because of reasons 
other than DVT/PE, or subjects who withdrew informed consent before the end of the 12-
month treatment period and who did not have a primary outcome, will be censored at the 
last day the subject had a complete assessment for study outcomes.  The 
LMWH/edoxaban-to-comparator Hazard Ratio will be computed with 95% CI (two-sided 
testing), based on this model.  LMWH/edoxaban will be considered non-inferior to 
comparator if the upper limit of the CI is < 1.5.
The assumption of proportional hazards will be checked using graphical methods as log
(log)-plots and plots of scaled Schoenfeld residuals for the primary analysis.  If the 
assumption is seriously violated, then a logistic model including treatment group and the 
stratification factors as covariates will be used.  The impact of selected baseline 
covariates on the primary outcome will be described by calculating adjusted Hazard 
Ratios and corresponding 95% CI of the treatment effect.  
The frequencies of the each components contributing to the primary outcome will be 
described.
The following sensitivity analyses will be performed for the Primary Outcome:
 On-Treatment events based on the PP Analysis Set will be analyzed using the 
counting process approach of the Cox proportional hazards regression model 
including treatment group, and the stratification factors as covariates.    An 
On-Treatment event is defined as the event occurring during the time period 
the subject is taking study drug up to 3 days after their last dose for that time 
period.  Only events occurring prior to or on Day 365 will be included into 
this analysis. Subjects who do not experience an On-Treatment event will be 
censored at Day 365, or the time study drug is permanently discontinued plus 
3 days or on the last day the subject had a complete assessment (in-person 
visit or by telephone) for study outcomes, or the day of global end of 
treatment, whichever comes first. 
 Events occurring during the first 6 months (180 days) based on the mITT
Analysis Set will be analyzed using the same statistical model as the primary 
analysis of the primary outcome. The time to event is defined as the time 
(days) from the randomization to the first event during the first 6 months after 
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randomization.  Subjects who do not experience an event until Day 180 will 
be censored at Day 180, or the time study drug is permanently discontinued or 
on the last day the subject had a complete assessment (in-person visit or by 
telephone) for study outcomes, whichever comes first.
11.4.2. Superiority Analysis of the Primary Outcome
If non-inferiority in the primary outcome is established, LMWH/edoxaban will be 
compared to dalteparin for superiority (α=0.05, two-sided) with regard to the time to an 
event in the composite clinical outcome of recurrent VTE (symptomatic recurrent DVT, 
non-fatal symptomatic recurrent PE, unsuspected PE, and fatal-PE) or major bleed during 
the 12-month study period.  This analysis will be based on the mITT Analysis Set using 
the same proportional hazard model as for the primary outcome.
11.4.3. Secondary Efficacy Outcome Analyses
Summary statistics will be provided for following efficacy outcomes:
 recurrent VTE;
 event-free survival, the proportion of subjects over time free of recurrent 
VTE, major bleeding events, and death;
 VTE -related death;
 recurrent DVT;
 recurrent PE.  
The impact of cancer status on the primary outcome will also be assessed.




All safety analyses will be performed on the Safety Analysis Set.
11.6.1. Analysis of the Primary Safety Outcome
The primary analysis of the primary safety outcome is based on an “On-Treatment” 
approach.  The “on-treatment” major bleeding events will be compared between 
treatment groups for superiority (α=0.05, two-sided) for subjects in the Safety Population, 
using the counting process approach of the Cox proportional hazards regression model 
including treatment group, and the stratification factors as covariates.  However, subjects 
will be censored 3 days after the day of permanent study medication discontinuation.
11.6.2. Analysis of Secondary Safety Outcomes
Incidence and Hazard Ratio (with 95% CI) for the following outcomes will be calculated 
based on the Safety Analysis Set and On-Treatment-approach using the same counting 
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process approach of the Cox proportional hazards regression model as for the primary 
safety outcome analysis:
 Major bleeding;
 Clinically relevant non-major bleeding;
 Major + clinically relevant non-major bleeding;
 Mortality from all causes.
Healthcare resource utilization for potential recurrent VTE and bleeding events will be 
analyzed separately.
11.6.3. Exploratory Analyses for Safety Outcomes
The incidence of cardiovascular events (myocardial infarction, stroke, SEE) and 
thrombotic events at other locations will be summarized by treatment.
The reason for permanent early discontinuation of study drug will be summarized by 
treatment group.
Details are specified in the SAP.
11.6.4. Adverse Event Analyses
Adverse events will be coded according to the Medical Dictionary for Regulatory 
Activities (MedDRA).
Any AE that occurs during the study is a study AE.  Treatment-emergent adverse events 
(TEAEs) are defined as an event that emerges during treatment having been absent 
pre-treatment, or worsens relative to the pre-treatment state.  The incidence of TEAEs 
will be presented for the Safety Analysis Set by treatment group, by relationship to the 
study drug, and by severity.  Frequent TEAEs (reported by at least 5% of subjects in any 
treatment group) will be summarized by treatment group.  Adverse events that start or 
worsen after the third day following the calendar date of any “last dose” and before the 
date of the next “first dose” are defined as post-treatment AEs.  Because a subject can 
have study drug interruptions, it will be possible to have a post-treatment AE that occurs 
at an earlier calendar date than a TEAE.
The incidence of death, SAEs, drug-related SAEs, and AEs leading to discontinuation of 
study drug will be summarized by treatment group.  All AEs will be included in a data 
listing and a listing to display the coding of AEs will be prepared as well.
11.6.5. Clinical Laboratory Evaluation Analyses
The clinical laboratory evaluations at each scheduled visit and the change from baseline 
will be summarized for the Safety Analysis Set by treatment group.  Shift tables (low, 
normal, and high) will be provided for each treatment group for selected clinical
laboratory parameters.  The number and percentage of subjects with clinically relevant 
abnormal clinical laboratory values while on study drug will be calculated for each 
treatment group for selected clinical laboratory parameters.  All abnormal clinical
laboratory values will be presented in a listing.  
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11.6.6. Vital Sign Analyses
Vital signs at each evaluation point and the change from baseline will be summarized for 
the Safety Analysis Set by treatment group.  The number and percentages of subjects 
with abnormal vital signs while on study drug will be summarized by treatment group.
11.6.7. Physical Finding Analyses
Abnormalities in physical examinations by body system will be listed.
11.7. Other Analyses
11.8. Interim Analyses
No formal interim analysis is planned.  Risk-benefit will be evaluated by the DMC, 
which will give recommendations on a regular basis to the Executive Committee.  Access 
to interim tabular risk-benefit data will be restricted.  The procedures of the DMC will be 
described in its charter.
11.9. Data and Safety Monitoring Board
An independent DMC will be created to further protect the rights, safety, and well-being 
of subjects who will be participating in this study.  The DMC will be composed of 
qualified scientists, who are not Investigators in the study and not otherwise directly 
associated with the Sponsor.  The DMC will be described in detail in the DMC Charter.
Activities of the DMC will be documented.  This documentation will include data 
summaries and analyses provided to the committee as well as minutes of the meeting.  
The DMC can recommend study or treatment regimen/group termination to the Executive 
Committee based on pre-specified concerns described in the DMC Charter.
11.10. Subgroup Analyses for Efficacy and Safety
Exploratory subgroup analyses, relative to primary study outcomes and key safety 
outcomes may include, but are not limited to, treatment group comparisons within subject 
characteristics (age, gender, geographic region, dose adjustment) as described in the SAP.
11.11. Sample Size Determination
Assuming a hazard ratio of 1, a total of 191 overall primary events are projected to accrue 
in the mITT analysis set which will ensure at least 80% power for the primary analysis at 
a non- inferiority margin for the hazard ratio of 1.5 and a Type I error of 0.05 (two-
sided).
Assuming a primary combined outcome rate (recurrent VTE or major bleed) of 20.0%, a 
total of 1000 subjects are expected to be randomized to study treatment in order to accrue 
191 overall primary events in the mITT analysis set.
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12. DATA INTEGRITY AND QUALITY ASSURANCE
The Investigator/investigational site will permit study-related monitoring, audits, 
IEC/IRB review and regulatory inspections by providing direct access to source 
data/documents.  Direct access includes permission to examine, analyze, verify, and 
reproduce any records and reports that are important to the evaluation of a clinical study.
This study will utilize Quintiles Data-driven Trial Execution (DTE), which is Quintiles 
model for risk-based monitoring. 
Quintiles’ DTE and Daiichi Sankyo will begin with a risk assessment to evaluate the 
scientific and operational risks of the study. During this risk assessment key data points 
for the study will be identified and the optimum method for monitoring (eg, remote, on-
site, and/or centralized monitoring processes) each key data point will be determined.  
Key data points are data items that are critical to study analysis, indicate if the objectives 
of the study have been met, support patient safety, and/or are deemed as a priority for 
monitoring.
12.1. Monitoring and Inspections
The Quintiles monitor and regulatory authority inspectors are responsible for contacting 
and visiting the Investigator for the purpose of inspecting the facilities and, upon request, 
inspecting the various records of the study (eg, eCRFs, source data, and other pertinent 
documents).
The monitor is responsible for conducting both onsite and remote monitoring visits 
throughout the study to verify adherence to the protocol; completeness, accuracy, and 
consistency of the data; and adherence to ICH GCP and local regulations on the conduct 
of clinical research.  The frequency of monitoring visits will be dependent on the 
activities at the site. At a minimum the monitor will visit active sites on an annual basis. 
The monitor is responsible for inspecting the eCRFs and ensuring completeness of the 
study essential documents.  The monitor is responsible for inspecting the eCRFs and 
ensuring completeness of the study essential documents.  The monitor should have access 
to subject medical records and other study-related records needed to verify the entries on 
the eCRFs.
Transcription-Based source data verification (SDV) is a strategic monitoring task that 
will be used to detect transcription errors between the source documents and the eCRF. 
SDV will be performed on 100% of data for a sample of enrolled subjects at each site. 
The sample size may be increased where issues are identified. 
Source data review (SDR) is an on-site monitoring process in which source 
documentation is reviewed to ensure that the site’s process for documenting source notes 
is appropriate and that the site is adhering to the requirements of the protocol. The SDR 
will be performed on the same subjects as SDV. The SDR may be performed on 
additional subjects where issues are identified.
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The monitor will communicate deviations from the protocol, SOPs, GCP and applicable 
regulations to the Investigator and will ensure that appropriate action designed to prevent 
recurrence of the detected deviations is taken and documented.
The Investigator agrees to cooperate with the monitor to ensure that any problems 
detected in the course of these monitoring visits are addressed and documented.
Monitoring triggers consisting of essential operational data elements will be used to 
assess site performance, data quality, and patient safety. Monitoring triggers may 
independently trigger a site contact or monitoring visit.
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected 
for audit by representatives from Sponsor.  Inspection of site facilities (eg, pharmacy, 
drug storage areas, laboratories, etc) and review of study related records will occur in 
order to evaluate the study conduct and compliance with the protocol, ICH GCP, and 
applicable regulatory requirements.
12.2. Data Collection
The eCRF completion and query resolution should be kept current to enable the monitor 
to review the subject’s status throughout the course of the study and to enable review of 
the data by Clinical Data Management.
12.3. Data Management
Each subject will be identified in the database by a unique subject identifier as defined by 
the sponsor.
To ensure the quality of clinical data across all subjects and sites, two levels of review 
will be performed:
The first level review will comprise of traditional data management review. The second 
level review is a manual check for clinical congruency of the data.
Both the first and second levels of the Clinical Data Management review will be 
performed on subject data according to specifications agreed by Sponsor and CRO.  Data 
will be vetted both electronically and manually; eCRFs data will be electronically vetted 
by programmed data rules within the Electronic Data Capture (EDC).  Queries generated 
by rules and raised by reviewers will be generated and resolved within the EDC 
application.  During these reviews, subject data will be checked for consistency, 
omissions, and any apparent discrepancies.  To resolve any questions arising from the
Clinical/Data Management review process, eCRFs queries will be raised and resolved 
within the EDC application. 
Data received from external sources such as central laboratories will be reconciled to the 
clinical database.
Serious AEs in the clinical database will be reconciled with the safety database.
All Adverse Events and medical history entries will be coded using MedDRA. 
Concomitant medications, when necessary, will be coded using the World Health 
Organization Drug Reference (WHODRUG) List.  
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12.4. Study Documentation and Storage
The Investigator will maintain a Signature List of appropriately qualified persons to 
whom he/she has delegated study duties.  All persons authorized to make entries and/or 
corrections on eCRFs will be included on the Signature List.
Source documents are original documents, data, and records from which the subject’s 
eCRF data are obtained.  These include but are not limited to hospital records, clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, X-rays, and 
correspondence.
The Investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system (Trial Master File) of all study-related (essential) 
documentation, suitable for inspection at any time by representatives from the Sponsor
and/or applicable regulatory authorities.  Essential documents include:
 Subject files containing completed eCRFs, informed consents, and supporting 
copies of source documentation (if kept).
 Study files containing the protocol with all amendments, Investigator’s 
Brochure, copies of relevant essential documents required prior to 
commencing a clinical study, and all correspondence to and from the IEC/IRB 
and the Sponsor.
 Records related to the Investigational Product(s) including acknowledgment 
of receipt at site, accountability records and final reconciliation and applicable 
correspondence.
In addition, all original source documents supporting entries in the eCRFs must be 
maintained and be readily available.
12.5. Record Keeping
Records of subjects, source documents, monitoring visit logs, data correction forms, 
eCRFs, inventory of study product, regulatory documents (eg, protocol and amendments, 
IRB/EC correspondence and approvals, approved and signed informed consent forms, 
Investigator’s Agreement, clinical supplies receipts, distribution and return records), and 
other sponsor correspondence pertaining to the study must be kept in appropriate study 
files at the site.  Source documents include all recordings and observations or notations of 
clinical activities and all reports and records necessary for the evaluation and 
reconstruction of the clinical study.  These records will be retained in a secure file for the 
period required by the institution or site policy.  Prior to transfer or destruction of these 
records, the Sponsor must be notified in writing and be given the opportunity to further 
store such records.
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13. FINANCING AND INSURANCE
13.1. Finances
Prior to starting the study, the Principal Investigator and/or institution will sign a clinical 
study agreement with Quintiles. This agreement will include the financial information 
agreed upon by the parties.
13.2. Reimbursement, Indemnity, and Insurance
Reimbursement, indemnity and insurance shall be addressed in a separate agreement on 
terms agreed upon by the parties.
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A site may not publish results of a study until after a coordinated multicenter publication 
has been submitted for publication or until 1 year after the study has ended, whichever 
occurs first.  Therefore, the site will have the opportunity to publish the results of the 
study, provided that Daiichi Sankyo has had the opportunity to review and comment on 
the site’s proposed publication prior to its being submitted for publication with the prior 
advice of Daiichi Sankyo Legal Affairs (intellectual property council) and with proper 
regard to the protection of subjects’ identities.
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15. STUDY ADMINISTRATIVE INFORMATION
15.1. Protocol Amendments
Any amendments to the study protocol that seem to be appropriate as the study 
progresses will be communicated to the Investigator by the Sponsor.  All protocol 
amendments will undergo the same review and approval process as the original protocol.  
A protocol amendment may be implemented after it has been approved by the IRB/EC, 
unless immediate implementation of the change is necessary for subject safety.  In this 
case, the situation must be documented and reported to the IRB/EC within 5 working 
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17.1. Additional Information on Investigational Products
17.1.1. Fragmin Package Insert
The Fragmin (dalteparin) package insert can be accessed at the following link: 
http://www.medicines.org.uk/emc, then typing Fragmin in the search field.
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17.2. Transition from Edoxaban to Other anticoagulants
17.2.1. Edoxaban to VKA
Discontinue edoxaban and administer a parenteral anticoagulant and VKA at the time of 
the next scheduled edoxaban dose.  Once a stable INR ≥ 2.0 is achieved, the parenteral 
anticoagulant must be discontinued and the VKA continued.
17.2.2. Edoxaban to non-VKA Oral Anticoagulants
Discontinue edoxaban and start the non-VKA anticoagulant at the time of the next 
scheduled dose of edoxaban.
17.2.3. Edoxaban to Parenteral Anticoagulants
Discontinue edoxaban and start the parenteral anticoagulant at the time of the next 
scheduled dose of edoxaban.
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17.3. Prohibited Concomitant Medications
Specifically excluded concomitant medications and cautions regarding other concomitant 
medications are provided below.  The list in this appendix reflects exclusionary 
concomitant medications at the beginning of the study.  If there are changes to this list 
during the study, the changes will be provided as an update to this appendix, but will not 
be considered a protocol amendment.
17.3.1. Antiplatelet Drugs
Dual antiplatelet therapy (any 2 antiplatelet agents including aspirin plus any other oral or 
IV antiplatelet drug) is prohibited while on study drug.  If a clinical indication for dual 
antiplatelet therapy arises after randomization (eg, placement of an intracoronary stent), 
study drug should be interrupted and use of open-label LMWH/VKA is permitted at the 
physician’s discretion.
Use of any antiplatelet medication, including aspirin, as single agent antiplatelet therapy 
is allowed while on study drug.
It is strongly encouraged to restrict the dose of aspirin (if indicated) to ≤ 100 mg daily, 
although higher doses are permitted for a strong clinical indication (eg, development of 
an acute MI).
Examples of non-aspirin oral antiplatelet agents include the following: 
























IV antiplatelet agents include the following: 






 PGY12 Inhibitor: Cangrelor 
 Dextran 
17.3.2. Oral Anticoagulants Other Than Study Drug
Oral anticoagulants including vitamin K antagonists (eg, warfarin), Factor IIa inhibitors 
(eg, dabigatran), and FXa inhibitors (eg, rivaroxaban, apixaban) after randomization are 
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prohibited (unless used to bridge a temporary study drug interruption). The only allowed 
oral antithrombotics are the study drugs.
17.3.3. Parenteral Anticoagulants
Parenteral anticoagulants such as heparin, LMWHs, direct thrombin inhibitors, and FXa 
inhibitors are prohibited except as specifically outlined in the protocol. For instance, 
LMWHs are allowed as lead-in therapy prior to edoxaban administration. Examples of 
prohibited parenteral anticoagulant medications, when used contrary to protocol 
specifications, include the following: 

































Examples of fibrinolytics include the following:
 Tissue plasminogen activator (alteplase, Activase
®
) 
 TNK (tenecteplase, TNKase
®
) 









If a subject requires treatment with a fibrinolytic agent, then study drug must be 
interrupted while the subject is taking the fibrinolytic drug and at least 24 hours after 
administration of a fibrinolytic agent.
17.3.5. NSAIDs (Excluding Aspirin) 
While on study drug, NSAIDs cannot be taken for  4 days per week.  Less frequent use 
of NSAIDs is permitted while on study drug.  However, the Investigator should weigh the 
benefit/risk of NSAID use in combination with an oral anticoagulant for the individual 
subject.  Examples of NSAIDs include the following:
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Meclofenamate Mefanamic Acid Meloxicam
Morniflumate Nabumetone Naproxen





Tiaprofenac Acid Tolmetin Zomepirac
17.3.6. COX-2 Inhibitors 
While on study drug, COX-2 inhibitors cannot be taken for  4 days per week.  Less 
frequent use of COX-2 inhibitors is permitted while on study drug.  However, the 
Investigator should weigh the benefit/risk of COX-2 inhibitor use in combination with an 



















Concomitant use of protease inhibitors (such as ritonavir, nelfinavir, indinavir, and
saquinavir) anticipated to continue during the course of the study is prohibited.  
Concomitant use of certain macrolide antibiotics (erythromycin, azithromycin, and 
clarithromycin) and azole antifungals (ketoconazole and itraconazole) are also prohibited 
at the time of randomization, but subsequent use of these agents is permitted after 
randomization with appropriate dose reduction of edoxaban to 30 mg QD.  Once 
treatment with these P-gp inhibitors is complete, the full 60 mg edoxaban dose should be 
resumed.  
The following common P-gp inhibitors that might be administered to study subjects 
require a reduction in the edoxaban dose to 30 mg QD:
 Tyrosine kinase inhibitors: imatinib, nilotinib, lapatinib, sunitinib, criozitinib,
vandetanib
 Hormonal agents: tamoxifen, enzalutamide, abiraterone,
 Immuno-modulating agents: cyclosporine, tracolimus, dexamethasone
Once treatment with these P-gp inhibitors is complete, the full 60 mg edoxaban dose 
should be resumed.
Note:  Other agents in these classes may be administered concurrently without reducing 
the edoxaban dose.
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17.4. Precautions and Dose Modifications for Dalteparin 






47 to 56 10000
57 to 68 12500
69 to 82 15000
≥ 83 18000






57 to 68 10000
69 to 82 12500
83 to 98 15000
≥ 99 18000
Precautions and Dose Modifications
Month 1: 
In the case of chemotherapy-induced thrombocytopenia, the dalteparin dose should be 
adopted as follows: 
 In subjects receiving dalteparin who experience platelet counts between 
50,000 and 100,000/mm
3
, the daily dose of dalteparin should be reduced by 
2,500 IU until the platelet count recovers to ≥100,000/mm
3
. 
 In subjects receiving dalteparin who experience platelet counts < 50,000/mm
3
, 









In the case of chemotherapy-induced thrombocytopenia, frequent monitoring of peak 
anti–FXa levels should be undertaken and the dalteparin dose should be adopted as 
follows: 
 With platelet counts < 50,000/mm
3
, dalteparin dosing should be interrupted 
until the platelet count recovers above 50,000/mm
3
. 
 For platelet counts between 50,000 and 100,000/mm
3
, dalteparin should be 
reduced as illustrated in the table below in accordance with the subject's 
weight.  Once the platelet count has recovered to > 100,000/mm
3
, dalteparin 
should be re-instituted at full dose.











57 to 68 10000 7500
69 to 82 12500 10000
83 to 98 15000 12500
≥99 18000 15000
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17.5. Definitions of Cardiovascular and Thrombotic Events
17.5.1. Systemic Embolic Event (SEE)
A systemic embolic event is defined as an abrupt episode of arterial insufficiency 
associated with clinical or radiologic evidence of arterial occlusion in the absence of 
other likely mechanisms (eg, atherosclerosis, instrumentation).  Arterial embolic events 
involving the CNS (including the eye), coronary, and pulmonary arterial circulation are 
not considered SEEs, but will be classified respectively as stroke/TIA, myocardial 
infarction, and pulmonary embolism.  In the presence of atherosclerotic peripheral 
vascular disease, diagnosis of embolism to the lower extremities requires arteriographic 
demonstration of abrupt arterial occlusions.
17.5.2. Thrombotic Events at Other Locations
These include:
 Catheter-associated thrombosis
 Cerebral venous and sinus thrombosis
 Retinal vein occlusion
 Upper extremity venous thrombosis
 axillary, subclavain and brachial vein thrombosis
 Jugular vein thrombosis
 Superior caval vein thrombosis
 Abdominal vein thrombosis
 Splanchnic vein thrombosis 
 Portal vein thrombosis
 Mesenteric vein thrombosis
 Splenic vein thrombosis
 Hepatic vein thrombosis
 Genito-urinary venous thrombosis
 Renal vein thrombosis
 Ovarian vein thrombosis
 Penile vein thrombosis
 Distal deep vein thrombosis
 distal DVT: tibial veins, peroneal veins
 muscular vein thrombosis
 Superficial vein thrombosis of the lower or upper limb
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17.6. Eastern Cooperative Oncology Group (ECOG) Performance Status
These scales and criteria are used by doctors and researchers to assess how a patient's 
disease is progressing, assess how the disease affects the daily living abilities of the 
patient, and determine appropriate treatment and prognosis. They are included here for 




0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, e.g., light house work, office work
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
* As published in Am. J. Clin. Oncol.: 
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity 
And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 
1982
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17.7. Schedule of Events


























Vital Signs/Weight X X
Cancer Status/Stage X X X
Clinical Assessments and ECOG 
Performance Status




X X X X X
Serum Creatinine/CrCL X X X X X




Prior and Concomitant Medication X X X X X X X X
AE Reporting
e
X X X X X X X
Outcome Events Reporting
e
X X X X X X X
Healthcare Resource Utilization X X X X X X
Study Drug Dispensing
f
X X X X X
Study Drug Compliance X X X X X X
Contact IXRS for study drug 
assignment or to enter subject status 
changes
g
X X X X X
Protocol DU176b-D-U311



















LFT-liver function test; VTE-venous thromboembolism; AE-adverse event(s); IXRS-Interactive web/voice response system; CrCL-creatinine clearance; 
ALT-alanine transferase; AST-aspartate transferase; EOT-end-of-treatment; ECOG-Eastern Cooperative Oncology Group.
a
Review inclusion/exclusion criteria and ensure that the subject qualifies with regard to the laboratory tests for exclusion criteria (CrCl , 30 mL/min; 




Physical examination at pre-randomization may be performed by an Investigator or other healthcare provider designated by the Investigator.  The 
physical examination includes vital signs (sitting blood pressure and heart rate), record height, and record body weight.
c
ALT/AST, total bilirubin, and alkaline phosphatase at randomization and subsequent assessments.
d
One serum sample will be collected at randomization for archiving.
e
AE reporting and Outcome Events Reporting should occur throughout the study and not be restricted to specific visits; capture healthcare resource 
utilization data for potential recurrent VTE and bleed events.
f
Study drug assigned by the IXRS will be dispensed as a 3-month supply.
g
All subjects should be seen by qualified medical personnel for the following procedures at Month 12 or whenever study treatment is permanently 
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Study Title: A Phase 3b, prospective, randomized, open-label, blind 
evaluator (PROBE) study evaluating the efficacy and safety 
of (LMW) heparin/edoxaban versus dalteparin in venous 
thromboembolism associated with cancer
Short Title: Edoxaban in Venous Thromboembolism Associated with 
Cancer (Hokusai VTE Cancer)
Study Phase: Phase 3b trial
Indication Under 
Investigation:
Venous thromboembolism associated with cancer
Study Objectives: Primary Objectives: The primary objective is to 
demonstrate the non-inferiority of edoxaban (preceded by a 
short course of LMWH) compared with dalteparin for the 
prevention of the combined outcome of recurrent venous 
thromboembolism (VTE) or major bleeding in subjects 
with VTE associated with cancer during a 12-month study 
period.  If non-inferiority is established, LMWH/edoxaban 
will be compared with dalteparin for superiority.
Secondary Objectives: To compare LMWH/edoxaban with 
dalteparin with regards to rates of:
1. Recurrent VTE;
2. Major bleeding;
3. Clinically relevant non-major (CRNM) bleeding;
4. Major + CRNM bleeding;
5. All bleeding;
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6. Event-free survival, defined as the proportion of 
subjects over time free of recurrent VTE, major 
bleeding events, and death;
7. VTE-related death;
8. Mortality from all causes;
9. Recurrent deep vein thrombosis (DVT);
10. Recurrent pulmonary embolism (PE);
11. Healthcare resource utilization for potential 
recurrent VTE and bleed events.
Exploratory Objectives: To compare LMWH/edoxaban 
with dalteparin with regards to:
1. Cardiovascular events (myocardial infarction [MI], 
stroke, systemic embolic events [SEE; see 
Appendix 17.5.1]);
2. Thrombotic events at other locations (see 
Appendix 17.5.2)
3. Reason for permanent early discontinuation of study 
drug.
Study Design: This is a multinational, prospective, randomized, open-
label, blind-evaluator (PROBE), non-inferiority study
comparing edoxaban with dalteparin for prevention of the 
combined outcome of recurrent VTE or major bleeding in 
patients with VTE associated with cancer. One thousand 
subjects (1000) will be equally randomized to 1 of the 
2 treatment groups.
After a subject’s eligibility is confirmed, the subject will be 
stratified by 1) bleeding risk, and 2) the need for dose 
adjustment, and then randomly assigned via interactive 
voice/web response system (IXRS) in a 1:1 ratio to 
treatment with either LMWH/edoxaban or dalteparin (see 
details in Section 3.1.2.
LMWH/Edoxaban group: Therapeutic doses of LMWH 
(subcutaneous [SC]) will be administered for at least 
5 days; this 5 day period may include the pre-
randomization LMWH (if applicable). The choice of this 
parenteral LMWH is up to the treating physician. 
Thereafter, edoxaban will be started orally at 60 mg once 
daily [QD] (2 × 30 mg tablets) (30 mg QD for subjects 
requiring dose adjustment) for the remainder of the 
treatment period.
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Dalteparin group: After randomization, dalteparin will be 
administered at a dose of 200 IU/kg SC (maximum daily 
dose 18,000 IU) for 30 days.  The 30 day period may 
include the pre-randomization anticoagulant treatment if 
dalteparin was used in therapeutic doses.  Thereafter 
(approximately Day 31 forward), dalteparin will be 
administered at a dose of 150 IU/kg SC (~ 75% - 83% of 
the initial dose) for the remainder of the treatment period.
The intended treatment duration and follow-up for all 
subjects is 12 months, except for the final subject(s) 
randomized to the study.  Once 1000 subjects are 
randomized, a global End-of-Treatment (EOT) date will be 
established that ensures a minimum of 6 months of study 
treatment and follow-up for the final subject(s) randomized.
All subjects will permanently discontinue study treatment 
on or before the EOT date.
After randomization subjects will be assessed at Month 1, 
Month 3, and quarterly thereafter for up to 12 months until 
they complete the study.
Subjects requiring additional anti-coagulation therapy who 
complete their treatment and full 12-month post 
randomization follow-up or whose treatment is truncated 
due to the global End of Treatment date will be managed 
according to local practice.
Guidance for switching from edoxaban to other 
anticoagulants is provided in Appendix 17.2.
Additional guidance for long-term management of cancer 
subjects with VTE is provided by Lyman, et al.
1
Study Duration: The expected study duration is approximately 30 months 
from the time the first subject is enrolled (July 2015) to the 
time of the last subject’s last follow-up visit.
Study Sites and Location: Approximately 140 study sites in North America, Europe, 
and Australia/New Zealand are planned to enroll subjects in 
this study.
Planned Sample Size: Assuming a hazard ratio of 1, a total of 191 overall primary 
events is projected to accrue in the modified intention-to-
treat (mITT) analysis set which will ensure at least 80% 
power for the primary analysis at a non- inferiority margin 
for the hazard ratio of 1.5 and a Type I error of 0.05 (two-
sided).
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Assuming a primary combined outcome rate (recurrent 
VTE or major bleed) of 20.0%, a total of 1000 subjects are 
expected to be randomized to study treatment in order to 
accrue 191 overall primary events in the mITT analysis.
Subject Eligibility Criteria: Adult male or female subjects who present with VTE 
associated with cancer (other than basal-cell or squamous-
cell carcinoma of the skin) for whom long-term treatment 
with LMWH is indicated, are eligible to participate in this 
study.
Key eligibility criteria include:
Inclusion Criteria:
1. Male or female subjects with age ≥ 18 years or the 
otherwise legal lower age according to the country 
of residence;
2. Confirmed symptomatic or unsuspected lower 
extremity proximal DVT (ie, popliteal, femoral, 
iliac or inferior vena cava vein thrombosis), or 
confirmed symptomatic PE, or unsuspected PE of a 
segmental or larger pulmonary artery;
3. Cancer, other than basal-cell or squamous-cell 
carcinoma of the skin.  Cancer should be active (see 
Section 6.1) or diagnosed within 2 years prior to 
randomization.  The diagnosis/history of cancer 
must be objectively documented;
4. Intention for long-term treatment (at least 6 months) 
with parenteral LMWH;
5. Able to provide written informed consent.
Exclusion Criteria:
1. Thrombectomy, insertion of a caval filter, or use of 
a fibrinolytic agent to treat the current (index) 
episode of DVT and/or PE;
2. More than 72 hours pre-treatment with therapeutic 
dosages of anticoagulant treatment (LMWH, 
unfractionated heparin, and fondaparinux per local 
labeling), oral direct anticoagulants or vitamin K 
antagonist (VKA) prior to randomization to treat the 
current (index) episode;
3. Treatment with therapeutic doses of an 
anticoagulant including dalteparin for an indication
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other than VTE prior to randomization;
4. Active bleeding or any contraindication for
treatment with LMWH/dalteparin or edoxaban;
5. An Eastern Cooperative Oncology Group (ECOG) 
Performance Status of 3 or 4 at the time of 
randomization (see Appendix 17.6);
6. Calculated creatinine clearance (CrCL)
< 30 mL/min;
7. History of heparin associated thrombocytopenia;
8. Acute hepatitis, chronic active hepatitis, liver 
cirrhosis;
9. Hepatocellular injury with concurrent transaminase 
(alanine transaminase [ALT]/aspartate transaminase
[AST] > 3 x upper limit of normal [ULN]) and 
bilirubin (> 2 x ULN) elevations in the absence of 
a clinical explanation;
10. Life expectancy < 3 months;
11. Platelet count < 50,000/mL;
12. Uncontrolled hypertension as judged by the 
Investigator (eg, systolic blood pressure > 
170 mmHg or diastolic blood pressure > 100 mmHg 
despite antihypertensive treatment);
13. Women of childbearing potential without proper 
contraceptive measures, and women who are 
pregnant or breast feeding;
14. Chronic treatment with non-aspirin non-steroidal 
anti-inflammatory drugs (NSAIDs) including both 
cyclooxygenase-1 (COX-1) and cyclooxygenase-2 
(COX-2) inhibitors for ≥ 4 days/week anticipated to 
continue during the study;
15. Treatment with aspirin in a dosage of more than 100 
mg/per day or dual antiplatelet therapy (any 2
antiplatelet agents including aspirin plus any other 
oral or intravenous antiplatelet drug) anticipated to 
continue during the study;
16. Treatment with the P-gp inhibitors ritonavir, 
nelfinavir, indinavir, or saquinavir anticipated to 
continue during the study;
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17. Systemic use of the P-gp inhibitors ketoconazole, 
itraconazole, erythromycin, azithromycin or 
clarithromycin at the time of randomization; 
subsequent use is permitted (with appropriate dose 
reduction of edoxaban see Appendix 17.3.7);
18. Subjects with any condition that as judged by the 
Investigator would place the subject at increased 
risk of harm if he/she participated in the study.
Dosage Form, Dose and 
Route of Administration:
Edoxaban (30 mg) will be supplied by the Sponsor as 
yellow film-coated tablets and administered per oral (PO).
LMWH for the edoxaban lead-in will be as prescribed by 
the Principal Investigator (see Study Design, above).
Dalteparin will be supplied by the Sponsor as single-use
pre-filled syringes and administered by SC injection.
Study Outcomes: The primary study outcome is the composite of recurrent 
VTE, and major bleeding.
Recurrent VTE is either:
 symptomatic confirmed (new) DVT or (new) PE;
 unsuspected (new) proximal DVT of the legs or 
unsuspected (new) PE located in segmental or more 
proximal arteries:
 Unsuspected DVT or PE are thrombi that 
are detected during imaging testing 
performed for other reasons (eg, computed 
tomography (CT) for cancer staging) and not 
for suspicion of DVT or PE.
 fatal PE (including unexplained death for which PE 





 Major + CRNM bleeding;
 All bleeding;
 Event-free survival, defined as the proportion of 
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subjects over time free of recurrent VTE, major 
bleeding events, and death;
 VTE-related death;
 Mortality from all causes; 
 Recurrent DVT;
 Recurrent PE;
 Healthcare resource utilization for potential 
recurrent VTE and bleed events.
Other outcomes include:
 Cardiovascular events (MI, stroke, SEE [see 
Appendix 17.5.1]);
 Thrombotic events at other locations (see 
Appendix 17.5.2);
 Reason for permanent early discontinuation of 
study drug.
Statistical Analyses: Analysis of the Primary Study Outcome
The primary analysis will be based on the mITT Analysis 
Set (which includes all randomized subjects who receive at 
least 1 dose of study drug) using all primary outcome 
events (ie, recurrent VTE or major bleeding) occurring 
from randomization through the end of the 12 month study 
period or up to the global EOT visit when the study has 
been stopped, regardless of whether the subject is taking 
study drug. In this analysis, the time to the first event of 
the composite outcome will be analyzed using a Cox’s 
proportional hazards model including treatment and the 
stratification factors as covariates.  The LMWH/edoxaban
to comparator hazard ratio will be computed along with a 
95% confidence interval [CI] (two-sided) based on this 
model.  The LMWH/edoxaban will be considered non-
inferior to the comparator if the upper limit of the CI is 
< 1.5.
The following sensitivity analyses will be performed for the 
Primary Outcome:
 On-Treatment events based on the per-protocol 
(PP) Analysis Set will be analyzed using the 
counting process approach of the Cox 
proportional hazards regression model including 
treatment group, and the stratification factors as 
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covariates.    An On-Treatment event is defined 
as the event occurring during the time period the 
subject is taking study drug up to 3 days after 
their last dose for that time period.  Only events
occurring prior to or on Day 365 will be 
included into this analysis. Subjects who do not 
experience an On-Treatment event will be 
censored at Day 365, or the time study drug is 
permanently discontinued plus 3 days or on the 
last day the subject had a complete assessment 
(in-person visit or by telephone) for study 
outcomes, or the day of global end of treatment, 
whichever comes first.
 Events occurring during the first 6 months 
(180 days) based on the mITT Analysis Set will 
be analyzed using the same statistical model as 
the primary analysis of the primary outcome. 
The time to event is defined as the time (days) 
from the randomization to the first event during 
the first 6 months after randomization.  Subjects 
who do not experience an event until Day 180
will be censored at Day 180, or the time study 
drug is permanently discontinued or on the last 
day the subject had a complete assessment (in-
person visit or by telephone) for study 
outcomes, whichever comes first.
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1. INTRODUCTION AND BACKGROUND INFORMATION
Venous thromboembolism (VTE) is a common and clinically important disease in cancer 
patients and current standard treatment consists of long-term low-molecular weight 
heparin (LMWH).
1,2,3,4
Although subcutaneous (SC) injections with LMWH are 
effective they are often difficult to tolerate and inconvenient for long-term use by cancer 
patients. Therefore, if oral medications, such as the current direct oral anticoagulants 
(DOACs) are effective and safe without the need for SC punctures, they are potentially 
an attractive alternative in this population.  The Hokusai VTE study has shown that 
edoxaban, an oral direct Factor Xa (FXa) inhibitor, was effective and safe in the 
treatment of VTE.
5
In a subgroup analysis among 771 cancer patient randomized to the 
Hokusai VTE study, edoxaban was non-inferior in terms of efficacy and associated with a 
relative risk reduction of 19% in clinically relevant bleeding compared to warfarin.
6
  In 
view of these results, a clinical study with edoxaban versus LMWH in cancer-associated 
VTE is proposed.
1.1. Data Summary
The efficacy and safety of edoxaban for the treatment of VTE, including deep vein 
thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent VTE 
was demonstrated in the Phase 3 Hokusai VTE study. A large pivotal Phase 3 study in 
non-valvular atrial fibrillation (NVAF) (ENGAGE AF-TIMI 48) has also been completed 
and provides important information regarding the safety of long-term edoxaban 
treatment. Features of the Hokusai VTE and ENGAGE AF-TIMI 48 studies are 
summarized in Table 1.1.































Edoxaban 60 mg 4118 0.7 years Recurrent 
VTE




















HR (95% CI) 
0.80 (0.71, 
0.91)
Edoxaban 30 mg 7002
Warfarin 7012
VTE – venous thromboembolism; HR – Hazard Ratio; CI – confidence interval; CRNM – clinically relevant non-major; 
NVAF – non-valvular atrial fibrillation; SEE – systemic embolic event
Other completed studies include Phase 1 clinical pharmacology studies, Phase 2 
dose-ranging studies in subjects with NVAF and subjects undergoing lower-extremity 
orthopedic surgery, and Phase 3 studies in subjects undergoing lower-extremity 
orthopedic surgery. In the edoxaban program, a combined total of 18,132 subjects were 
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treated with edoxaban (7002 with edoxaban 30 mg and 11,130 with edoxaban 60 mg) 




Name of Investigational Product: Edoxaban tosylate (DU-176b)
Edoxaban (INN), anhydrous free base (DU-176)
Active Ingredient: N-(5-Chloropyridin-2-yl)-N -[(1S,2R,4S)-4-(N,N-
dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-
carboxamido)cyclohexyl] oxamide mono(4-methylbenzenesulfonate) monohydrate
1.1.1.2. Description
Edoxaban tosylate is an antithrombotic agent, an orally active, selective, direct, and 
reversible inhibitor of FXa, manufactured by Daiichi Sankyo Co., Ltd., Japan.  Inhibition 
of FXa in the coagulation cascade prolongs clotting time and potentially reduces the risk 
of spontaneous or induced thrombus formation.
Edoxaban refers to the anhydrous free base of edoxaban tosylate.  Subjects are given 
edoxaban tosylate (a monohydrate salt) but all doses and plasma concentrations are 
expressed in terms of edoxaban, the anhydrous free base.
For simplicity, this protocol uses the term “edoxaban” to refer to either or both forms.
1.1.1.3. Nonclinical Studies
In nonclinical studies, edoxaban showed excellent potential as an antithrombotic agent.  
Nonclinical data indicate no evidence of liver function abnormalities in study animals 




The global clinical experience with edoxaban includes 43 completed Phase 1 studies, 
12 completed Phase 2 studies and 8 completed Phase 3 studies.
Edoxaban has been evaluated in the treatment of VTE in a large pivotal Phase 3 study, 
the Hokusai VTE study.
5
In this study, 8292 patients were enrolled: 4921 with DVT and 
3319 with PE.  Patients were randomized to an initial course of LMWH followed by 
edoxaban or LMWH/warfarin followed by warfarin alone.  The primary efficacy analysis 
of non-inferiority versus the current standard of care (ie, heparin overlapped with 
warfarin until the international normalized ratio (INR) reaches ≥ 2.0) was demonstrated 
with a high degree of confidence (hazard ratio [HR]: 0.89; 95% confidence interval [CI]: 
0.703, 1.128; p<0.0001).  The efficacy was consistent across analysis populations, 
individual components of the primary endpoint and subgroups of subjects including older 
individuals, those with renal impairment and subjects with lower body weight.  For the 
primary safety outcome (adjudicated major/clinically relevant non-major (CRNM)
bleeding, Safety Analysis Set, On-Treatment Study Period), edoxaban was superior to 
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warfarin (HR: 0.81; 95% CI: 0.71, 0.94; p=0.0040) for a relative risk reduction of 19%.  
The benefit was most apparent for more serious bleeding including intracerebral 
hemorrhage. There was an increase in gastrointestinal (GI) bleeding, in line with other 
FXa inhibitors.
8
  There was also an increase in vaginal bleeding, where the majority of 
cases were menses-related, but few cases were serious or led to discontinuation of 
treatment.  
It was concluded that once daily edoxaban after heparin was equally efficacious and 
caused significantly less bleeding compared with high-quality standard therapy with 
warfarin in a broad spectrum of VTE patients, including those with severe PE.
Additional details are available in the edoxaban Investigators’ Brochure.
7
1.2. Study Rationale
Venous thromboembolism (comprising DVT and PE) is a serious and frequently 
occurring comorbidity in cancer patients. It is the second most common cause of death in 
these patients
9
and compared with healthy persons cancer patients have a 4- to 7-fold 
increased risk for developing VTE.
10,11
The association between thrombotic disease and 
cancer can be explained by pathophysiological mechanisms, while chemotherapy and 
central venous catheters (CVCs) often used in this population further increase the risk of 
VTE. 
In addition to a higher risk for developing VTE, patients with a malignancy when treated 
with anticoagulants also have an increased risk of bleeding, with major bleeding rates that 
are in the same range as the rate of recurrent VTE (ie, 8% - 12% per year as shown in 
contemporary studies).
12,13,14
Given these findings, clinical studies evaluating effective and safe VTE treatment are 
considered a priority for cancer patients. Since the principal problem in cancer patients 
with VTE is the underlying cancer, VTE management should preferably not interfere 
with the cancer therapy and have minimal impact on the patient’s already compromised 
quality of life (QOL). In this respect, VTE treatment in cancer patients is more 
challenging and different than VTE treatment in non-cancer patients. Current standard 
therapy for cancer-associated VTE is daily SC injected LMWH-dalteparin for at least 
6 months.
1,2,3,4
  Although SC injections are effective they are often difficult to tolerate 
and inconvenient for long-term use by cancer patients.  Therefore, if oral medications
such as the current direct oral anticoagulants are effective and safe without the need for 
SC punctures then they are potentially an attractive alternative for patients with cancer 
and VTE. The Hokusai VTE study has shown that edoxaban, an oral direct FXa inhibitor 
(DOAC), was effective and safe in treatment of venous thromboembolism.
5
Additionally, among 771 patients with cancer randomized in the study, the recurrence 
rate over the 12-month study period in the edoxaban group was 3.7% compared with 
7.1% in the warfarin group (HR: 0.53; 95% CI: 0.28, 1.00). In these same patients, the 
clinically significant bleeding rates were 12.4% versus 18.8% (HR: 0.64; 95% CI: 0.45, 
0.92) in the edoxaban and warfarin treatment groups, respectively.
6
Interestingly, in the 
subgroup of patients classified by the treating physician as having cancer active at entry 
in the study (n=208), the risk of VTE recurrence was 3.7% in the edoxaban group and 
7.1% in the warfarin group (HR, 0.55; 95% CI, 0.16, 1.85), showing virtually identical 
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results between patients with a history of cancer and the subset of those considered by the 
physician to have “active” cancer. This novel observation illustrates that the risk with 
respect to recurrent VTE is more the history of cancer than the more narrow definition of 
cancer that is “active.” This conclusion was reached also in another recent study in a 
subgroup of cancer patients with VTE.
15
In view of these results, a comparative clinical study between standard treatment 
consisting of long-term SC LMWH-dalteparin and the new oral direct FXa inhibitor, 
edoxaban, is proposed. 
In a clinical study evaluating new anticoagulant therapy in the cancer patient population 
several design aspects require consideration. 
 Both recurrent VTE and major bleeding are potential life-threatening 
complications occurring at a comparable rate and with a significant and 
similar impact on the patient’s clinical status. The VTE-treatment should 
therefore aim to prevent both recurrent VTE and major bleed and in a study 
evaluating a new treatment option and the 2 outcomes will need to be equally 
considered. Therefore, in this novel design it is proposed that the primary 
outcome of the study will be a combined outcome consisting of recurrent VTE 
and major bleeding.
 In cancer patients, VTE-symptoms often are not obvious and erroneously 
attributed to the cancer or its treatment.  This unsuspected VTE occurs 
frequently
16,17,18
and the prognosis of these unexpected VTEs in terms of 
recurrent VTE and mortality are similar to those with symptomatic 
disease.
1,19,20,21,22
As a consequence, current guidelines advise a similar 
treatment strategy for unsuspected PE and DVT as for clinically apparent 
VTE.
1
Therefore, unsuspected PE and DVT will be considered as an 
inclusion criterion and also as a component of the primary outcome.
 In non-cancer patients the duration of VTE-treatment is at least 3 months and 
prolonged up to 12 months or indefinitely depending on the clinical judgment 
balancing risk and benefit.  In cancer patients the recommended treatment 
duration is at least 6 months.  Consistent with guideline recommendations 
prolonging treatment needs to be strongly considered especially in patients in 
whom cancer is still present.
1,2,3
However, after 6 months physicians are 
faced with a dilemma since data from studies beyond 6 months are absent.
1,2,3
In evaluating a new anticoagulant treatment it is desirable to document the 
effects of treatment over a longer period of time.  Therefore, the intent in the 
present study is to treat all subjects for 12 months, and to follow all subjects 
for 12 months after randomization whether or not they complete 12 months of 
treatment.  This is important because bleeding, including CRNM bleeding 
events, may lead to discontinuation or interruption of anticoagulant therapy, 
which then increases the risk of subsequent recurrent VTE events, with such 
events not captured using traditional On-Treatment analyses.
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1.3. Risks and Benefits for Study Subjects
Edoxaban is a selective FXa inhibitor with rapid onset of action and predictable 
antithrombotic properties.  Edoxaban appears to be well tolerated up to a dose of 90 mg 
QD, with expected transient and manageable bleeding adverse events (AEs) and transient 
and reversible liver enzyme and bilirubin elevations.
In the edoxaban program, a combined total of 18,132 subjects were treated with 
edoxaban (7002 with edoxaban 30 mg and 11,130 with edoxaban 60 mg) encompassing 
over a total exposure of > 34,048 subjects years for edoxaban.
7
This exceptionally large 
database allowed the overall safety of edoxaban to be adequately characterized in terms 
of adverse reactions with rare frequency and those occurring after a long latency period.  
The program also conducted a large number of specific studies to allow characterization 
of the pharmacokinetic (PK) and safety profile of edoxaban in subjects with hepatic 
dysfunction, severe renal impairment, and concomitant medications.  These specific 
studies together with the large clinical database allowed for the safety of edoxaban to be 
assessed in a large number of subject subgroups of intrinsic and extrinsic factors.  
Edoxaban demonstrated a consistent safety profile across subgroups.  An effective oral 
and parenteral transition scheme from edoxaban to other anticoagulants has also been 
demonstrated.
The completed Phase 3 clinical trials in AF and VTE have demonstrated efficacy and 
safety of edoxaban 60-mg dose (with a 30-mg dose reduction in subjects with 1 or more 
of the following: moderate to severe renal impairment, weight ≤ 60 kg, or concomitant 
use of specified P-gp inhibitors) in the prevention of stroke and systemic embolism in 
adult subjects with NVAF and in the treatment of VTE including DVT and PE, and 
prevention of recurrent VTE.
For VTE in particular, the primary efficacy analysis of non-inferiority versus the current 
standard of care (ie, heparin overlapped to warfarin until the INR reaches ≥2.0) was 
demonstrated with a high degree of confidence. In the primary efficacy modified 
intention-to-treat (mITT) overall analysis, the edoxaban regimen demonstrated non-
inferiority versus warfarin (HR: 0.89; 95% CI: 0.703, 1.128; p<0.0001).  The efficacy was 
consistent across analysis populations, individual components of the primary endpoints 
and subgroups of subjects including older individuals, those with renal impairment, and 
lighter subjects. 
Edoxaban 60 mg showed a clear benefit in terms of reduced bleeding when compared 
with well-controlled warfarin treatment.  In the Hokusai VTE study, the primary safety 
endpoint (adjudicated major/CRNM bleeding, Safety Analysis Set, On-Treatment Study 
Period), edoxaban was superior to warfarin (HR: 0.81; 95% CI: 0.71, 0.94; p=0.0040) for a 
relative risk reduction of 19%. The benefit was most apparent for more serious bleeding 
including ICH, and intra-articular and intra-ocular bleeds.  There was an edoxaban 
associated increase in GI bleeding, in line with other FXa inhibitors. There was also an 
increase in vaginal bleeding, where the majority of cases were menses-related, but few 
cases were serious or led to discontinuation of treatment.  
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Bringing together quantitatively the benefits and risks as a net clinical outcome, Table 1.2
summarizes the benefit-risk outcomes.  For each indication, the net clinical outcome 
covers the principal efficacy and safety outcomes, and includes all-cause mortality.
Table 1.2: Quantitative Benefit Risk
Composite Endpoint HR (95% CI) for Edoxaban 60 mg versus 
Warfarin
NVAF: Net Clinical Outcome mITT, Overall 0.89 (0.83 to 0.96)
VTE: Net Clinical Outcome PP, On-Treatment 0.87 (0.70 to 1.10)
HR – Hazard Ratio; CI – confidence interval; NVAF – non-valvular atrial fibrillation; mITT – modified 
intention-to-treat; VTE – venous thromboembolism; PP – per protocol
For NVAF, net clinical outcome is a composite of stroke, systemic embolic event, major bleeding, and 
all-cause mortality. 
For VTE, net clinical outcome is a composite of symptomatic recurrent deep vein thrombosis, non-fatal 
symptomatic recurrent pulmonary embolism, fatal pulmonary embolism, and major bleeding, 
and all-cause mortality.
Overall, edoxaban has an adequately characterized positive benefit-risk ratio in large and 
representative populations globally in patients with NVAF and VTE, demonstrating 
efficacy in the overall populations and subgroups (with dose reduction as required) in 
conjunction with a favorable bleed profile as well as demonstrating its effectiveness in a 
dose-dependent manner for VTE prevention after orthopedic surgery such as hip or knee 
replacement.  Additional advantages of edoxaban are its once daily (QD) dosing, 
dose-reduction strategies to minimize the risk of bleeding with preserved efficacy and no 
necessity for constant monitoring of therapy.
Dalteparin is the only licensed anticoagulant for the extended treatment and prevention of 
recurrence of VTE in cancer patients and thus is considered the “gold” standard 
treatment.  Six months of dalteparin was found to be more effective than, and as safe as, 
vitamin K antagonists [VKAs] (ie, warfarin/coumarin) for patients with cancer and acute 
VTE, without significantly increasing the risk of major bleeding.  The authors concluded 
that “longer term” dalteparin is safe in cancer patients.
23
References and information on dalteparin (Fragmin
®
) is available in the Summary of 
product Characteristics/Product Monograph and the package inserts.
24
Complete prescribing information for dalteparin can be found in Appendix 17.1.1.
1.4. Population, Route, Dosage, Dosage Regimen, Treatment Period
Adult subjects who present with VTE associated with cancer (other than basal-cell or 
squamous-cell carcinoma of the skin) for whom long-term treatment with LMWH is
intended are eligible to participate in this study. Section 4 lists all eligibility 
requirements necessary to qualify for the study. 
Eligible subjects will be stratified by 1) bleeding risk, and 2) the need for dose 
adjustment, and then randomized to receive either LMWH/edoxaban or dalteparin (see 
full details below; Section 3 provides complete treatment details).  
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 Edoxaban group: Therapeutic doses of LMWH (SC) for at least 5 days will be 
administered; this 5 day period may include the pre-randomization LMWH
treatment (if applicable). The choice of parenteral LMWH is up to the 
treating physician.  Thereafter, edoxaban will be started orally at 60 mg QD (2 
× 30 mg tablets; 30 mg QD for subjects requiring dose adjustment) for the 
remainder of the treatment period.
 Dalteparin group: After randomization, dalteparin will be administered at a 
dose of 200 IU/kg SC (maximum daily dose 18,000 IU) for 30 days.  The 
30 day period may include the pre-randomization anticoagulant treatment if 
dalteparin was used in therapeutic doses. Thereafter (approximately Day 31 
forward), dalteparin will be administered at a dose of 150 IU/kg SC (~ 75% -
83% of the initial dose) for the remainder of the treatment period.
1.5. Compliance Statement, Ethics and Regulatory Compliance
This study will be conducted in compliance with the protocol, the ethical principles that 
have their origin in the Declaration of Helsinki, the International Conference on 
Harmonisation (ICH) consolidated Guideline E6 for Good Clinical Practice (GCP) 
(CPMP/ICH/135/95), and applicable regulatory requirement(s).
 European Commission Directive (2001/20/EC Apr 2001) and/or
 European Commission Directive (2005/28/EC Apr 2005) and/or
 Food and Drug Administration (FDA) GCP Regulations: Code of Federal 
Regulations (CFR) Title 21, Parts 11, 50, 54, 56 and 312 as appropriate and/or
 Other applicable local regulations.
1.5.1. Subject Confidentiality
The Investigators and the Sponsor will preserve the confidentiality of all subjects taking 
part in the study, in accordance with GCP and local regulations.
For European Union (EU) sites, the Sponsor will observe the rules laid down in the 
European Data Protection Directive 95/46/EC on the protection of individuals with 
regard to the processing of personal data and the free movement of such data.
The Investigator must ensure that the subject’s anonymity is maintained.  On the Case 
Report Forms (CRFs/electronic CRF [eCRF]) or other documents submitted to the 
Sponsor and/or its designated representatives, subjects should be identified by a unique 
subject identifier as designated by the sponsor.  Documents that are not for submission to 
Sponsor and/or it’s designated representatives (eg, signed Informed Consent Forms 
[ICFs]) should be kept in strict confidence by the Investigator.
In compliance with Federal regulations/ICH GCP Guidelines, it is required that the 
Investigator and institution permit authorized representatives of the company, of the 
regulatory agency(s), and the Independent Ethics Committee (IEC) or Institutional 
Review Board (IRB) direct access to review the subject’s original medical records for 
verification of study-related procedures and data.  The Investigator is obligated to inform 
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the subject that his/her study-related records will be reviewed by the above named 
representatives without violating the confidentiality of the subject.
1.5.2. Informed Consent Procedure
Before a subject’s participation in the study, it is the Investigator’s responsibility to 
obtain freely given consent, in writing, from the subject or legally acceptable 
representative after adequate explanation of the aims, methods, anticipated benefits, and 
potential hazards of the study and before any protocol-specific screening procedures or 
any study drugs are administered (see Section 6.1 Study Qualification).  A legally 
acceptable representative is an individual or other body authorized under applicable law 
to consent, on behalf of a prospective subject, to the subject’s participation in the clinical 
study.  The written ICF should be prepared in the local language(s) of the potential 
subject population.
In obtaining and documenting informed consent, the Investigator should comply with the 
applicable regulatory requirements, and should adhere to GCP and to the ethical 
principles that have their origin in the Declaration of Helsinki.  The consent form and any 
revision(s) should be approved by the IEC or IRB prior to being provided to potential 
subjects.
The subject’s written informed consent should be obtained prior to his/her participation in 
the study, and should be documented in the subject’s medical records, as required by 21 
CFR Part 312.62.  The ICF should be signed and personally dated by the subject or a 
legally acceptable representative, and by the appropriate qualified person who conducted 
the informed consent discussion (not necessarily the Investigator but delegated by the 
Investigator).  The original signed ICF should be retained in accordance with institutional 
policy, and a copy of the signed consent form should be provided to the subject or legal 
representative.  The date that informed consent was given should be recorded on the 
CRF.
If the subject or legally acceptable representative cannot read, then according to ICH 
GCP Guideline, Section 4.8.9, an impartial witness should be present during the entire 
informed consent discussion.  This witness should sign the ICF after the subject or the 
legally acceptable representative has orally consented to the subject’s participation and, if 
possible, signed the ICF.  By signing the ICF, the witness attests that the information in 
the ICF and any other written information was adequately explained to and apparently 
understood by the subject or the legally acceptable representative and that informed 
consent was freely given by the subject or the legally acceptable representative.
Suggested model text for the ICF for the study and any applicable subparts (genomic, 
pharmacokinetic, etc) are provided in the Sponsor ICF template for the Investigator to 
prepare the documents to be used at his or her site.  Updates to applicable forms will be 
communicated via letter from the Clinical Study Manager.
This study will be conducted in the United States (US), therefore, additional consent is 
required for the Health Insurance Portability and Accountability Act (HIPAA).  
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The study protocol, subject information and consent form, the Investigator brochure, any 
subject diary card or written instructions to be given to the subject, available safety 
information, subject recruitment procedures (eg, advertisements), information about 
payments and compensation available to the subjects and documentation evidencing the 
Investigator’s qualifications should be submitted to the IEC or IRB for ethical review and 
approval according to local regulations, prior to the study start.  The written approval 
should identify all documents reviewed by name and version.
Changes in the conduct of the study or planned analysis will be documented in a protocol 
amendment and/or the Statistical Analysis Plan (SAP).
The Investigator must submit and, where necessary, obtain approval from the IEC or IRB 
and/or Sponsor for all subsequent protocol amendments and changes to the informed 
consent document or changes of the site, facilities or personnel.  The Investigator should 
notify the IEC or IRB of deviations from the protocol or serious adverse events occurring 
at the site and other adverse event reports received from Sponsor/contract research 
organization (CRO), in accordance with local procedures.
As required by local regulations, the Sponsor’s local Regulatory Affairs group will 
ensure all legal aspects are covered, and approval of the appropriate regulatory bodies 
obtained, prior to study initiation, and that implementation of changes to the initial 
protocol and other relevant study documents happen only after the appropriate 
notification of or approval by the relevant regulatory bodies.
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2. STUDY OBJECTIVES AND HYPOTHESES
2.1. Study Objectives
2.1.1. Primary Objective
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a 
short course of LMWH) compared with dalteparin for the prevention of the combined 
outcome of recurrent VTE or major bleeding in subjects with VTE associated with cancer
during a 12-month study period.  If non-inferiority is established, LMWH/edoxaban will 
be compared with dalteparin for superiority.
2.1.2. Secondary Objectives





4. Major + CRNM bleeding;
5. All bleeding;
6. Event-free survival, defined as the proportion of subjects over time free of 
recurrent VTE, major bleeding events, and death;
7. VTE-related death;
8. Mortality from all causes;
9. Recurrent DVT;
10. Recurrent PE;
11. Healthcare resource utilization for potential recurrent VTE and bleed events.
2.1.3. Exploratory Objectives
Exploratory objectives include comparing LMWH/edoxaban with dalteparin with regards 
to:
1. Cardiovascular events (myocardial infarction (MI), stroke, SEE [see 
Appendix 17.5.1]);
2. Thrombotic events at other locations (see Appendix 17.5.2);
3. Reason for permanent early discontinuation of study drug.
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Edoxaban will be non-inferior to dalteparin with respect to the occurrence of recurrent 
VTE or major bleeding in the treatment of VTE associated with cancer. 
The study treatment (edoxaban) will be considered non-inferior to the standard therapy 
(dalteparin) if the upper limit of the two-sided 95% CI for the hazard ratio 
(edoxaban/standard therapy) is < 1.5.
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This is a multinational, prospective, randomized, open-label, blind-evaluator (PROBE), 
non-inferiority study comparing edoxaban with dalteparin for prevention of the combined 
outcome of recurrent VTE or major bleeding in patients with VTE associated with 
cancer. Adult subjects with VTE associated with cancer (other than basal-cell or 
squamous-cell carcinoma of the skin; cancer should be active (see Section 6.1) or 
diagnosed within the previous 2 years), and who present with confirmed acute 
symptomatic or unsuspected lower extremity proximal DVT, confirmed symptomatic PE, 
or unsuspected PE in a segmental or larger pulmonary artery for whom long-term 
treatment (at least 6 months) with LMWH is indicated are eligible to participate in this 
study. One thousand subjects (1000) will be equally randomized to 1 of the 2 treatment 
groups.  
After a subject’s eligibility is confirmed, the subject will be stratified by 1) bleeding risk,
and 2) the need for dose adjustment, and then randomly assigned via interactive 
voice/web response system (IXRS) in a 1:1 ratio to treatment with either 
LMWH/edoxaban or dalteparin (see Section 5.1.1 for complete details).
After randomization subjects will be assessed at Month 1, Month 3, and then quarterly 
thereafter for up to 12 months until they complete the study.
Approximately 140 study sites in North America, Europe, and Australia/New Zealand are
planned to enroll subjects in this study.
3.1.2. Treatment Groups and Dosing
Figure 3.1 depicts the study design and treatment plan.  The detailed Schedule of Events 
is provided in Appendix 17.7 and the protocol-required study procedures are provided in 
Section 6. 
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Figure 3.1: Study Design
Eligible subjects will be stratified by 1) bleeding risk, and 2) the need for dose 
adjustment: 
1. Bleeding risk (assessed at time of randomization)
 surgery within 2 weeks prior to randomization
 use of antiplatelet agents (eg, aspirin ≤ 100 mg/day) that will continue during 
the study
 brain tumor or brain metastases present at the time of randomization
 metastatic disease present at the time of randomization
 regionally advanced cancer present at the time of randomization
 gastrointestinal cancer at randomization or diagnosed within a 6-month period 
prior to randomization
 urothelial cancer at randomization or diagnosed within a 6-month period prior 
to randomization
 Avastin (bevacizumab) use at randomization or given within the 6-week 
period prior to randomization
2. The need for dose adjustment
 body weight ≤ 60 kg, or
 creatinine clearance (CrCL) between 30 and 50 mL/min inclusive
 concomitant use of P-gp inhibitors
After stratification, subjects will be assigned randomly via IXRS in a 1:1 ratio to 1 of the 
2 following treatment groups:
 LMWH/Edoxaban group: Therapeutic doses of LMWH (SC) will be 
administered for at least 5 days; this 5-day period may include the pre-
randomization LMWH (if applicable). The choice of this parenteral LMWH
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is up to the treating physician. Thereafter, edoxaban will be started orally at 
60 mg QD (2 × 30 mg tablets; 30 mg QD for subjects requiring dose 
adjustment) for the remainder of the treatment period.
The first dose of edoxaban should be taken: 
 12 (±3) hours after the last injection of the initial LMWH if this was a twice 
daily regimen, 
 24 (±3) hours after the last injection of the initial LMWH if this was a once 
daily regimen.
The edoxaban daily dose should be decreased to 30 mg QD for:
 body weight ≤ 60 kg; or
 creatinine clearance [CrCL] between 30 and 50 mL/min inclusive;
 concomitant use of P-gp inhibitors (eg, hormonal agents: tamoxifen, 
enzalutamide, abiraterone).
Dose reduction of edoxaban to 30 mg QD is intended only during concomitant use of 
P-gp inhibitors.  When use of these inhibitors is discontinued/intermittent (eg, between 
chemotherapy cycles) the full 60 mg edoxaban dose should be used.
After randomization, if the subject’s CrCL becomes ≤ 50 mL/min and ≥ 30 mL/min and 
the decrease in CrCL is > 20% from the subject’s baseline CrCL value, repeat the 
measurement preferably within 1 week. If the repeat measurement confirms this 
decrease, the edoxaban dosage regimen will be reduced permanently, even if the subject 
subsequently experiences improved CrCL to > 50 mL/min at a later measurement.
After randomization, if the subject’s body weight drops to ≤ 60 kg (confirmed by repeat 
measurement at least 1 week apart) and the body weight change is > 10% of the subject’s 
baseline body weight, the edoxaban dosage regimen will be reduced permanently, even if 
the subject subsequently re-gains weight to > 60 kg.
More details are provided in Appendix 17.3.7.
 Dalteparin group: After randomization, dalteparin will be administered at a 
dose of 200 IU/kg SC (maximum daily dose 18,000 IU) for 30 days.  The 
30 day period may include the pre-randomization anticoagulant treatment if 
dalteparin was used in therapeutic doses. Thereafter (approximately Day 31 
forward), dalteparin will be administered at a dose of 150 IU/kg SC (~ 75% -
83% of the initial dose) for the remainder of the treatment period.  
Dalteparin doses by weight and precautions for dose modifications are listed in 
Appendix 17.4.
3.1.2.1. Treatment Duration
The intention is to treat patients for 12 months with the allocated study treatment. 
Continuation of anticoagulant treatment beyond 6 months will be based on the 
risk-benefit evaluation by the treating physician.  
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Continue anticoagulation treatment if the benefit of doing so outweighs the risk and/or 
cancer is still “active”.  In this case ongoing anticoagulation with the allocated treatment 
regimen is preferred (if this is considered appropriate by the Investigator).  If however the 
Investigator decides to switch to another treatment regimen (eg, in the dalteparin arm the 
decision can be made to stop the parenteral administration and switch to oral therapy), it 
is recommended to switch to VKA and strongly discouraged to switch to a DOAC. 
Note: All subjects, including those in whom study medication is stopped or those who 
switch to VKA, will be followed up to 12 months with the following exception:
Once 1000 subjects are randomized in the study, a global end-of-treatment (EOT) date 
will be established that ensures a minimum of 6 months of study treatment and follow-up 
for the final subject(s) randomized. All subjects will permanently discontinue study 
treatment on or before the EOT date.
3.1.3. Study Governance
3.1.3.1. Steering Committees
The study oversight will be managed by a Steering Management Coordinating 
Committee (SMCC) whose members are country coordinators, as well as, non-voting 
representatives of the Sponsor and Academic Research Organization (ARO). In this 
study, International Trial Expertise Advisory and Services (ITREAS) will function as the 
ARO.
An Executive Committee to the SMCC will have a scientific advisory function and will 
not be involved in operational matters.
Ongoing study oversight and management will be the responsibility of a joint supervisory 
committee.  The members of this committee are the chairman and co-chair of the SMCC 
and designated representatives from the Sponsor, CRO and ARO.  
3.1.3.2. Data Monitoring Committee
An independent Data Monitoring Committee (DMC) will monitor safety during the study 
and give recommendations to the Executive Committee.  The DMC will periodically 
review and examine the safety and efficacy data (mortality and events, bleeding events, 
serious adverse events [SAEs], systemic embolic event [SEE]) and alert the Chairman of 
the Executive Committee in case of any clinically concerning safety issues.
3.1.3.3. Clinical Events Committee
An independent Clinical Events Committee (CEC) will be established to objectively 
adjudicate and categorize the presenting index diagnosis, VTE outcomes, cardiovascular 
events, bleeding events, selected hepatic events, and death.  Adjudicators will be blinded 
as to subject treatment allocation.  
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The primary outcome is the composite of recurrent VTE, and major bleeding.
All suspected recurrent VTE and bleeding events will be adjudicated by the CEC.  
Adjudicated results will be the basis for the final analyses. 





 CRNM bleeding; 
 Major + CRNM bleeding;
 All bleeding;
 Event-free survival, defined as the proportion of subjects over time free of 
recurrent VTE, major bleeding events, and death;
 VTE -related death;
 Mortality from all causes;
 Recurrent DVT;
 Recurrent PE;
 Healthcare resource utilization for potential recurrent VTE and bleed events.
All suspected VTE events, deaths, and bleeding events will be adjudicated by the CEC.  
Adjudicated results will be the basis for the final analyses.
3.1.4.3. Other Outcomes
Other outcomes include:
 Cardiovascular events (MI, stroke, SEE[see Appendix 17.5.1]);
 Thrombotic events at other locations (see Appendix 17.5.2);
 Reason for permanent early discontinuation of study drug.
All suspected cardiovascular events and other thrombotic events will be adjudicated by 
the CEC.  Adjudicated results will be the basis for the final analyses.
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3.2. Selection of Doses
3.2.1. Experimental Treatments
In the current guidelines extended LMWH therapy is the first choice for long-term 
treatment of VTE in cancer patients.
1, 2, 3
Dalteparin is the only approved anticoagulant 
specifically indicated for the extended treatment and prevention of recurrent VTE in 
cancer patients; thus, it is considered the standard of care.  The dalteparin regimen to be 
used in this study is based on the CLOT study which showed that 6 months of dalteparin 
was more effective than and as safe as VKAs (ie, warfarin/coumarin) for patients with 
cancer and acute VTE, without significantly increasing the risk of major bleeding.
23
The edoxaban regimen (60 mg QD with dose reduction for specific risk factors) was 
selected for this study based on the Hokusai VTE study results.  In the Hokusai VTE 
study, edoxaban produced a 47% relative reduction in risk for recurrent VTE in subjects 
with a history of cancer compared with warfarin.  Additionally, edoxaban resulted in a 
36% relative reduction for risk of clinically significant bleeding in these same subjects.
25
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Subjects must sign and date the ICF provided by the site before any study-specific 
qualification procedures are performed, except as noted in Section 6.1 Study 
Qualification/Pre-randomization.  
4.1.1. Inclusion Criteria
Adult subjects presenting with VTE associated with cancer (other than basal-cell or 
squamous-cell carcinoma of the skin) for whom long-term treatment with LMWH is 
intended are eligible to participate in the study. 
Subjects must satisfy all of the following criteria to be included in the study:
1. Male or female subjects with age ≥ 18 years or the otherwise legal lower age 
according to the country of residence;
2. Confirmed symptomatic or unsuspected lower extremity proximal DVT (ie, 
popliteal, femoral, iliac or inferior vena cava (IVC) vein thrombosis), or 
confirmed symptomatic PE, or unsuspected PE of a segmental or larger 
pulmonary artery;
3. Cancer (other than basal-cell or squamous-cell carcinoma of the skin), either 
active or diagnosed within 2 years prior to randomization.  [Note: Diagnosis of 
cancer must be objectively documented];
4. Intention for long-term treatment (at least 6 months) with parenteral LMWH;
5. Able to provide written informed consent.
4.1.2. Exclusion Criteria
Subjects who meet any of the following criteria are not eligible for enrollment:
1. Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the 
current (index) episode of DVT and/or PE;
2. More than 72 hours pre-treatment with therapeutic dosages of anticoagulant 
treatment (LMWH, unfractionated heparin, and fondaparinux per local labeling), 
oral direct anticoagulants or VKA prior to randomization to treat the current 
(index) episode;
3. Treatment with therapeutic doses of an anticoagulant including dalteparin for an 
indication other than VTE prior to randomization;
4. Active bleeding or any contraindication for treatment with LMWH/dalteparin or 
edoxaban;
5. An Eastern Cooperative Oncology Group (ECOG) Performance Status of 3 or 4 at 
the time of randomization (Appendix 17.6);
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6. Calculated CrCL < 30 mL/min;
7. History of heparin associated thrombocytopenia;
8. Acute hepatitis, chronic active hepatitis, liver cirrhosis;
9. Hepatocelullar injury with concurrent transaminase (ALT/AST > 3 x ULN) and 
bilirubin (> 2 x ULN) elevations in the absence of a clinical explanation;
10. Life expectancy < 3 months;
11. Platelet count < 50,000/mL;
12. Uncontrolled hypertension as judged by the Investigator (eg, systolic blood 
pressure (BP) > 170 mmHg or diastolic blood pressure > 100 mmHg despite 
antihypertensive treatment);
13. Women of childbearing potential without proper contraceptive measures, and 
women who are pregnant or breast feeding;
Note: Childbearing potential without proper contraceptive measures (ie, a method of 
contraception with a failure rate < 1 % during the course of the study including the 
observational period).  These methods of contraception according to the note for 
guidance on nonclinical safety studies for the conduct of human trials for pharmaceuticals 
(CPMP/ICH/286/95, modification) include consistent and correct use of hormone 
containing implants and injectables, combined oral contraceptives, hormone containing 
intrauterine devices, surgical sterilization, sexual abstinence, and vasectomy for the male 
partner).
14. Chronic treatment with non-aspirin non-steroidal anti-inflammatory drugs 
(NSAIDs) including both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 
(COX-2) inhibitors for ≥ 4 days/week anticipated to continue during the study;
15. Treatment with aspirin in a dosage of more than 100 mg/per day or dual 
antiplatelet therapy (any 2 antiplatelet agents including aspirin plus any other oral 
or intravenous [IV] antiplatelet drug) anticipated to continue during the study;
16. Treatment with the P-gp inhibitors ritonavir, nelfinavir, indinavir, or saquinavir 
anticipated to continue during the study;
17. Systemic use of the P-gp inhibitors ketoconazole, itraconazole, erythromycin, 
azithromycin or clarithromycin at the time of randomization; subsequent use is 
permitted (with appropriate dose reduction of edoxaban see Appendix 17.3.7);
18. Subjects with any condition that as judged by the Investigator would place the 
subject at increased risk of harm if he/she participated in the study.
4.2. Removal of Subjects From Therapy
4.2.1. Reasons for Withdrawal/Early Discontinuation
A subject may discontinue or interrupt study drug for a number of reasons including, but 
not limited to, those listed below: 
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 Withdraw of consent as defined in Section 4.2.1.2;
 Lost to follow-up as defined in Section 4.2.1.3 (every attempt will be made by 
the Investigator not to have subjects "lost to follow-up");
 CrCL decrease to < 30 mL/min, confirmed by repeat testing at least 1 week 
later or need for kidney dialysis;  
 Investigator judgment due to:
o SAE or other safety concern eg,
 Major life-threatening bleeding 
 Onset clinical jaundice or other overt signs of liver toxicity 
o Unfavorable benefit-to-risk evaluation for continuing anticoagulant 
treatment 
 Subject decision (refusal for intake or administration of study drugs). It is 
important to distinguish between withdrawal of consent with regards to 
continuing on study medication but continuing to be followed on study;
 Termination of all or part of the study by the SMCC acting in concert with the 
Sponsor.
4.2.1.1. Temporary Interruption
Temporary interruptions of initial LMWH, edoxaban and dalteparin for 4 or more 
consecutive days will be recorded in the eCRF.  Potential reasons may include:
 Short-term use of prohibited concomitant medications;
 Surgical procedures;
 Any medical condition where continuing study drug may expose the subject to 
an increased hazard;
 New onset of elevated liver enzymes in the absence of a known cause:
o ALT > 8 × ULN or
o AST or ALT > 5 x ULN for more than two weeks
o ALT or AST > 3 x ULN, but not reaching the limits in the above criteria, 
in combination with clinical symptoms suggestive of hepatitis 
o ALT or AST > 3 x ULN with TBL > 2 x ULN 
Interruptions for less than 4 consecutive days will not be recorded in the eCRF unless the 
medication was interrupted due to an adverse event (ie, any interruption in study 
medication due to an AE must be recorded in the eCRF).
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During a study drug interruption or after study drug discontinuation, a subject can be 
placed on antithrombotic therapy per local guidelines and the Investigator's discretion. It 
is, however, discouraged to switch to another DOAC. Guidance for switching from 
edoxaban to other anticoagulants is provided in Appendix 17.2.
Post-randomization changes (other than CrCL decreased to < 30 mL/min or need for 
kidney dialysis) in health status related to study exclusion criteria should not 
automatically lead to study drug interruption or discontinuation unless continuing study 
drug places the subject at undue hazard as determined by the Investigator. Such 
situations should be handled on a case-by-case basis.  It is strongly recommended that the 
Investigator consults with ITREAS (Medical Support Line:  +32 495 54 74 51) if a 
subject has a post randomization change in health status that is associated with an 
exclusion criterion.
Also, a decision to stop prematurely the overall recruitment in the study and/or intake of 
study drug can be taken by the Executive Committee /Sponsor following advice on safety 
aspects of the study by the DMC.  The IECs/IRBs will be informed of this decision. The 
DMC stopping guidelines will be defined prior to the start of the study.  The Sponsor has 
the right to close this study and the right to close a center, at any time, although this 
should occur only after consultation between involved parties and the Executive 
Committee. The IECs/IRBs must be informed.  Should the site be closed prematurely, all 
study materials (except documentation that has to remain stored at site) must be returned 
to the Sponsor. The Investigator will retain all other documents until notification by 
Sponsor for destruction
If the subject is withdrawn due to an adverse event, the Investigator will follow the 
subject until the adverse event has resolved or stabilized.
4.2.1.2. Withdrawal of Consent from Study Participation
In accordance with the Declaration of Helsinki and other applicable regulations, a subject 
has the right to withdraw consent from study participation at any time and for any reason 
without prejudice to his or her future medical care by the physician or at the institution.
However, it is important to distinguish between refusal to continue on study medication 
and continuing to be followed on study versus withdrawal of consent with regards to 
continuing the study all together (ie, withdrawal of consent with regards to continuing on 
study medication and any further study follow-up).
Only subjects who refuse all 4 of the following methods of follow-up will be considered 
to have withdrawn consent from study participation:
 Participation in the trial follow-up visits per protocol, either in clinic or by 
telephone;
 Contact by trial personnel even if only by telephone (quarterly, bi-annually, 
annually, End of Treatment visit only);
 Permission for trial personnel to contact an alternative person (eg, family
member, spouse, partner, legal representative, physician, the anticoagulation 
clinic, or another healthcare provider) even if only by telephone;
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 Permission for trial personnel to access and review their medical information 
from alternative sources (eg, doctor’s notes, hospital records).
If the subject refuses all 4 of the above methods of follow-up, the Investigator should 
personally speak to the subject to ensure the subject understands all of the potential 
methods of follow-up.  If the subject continues to refuse all potential methods of 
follow-up, the Investigator will document this as a withdrawal of consent in the medical 
record.
All subjects should be followed for the full duration of the trial using any or all of the 
above methods, unless there is written documentation by the Investigator of the subject's 
withdrawal of consent to ALL of the above methods of follow-up.
If a subject is withdrawn entirely from the study, the IXRS will be called by the site to 
register the subject as permanently discontinued from the study (and study treatment if 
not done previously).
The site will complete and report the observations as thoroughly as possible up to the 
date of consent withdrawal and including the date of the final dose of study drug. The 
reason(s) for limited follow-up/data collection will be clearly documented in the medical 
record and eCRF.
Public databases and subject finder services may be used to determine subject status and 
to locate potential lost to follow-up patients.
4.2.1.3. Subjects Lost to Follow-Up
The Investigator will make every effort not to have any subjects lost to follow-up.  If a 
subject is potentially lost to follow-up (eg, missed study visits, unable to be contacted by 
phone), the Investigator will make every effort to contact the subject before the subject is 
declared lost to follow-up.  These efforts may include but are not limited to:
 Calling all telephone numbers for the subject and their contacts (including 
during the evening and on weekends);
 Calling primary care physician, referring specialist and/or other listed 
physicians for more recent locator information, date of last office visit, or to 
determine mortality status;
 Sending email and follow with mailing certified letters (return receipt 
requested) to all known subject addresses and all listed contacts (eg, relatives, 
friends, neighbors);
 Reviewing subject’s records and medical notes for any details of a 
hospitalization, doctor’s visit, or other procedure that may indicate status of 
subject;
 Using the Internet to search for possible contact information for subject
 Try reverse directory for phone numbers to get possible addresses
 Utilize social networking sites (eg, Facebook); 
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 Checking local, regional, and national public records to locate subject or 
search for mortality status in accordance with local law;
 Possible home visit.
Once the site has exhausted and documented these actions, the Clinical Research 
Associate or monitor should be contacted for additional guidance and alternative options.
Public databases and subject finder services may be used to determine subject status and 
to locate potential lost to follow-up patients.
4.2.2. Withdrawal Procedures
4.2.2.1. Follow-Up of Subjects with Study Drug Discontinuations
The Investigator may contact ITREAS (Medical Support Line:  +32 495 54 74 51) or
email) in case of any questions regarding how to handle a study drug discontinuation or 
interruption.
All randomized subjects, including those who temporarily interrupted or discontinued 
study drug, will be followed for a 12-month period after randomization, except when the 
study is truncated as noted in Section 3.1.2.1.
In case of premature discontinuation of treatment, study outcomes can be collected by 
telephone contact until 12 months after the first dose of study drug. If the subject has an 
on-site visit at any time after study drug discontinuation, it is expected that a clinical 
status will be obtained along with any laboratory assessments deemed appropriate by the 
Investigator.
If the subject and Investigator agree that study drug can be resumed without increased 
hazard to the subject, study medication may be resumed at any time, regardless of the 
duration of study drug interruption.
Any subject who temporarily interrupts or discontinues study drug due to confirmed liver 
enzyme abnormalities or jaundice in the absence of a known cause (eg, underlying 
cancer), should have an evaluation to determine the cause of the event. Evaluation may 
include the following depending on the clinical situation:
 Abdominal ultrasound;
 Hepatitis A, B, C, and E screening (anti-HAV IgM, HbsAg, anti-HCV plus 
viral titer, and evaluation for Hep E), Antinuclear antibody (ANA) and anti-
SmAb, Cytomegalovirus (CMV), Epstein Barr virus (EBV);
 Additional evaluations as deemed appropriate by the Investigator to exclude 
other causes of liver enzyme and bilirubin elevations.
In the absence of a known cause, follow-up of liver enzymes and bilirubin (total and 
direct) should be performed on a regular basis until the values are stabilized.
All laboratory results, including local laboratory reference ranges are to be recorded in 
the eCRF.
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If the subject and Investigator agree that study drug can be resumed without increased
hazard to the subject, study drug may be resumed at any time, regardless of the duration 
of study drug interruption.
All clinically significant hepatic enzyme abnormalities and/or hepatic events are to be 
documented in the eCRF and prompt submission of the adjudication dossier should also 
occur when indicated/directed (see Section 9.3.1).
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The Investigator must ensure that the investigational products will be used only in 
accordance with the protocol.
 Edoxaban (30 mg) will be supplied by the sponsor as yellow film-coated 
tablets and administered orally (PO).
 LMWH for the edoxaban lead-in will be as prescribed by the Principal 
Investigator (PI).
 Dalteparin will be supplied by the Sponsor as single-use pre-filled syringes 
and administered by SC injection.
The Investigator or designee will be responsible for dispensing study drugs. 
The Investigators/study coordinators must ensure that the appropriate fields on the label 
are completed, including subject number and date of dispensing.  
Subjects must be supplied with sufficient study drug to last until the next scheduled 
dispensing visit.  
Subjects may take edoxaban with or with or without food, in the AM or PM, but at 
approximately the same time every day.  Dalteparin should also be consistently 
administered at approximately the same time every day as well.
5.1.1. Method of Assigning Subjects to Treatments and Dispensing of Study 
Drug
Eligible subjects will be stratified by 1) bleeding risk, and 2) the need for dose 
adjustment.  After confirmation of eligibility, the Investigator will provide the IXRS with 
the study center number, appropriate demographic information consistent with local 
regulations, bleeding risk profile, CrCL, body weight category (≤ 60 kg or > 60 kg), and 
whether the subject’s currently using P-gp inhibitors (see Appendix 17.3.7).
The IXRS will assign the unique subject identification number, stratify the subject by 
bleeding risk and need for dose adjustment, then allocate the treatment group assignment 
for the subject.  A fax or email will be sent by the IXRS to the study site noting the 
treatment group and dosage strength of the assigned medication.  The fax or e-mail will 
also provide a calendar of subsequent dispensing dates.  Study drug will be dispensed at 
randomization, approximately Day 31, Month 2 then at least once every 3 months (more 
frequent dispensing of study drug is allowed if necessary), thereafter while the subject 
remains on treatment.
This study has an open-label, blind-evaluator design with LMWH/edoxaban and 
dalteparin.  The subjects, Investigators, Sponsor, CRO, and ITREAS staff involved in the 
treatment or clinical evaluation of the subjects will be aware of the treatments received.  
There will be an independent DMC to monitor the efficacy and safety data on a periodic 
basis. All study outcome events will be adjudicated by the CEC using blinded evaluators.
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The specifications for generation of the randomization schedule will be prepared by the 
study biostatistician and the CRO in charge of the IXRS.  For this study, the 
randomization schedule refers to a list that includes the randomization number, 
randomization block number, and treatment.
5.1.2. Method of Assessing Treatment Compliance
Dosing compliance will be assessed by means of edoxaban tablet and dalteparin syringe
counts.  
5.1.3. Labeling and Packaging
Edoxaban 30 mg tablets for oral use will be supplied by the Sponsor in PVC/foil blister 
packs.  
Dalteparin will be supplied in pre-filled syringes.




Edoxaban must be stored by the site at 20°C to 25°C (68°F to 77°F) as measured by a 
thermometer in a secure, limited access storage area under the recommended storage 
conditions.  Temperature measurements will be recorded on a temperature log excluding 
weekends and holidays.
Excursions from 15°C to 30°C (59°F to 86°F) are permitted.  The Sponsor must be 
contacted in the event of a temperature excursion outside this range.
5.1.4.2. Dalteparin 
Dalteparin must be stored at controlled room temperature below 25°C (77°F).
5.1.5. Drug Accountability
The IXRS will contain a Drug Accountability Module for any medications provided by 
the Sponsor (eg, edoxaban, dalteparin).  The Investigator or designee will enter the 
required information (see IXRS user manual) in the IXRS drug accountability module. In 
addition, the Investigator or designee shall contact Sponsor as soon as possible if there is 
a problem with the shipment.
A Drug Accountability Record will be provided for the investigational products.  The 
record must be kept current and should contain, the dates and quantities of drug received, 
subject’s (identification number and/or initials or supply number as applicable), for 
whom the investigational product was dispensed, the date and quantity of investigational 
product dispensed and remaining, if from individual subject drug units as well as the 
initials of the dispenser.
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At the end of the study, or as directed, all medications supplied by the Sponsor, including 
any unused, partially used, and empty blisters and syringes will be destroyed at the site 
according to the site’s drug handling and disposition standard operating procedures 
(SOPs).  A copy of these SOPs must be available onsite.  The certificate of destruction 
must be provided to Daiichi Sankyo documenting the drug, the quantity (in tablets or 
syringes), method of destruction, and date of destruction. 
If sites are unable to destroy drug, the monitor will make arrangements to return drug to a 
designated depot for destruction.  
Medications provided by the Sponsor will be destroyed (or returned) only after the study 
monitor has completed an inventory to verify the quantity to be destroyed (or returned).  
The destruction (or return) of medications provided by the sponsor must be documented 
and the documentation filed (and if returned, included in the shipment).
5.2. Concomitant Medications
Pre-specified medications that the subject has taken within 30 days before randomization 
or during the study will be recorded in the “targeted concomitant medications” eCRF.  
These pre-specified medications taken by the subjects upon entry to the study or at any 
time during the study are regarded as targeted concomitant medications and must be 
documented on the appropriate pages of the eCRF.  If the subject has an endpoint event 
or an SAE, then information on targeted and non-targeted concomitant medications taken 
within the past 30 days must be documented on the appropriate eCRF pages.  
Concomitant therapy will be captured until the subjects completes the 12-month study 
period.
A list of specifically excluded medications is provided in Appendix 17.3.  The list reflects 
the list at the beginning of the study.  If there are changes to this list during the study, the 
changes will not be considered a protocol amendment but updated information.  It is 
strongly encouraged to restrict the dose of aspirin (if indicated) to ≤ 100 mg daily, 
although higher doses are permitted for strong clinical indication (eg, development of an 
acute MI).
5.3. Therapeutic Management of Subjects in Emergency Situations
5.3.1. Bleeding
There is no specific antidote to reverse the effect of edoxaban.  The following steps are 
recommended for subjects with ongoing life-threatening bleeding (bleeding resulting in 
hemodynamic compromise requiring intervention or any intracranial hemorrhage):
 Withhold study drug and all antiplatelets/anticoagulants;
 Institute standard of care for life-threatening bleeding (large bore IV or central 
venous line, type and crossmatch blood, admit to the intensive care unit, 
provide hemodynamic and respiratory support);
 Administer antidotes if applicable (eg, administer protamine if the subject had 
recently received heparin);
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 Administer packed red blood cells (or whole blood) as needed.
If life-threatening bleeding persists, it is recommended to contact the ITREAS Medical 
Support Line (+32 495 54 74 51) to discuss subject management.  Use of prothrombin 
complex concentrates (PCCs), recombinant Factor VIIa, other factor procoagulants, or 
antifibrinolytics (depending upon the clinical situation and local availability) should be 
considered in consultation with an expert and the ITREAS Medical Support Line.
5.3.2. Emergency Surgery
If an urgent surgical intervention is needed, anticoagulant therapy should be discontinued 
and the surgery should be deferred, if possible, until at least 12 hours and ideally 24 hours
after the last administration of anticoagulant therapy. There is no reversal agent for 
edoxaban. Protamine can be used to (partially) reverse the effect of LMWH. Depending 
upon the clinical situation and local availability, the use of factor procoagulants or other
measures can be considered in case of the recent intake of edoxaban prior to the surgical 
procedure. It is recommended to consult the ITREAS Medical Support Line (+32 495 54 
74 51) in case of urgent surgery.
5.3.3. Suspected Recurrent VTE
In case of suspected recurrent VTE, the Investigator may decide to treat the subject 
according to the standard of care.
5.4. Therapeutic Management of Subjects for Planned 
Interventions
Given the half-life of both study medications and the interval of dosing (ie, once a day) it 
is advised to withhold the study medications at least 24 hours prior to the planned 
intervention. Study drug can be resumed upon complete hemostasis and after the 
assessment of the bleeding risk, ie, after 6 to 24 hours for most minor procedures and 
after 2-3 days for most surgical procedures that carry a bleeding risk. Antithrombotic 
therapy other than the study drug can be initiated, eg, a (prophylactic) dose of LMWH, 
according to the institutional best practice, until re-initiating dosing of the study drug is 
considered to be appropriate.
It is recommended to consult the ITREAS Medical Support Line (+32 495 54 74 51) in 
case of any further questions on the management of subjects who need a planned 
intervention.
5.5. Therapeutic Management of Subjects in Other Critical 
Situations
Other critical situations could be admission to hospital for acute medical illness or active 
periods of chemotherapy.  In these circumstances gastrointestinal disorders might 
preclude intake of oral therapy with edoxaban and bridging to LMWH is allowed 
according to the guidance in Appendix 17.2.  In case of doubt it is recommended to 
contact the ITREAS Medical Support Line (+32 495 54 74 51).
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5.6. Therapeutic Management of Subjects Beyond Month 12 and at 
Global End-of-Treatment
Subjects requiring additional anti-coagulation therapy who complete their treatment and 
full 12-month post randomization follow-up or whose treatment is truncated due to the 
global End of Treatment date will be managed according to local practice.
Guidance for switching from edoxaban to other anticoagulants is provided in 
Appendix 17.2.
Additional guidance for long-term management of cancer subjects with VTE is provided 
by Lyman, et al.
1
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The Schedule of Study Procedures for this study is provided in Appendix 17.7.
6.1. Study Qualification/Pre-randomization
It is expected that most subjects will have had some or all of the study qualification 
procedures done as part of routine care outside the auspices of this study (for example, 
diagnostic work-up and associated care for VTE).  If these procedures are done prior to
randomization, they may be used to randomize the subject to study and begin completion 
of the eCRF, once the subject has signed the ICF.  The subject does not need to repeat 
recently completed procedures/tests for study qualification.  For such subjects it may be 
possible to combine the study qualification and randomization visits into a single visit.
Any protocol-specified study qualification procedures/tests not already done as part of 
routine care will be conducted only after the subject signs the ICF and before 
randomization.  Prior to signing the ICF, potential subjects will have the study risks and 
benefits explained to them, the associated ICF will be reviewed, and all questions 
answered for them.
The following study qualification procedures must be completed to ensure that the 
subject is eligible for the study.
 Sign ICF;
 Review inclusion/exclusion criteria, and ensure that the subject qualifies with 
regard to the clinical laboratory tests for exclusion criteria:
 Calculated CrCL < 30 mL/min;
 Platelet count < 50,000/mL
 Review concomitant medications for assessment of exclusion criteria;
 Ensure that the subject has a diagnosis of VTE confirmed by appropriate 
imaging methods;
The following imaging methods are typically considered part of routine hospital work-up 
for the management of VTE and/or cancer, and as such, will normally be obtained prior 
to informed consent as part of the subject’s normal standard-of-care.
o For a suspected symptomatic DVT:  compression ultrasonography (CUS), 
venography, or specific computerized tomography (CT) venography. 
o For unsuspected DVT:  a thrombus detected in the IVC or iliac veins on a 
(staging) abdominal or pelvic CT will be considered diagnostic. Because 
of potential flow artifacts and layering of contrast, a suspected thrombus 
detected in the common femoral vein or more distal can only be 
considered if confirmatory CUS or (CT) contrast venography diagnostic 
criteria are also met.
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o For suspected symptomatic PE: Computerized tomographic pulmonary 
angiography (CTPA; also called spiral CT angiography [spiral CT]), 
ventilation perfusion scan (V/Q scan; if perfusion scan only is done a 
confirmatory test for leg DVT is required), or catheter pulmonary 
angiography. 
Note: A perfusion scan (without ventilation scan) does not qualify for the diagnoses of 
PE, unless concomitant DVT is documented.
o For an unsuspected PE: found during a staging-CT a repeat test is not 
recommended in order to limit radiation and contrast exposure. This 
incidental finding will only be considered diagnostic if the clot is in a 
segmental or greater artery, whereas clots in sub-segmental or more 
peripheral arteries will not be accepted due to risk of a false positive 
result.
 Record demographic information;
 Record medical/surgical history, including co-morbidities;
 Record description of cancer (date of diagnosis, type, (ie, histologically or 
cytologically diagnosed solid tumor), location or hematological malignancy, 
stage (eg, early, regionally advanced, metastatic), details on therapeutic 
management);
 Based on data completed in the eCRF it will be assessed whether subject 
meets the criteria for active cancer which will be defined as:
 Diagnosed with cancer within the past 6 months; or
 Recurrent, regionally advanced or metastatic disease; 
 Currently receiving treatment or have received any treatment for cancer 
during the 6 months prior to randomization; or
 A hematologic malignancy not in complete remission
Note:  Subjects not meeting these criteria will be categorized as history of cancer and 
then cancer should have been diagnosed within the 2 years preceding randomization.
 Perform physical examination including vital signs (sitting BP and heart rate) 
and record height and body weight (may be performed by an Investigator or 
other healthcare provider designated by the Investigator);
 Assess the subject for active bleeding, high risk for bleeding, and any other 
contraindications for treatment with LMWH or edoxaban.
Samples obtained as part of routine care outside study auspices may be analyzed by local 
laboratories and the results used to qualify the subject provided the tests were performed 
within 7 days of randomization.  
Full documentation for the above study qualification procedures and related results are 
required, including local laboratory results used to qualify the subject.  Therefore, the
eCRF must be completed for every subject with a signed ICF.
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An index event dossier must be compiled, which includes copies of the diagnostic tests 
done to confirm the index VTE. The dossier will be reviewed by the CEC. Instructions 
for completing the dossier package will be provided in the outcome reporting manual. 
Due to logistical constraints, adjudication of index events will be performed after 
randomization; hence, the adjudicated result will not be used to qualify the subject for the 
study, but rather to subsequently define the outcome analyses sets.
The index event package must also contain copies of test reports or hospital letters 
confirming the subject’s cancer diagnosis.  The investigational site should ensure that any 
personal subject identification other than subject number and initials are removed from 
the index event dossier.
Based on the inclusion criterion that long term treatment with LMWH is intended to be 
given, it is expected that a large proportion of subjects will meet the criteria for active 
cancer.  Nevertheless, the percent of subjects with active cancer will be monitored during 
the study by a medical monitor who will report to the SMCC chair.  If necessary, the 
SMCC will take appropriate actions to ensure that the proportion of subjects with active 
cancer is sufficient (ie, > 75%) to draw valid conclusions in the active-cancer population
6.2. Day 1/Randomization
Before randomization, the Investigator will ensure that all protocol-specified 
pre-randomization requirements and procedures are met and/or completed.  For subjects 
who meet all the inclusion criteria and none of the exclusion criteria, the following will 
be performed on the day of randomization, prior to actual randomization.  
 Complete the IXRS Randomization Visit worksheet including review of 
subject’s age, bleeding risk profile, body weight, calculated CrCL, and 
concomitant medications;
 Record vital signs (sitting BP and heart rate) and weight;
 Assess and record ECOG Performance Status (see Appendix 17.6 for the 
ECOG performance scale);
 Collect serum sample for archiving by QLabs for later testing if necessary.  
Use the QLabs pre-dose Day 1 kit and ship the sample to QLabs;
 Record the following local laboratory results in the eCRF:
 Serum chemistry
 Total bilirubin (direct and indirect)
 Alanine transaminase (ALT)
 Aspartate transaminase (AST)
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 Hematology and platelet count
 Hematocrit  White blood cell (WBC) count 
with differential
 Hemoglobin  Platelet count
If all procedures and tests done before randomization confirm the subject's eligibility for 
the study, access the IXRS, register the subject for study qualification, and obtain the 
subject identification number.  
The following activities and/or assessments will be performed at/during randomization:
 Record AEs and treatments (drug and non-drug) given for AEs;
 Record prior targeted medications taken within 30 days before randomization;
 Record date and time for Day 1 dose of study drug;
 Dispense study drug (dalteparin or edoxaban) and record amount (number of 
tablets and syringes) dispensed;
 Explain the study medications and the proper daily dosing to the subject and 
confirm that the subject understands the proper daily dosing of study 
medication, including when to stop LMWH and begin edoxaban dosing;
 Instruct subject to bring unused study drugs to each study visit;
 Provide subjects with a patient information booklet, which will contain the 
following information:
 The study outline in layman’s terms;
 The local medical contact person and emergency telephone number;
 The visit schedule provided by the IXRS (fax or email with dates of 
telephone and/or hospital visits);
 How to recognize and report signs and symptoms of possible recurrent 
symptomatic PE/DVT or bleeding;
 Instructions to keep empty medication packages;
 How to use the study medication;
 A short list of prohibited medications.
 Provide subjects with a subject identification safety card.
Investigators will maintain a confidential subject identification code list of names of all 
the subjects randomized to study to allow the Investigator to reveal the identity of any 
subject when necessary.
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The treatment period begins with the first dose of LMWH (dalteparin or other LMWH 
depending on randomized treatment assignment) after randomization and ends with the 
last dose of study drug at the time of permanent discontinuation of study drug.  During 
the treatment period, the subject will be instructed to bring all study drug supplies to each 
scheduled (every 3 months) study assessment.  Outcome and other event reporting (eg, 
VTE, bleeding, AEs) will be done throughout the study as soon as site personnel learn of 
the event.  Recording of AEs and treatments (drug and non-drug) given for AEs will be 
done throughout the study.
Subjects who permanently discontinue study drug will be followed for efficacy and safety 
outcomes and SAEs by visit or telephone contact at least once every 3 months until 
Month 12, except as noted in Section 3.1.2.1.  If the subject has an on-site visit, obtain 
vital signs and any laboratory assessments deemed appropriate by the Investigator.  
Ideally, all subjects should have their final EOT post-randomization visit completed in 
person either in-clinic or home visit.
6.3.1. Day 31 (± 3) Visit
At Day 31 following randomization, all subjects should be seen by qualified medical 
personnel for the following procedures:
 Assess for AEs and outcome events;
 Record targeted concomitant medications, any interruptions in chemotherapy 
treatment due to a VTE or bleed event or medication given in association with 
an AE/SAE;
 Assess study drug dosing compliance;
 Record interruptions of edoxaban or dalteparin with the date of last dose and
the date of the first dose of resumption of drug (see also Section 4.2.1.1);
 Capture healthcare resource utilization as appropriate;
 Assess ECOG performance status;
 Monitor and record hemoglobin/hematocrit, platelet counts, weight, serum 
creatinine, creatinine clearance, and P-gp inhibitor use and determine if a 
study drug dose adjustment is necessary;
 Dispense study medications and down-titrate dalteparin subjects to 
maintenance dose.
6.3.2. Months 3, 6, and 9 (± 7 days)
All subjects should be seen by qualified medical personnel for the following procedures:
 Assess for AEs and outcome events;
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 Record targeted concomitant medications, any interruptions in chemotherapy 
treatment due to a VTE or bleed event or medication given in association with 
an AE/SAE;
 Assess study drug dosing compliance (if the subject is still on study 
treatment);
 Record interruptions of edoxaban or dalteparin with the date of last dose and 
the date of the first dose of resumption of drug (if the subject is still on study 
treatment; see also Section 4.2.1.1);
 Capture healthcare resource utilization as appropriate;
 Assess ECOG performance status;
 Monitor and record hemoglobin/hematocrit, platelet counts, weight, serum 
creatinine, creatinine clearance, and P-gp inhibitor use and determine if a 
study drug dose adjustment is necessary (if the subject is still on study 
treatment);
 Liver function test monitoring (only at Month 6 if the subject is still on study 
treatment):
 ie, record (or collect a serum sample for) transaminase (ALT/AST), 
alkaline phosphatase, and bilirubin levels
 Dispense study medications (if the subject is still on study treatment). 
6.4. End of Treatment/Month 12 (± 7 days)
All subjects should be seen by qualified medical personnel for the following procedures
at Month 12 or whenever study treatment is permanently discontinued.  Subjects 
permanently discontinuing study treatment before Month 12 will still be followed until 
Month 12 or the global EOT date whichever occurs first.
 Assess for AEs and outcome events;
 Record targeted concomitant medications, any interruptions in chemotherapy 
treatment due to a VTE or bleed event or medication given in association with 
an AE/SAE;
 Collect all unused study drug (if the subject is still on study treatment)
 Assess study drug dosing compliance (if the subject is still on study 
treatment);
 Record interruptions of edoxaban or dalteparin with the date of last dose and 
the date of the first dose of resumption of drug (if the subject is still on study 
treatment; see also Section 4.2.1.1);
 Count unused edoxaban tablets and dalteparin syringes and record in the 
IXRS drug accountability module (if the subject is still on study treatment);
 Capture healthcare resource utilization as appropriate;
Protocol DU176b-D-U311
Version 3.0, 20 Jan 2016 
Proprietary and Confidential
Page 57
 Assess ECOG Performance Status;
 Update cancer status/stage;
 Liver Function Test monitoring if the subject is still on study treatment:
 ie, record (or collect a serum sample for) transaminase (ALT/AST), 




The Investigator should conduct the study in compliance with the protocol agreed to by 
Sponsor and, if required, by the regulatory authority(ies), and which was given 
approval/favorable opinion by the IRB/IEC.
A deviation to any key protocol procedures, or waiver to any stated eligibility criteria will 
not be allowed except as noted below and where necessary to eliminate immediate 
hazard(s) to the subject.  
Subjects for whom experimental anticancer treatment is instituted after randomization to 
the cancer VTE trial will remain in the study and followed for 12 months or the global 
EOT date, whichever occurs first. The decision whether to discontinue the VTE study 
treatment will be at PI discretion according to local regulations.
Sponsor must be notified of any unintended deviations to the protocol (eg, 
inclusion/exclusion criteria, dosing, missed study visits).
The Investigator, or person designated by the Investigator, should document and explain 
any deviation from the approved protocol.
If a subject was ineligible or received the incorrect dose of investigational treatment, and 
had at least 1 administration of investigational product, the patient should be followed
until study discontinuation.
The Investigator should notify the IECs/IRBs of deviations from the protocol in 
accordance with local procedures.
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Subjects with suspected recurrent PE/DVT will undergo objective testing to assess the 
recurrent episode.  In subjects with bleeding additional examinations will be done if 
deemed necessary by the investigator (eg, hematology blood sample, diagnostic 
imaging/scoping). In subjects with other suspected outcomes such as death, 
cardiovascular events, or other thrombotic events the diagnostic work-up will be 
conducted according to the hospital routine.
For all suspected events an adjudication dossier must be prepared for shipment to the 
CEC. This dossier will contain the following documentation:
 copies of all diagnostic imaging (reports and/or images);
 clinically relevant notes/hospital letters/ laboratory reports/medical records.
Details regarding the definitions of the study outcomes and how they will be assessed are 
provided in the CEC Charter.  The requirements for testing and reporting are provided in 
the Outcome Reporting Manual and will be provided to all sites.
7.1. Primary Outcome Variable(s)
The primary study outcome is the composite of recurrent VTE and major bleeding.
Recurrent VTE is either: 
 symptomatic confirmed (new) DVT or (new) PE;
 unsuspected (new) proximal DVT
 Unsuspected DVT is a DVT coincidentally detected during other 
investigations (eg, abdominal or pelvic CT for cancer staging).  This DVT 
will only be included as an outcome if it concerns a (new) clot located in 
the popliteal or more proximal leg veins.  A thrombus detected in the IVC 
or iliac veins on an abdominal or pelvic CT does not require additional 
confirmation. A thrombus detected in the common femoral vein or more 
distal veins can only be confirmed if CUS (or venography) diagnostic 
criteria are also met.
 unsuspected (new) PE;
 unsuspected PE is an embolism coincidentally detected during other 
investigations (eg, CT for cancer staging), that involves segmental or more 
proximal pulmonary arteries.
 fatal PE (including unexplained death for which PE cannot be ruled out).
Major bleeding is defined as overt bleeding and:
 associated with a decrease in hemoglobin of ≥ 2 g/dL, or
 leading to a transfusion of ≥ 2 units of packed red blood cells or whole blood,
or 
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 occurring in a critical site: intracranial, intraspinal, intraocular, pericardial, 
intra-articular, intramuscular with compartment syndrome, retroperitoneal, or
 contributing to death.
7.2. Secondary Outcome Variable(s)
Secondary outcome variables include:
 Recurrent VTE;
 Major bleeding;
 CRNM bleeding; 
 Major + CRNM bleeding;
 All bleeding;
 Event-free survival, defined as the proportion of subjects over time free of 
recurrent VTE, major bleeding events, and death;
 VTE -related death;
 Mortality from all causes;
 Recurrent DVT;
 Recurrent PE;
 Healthcare resource utilization for potential recurrent VTE and bleed events.
7.3. Other Outcome Variable(s)
Other outcome variables include:
 Cardiovascular events (myocardial infarction, stroke, SEE [see 
Appendix 17.5.1]);
 Thrombotic events at other locations (see Appendix 17.5.2);
 Reason for permanent early discontinuation of study drug.
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8.1. Pharmacokinetic (PK) Variable(s)
Not applicable.
8.2. Pharmacodynamic (PD) Variable(s)
Not applicable.
8.3. Biomarker and Exploratory Variable(s)
Not applicable.
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This study will follow a targeted approach to AE and SAE reporting.  All AEs occurring 
after the subject signs the ICF and through Month 12 or the global EOT date, whichever 
occurs first (see Sections 4.2.2.1 and Section 6.4 ), whether observed by the Investigator 
or reported by the subject, will be recorded on the Master Event/AE page of the CRF if 
they fulfill 1 of the following criteria: 1) meet seriousness criteria (see Section 9.4.2) or 
result in interruption or discontinuation of study drug (edoxaban or dalteparin) ) [Events 
that are assessed by the investigator to be related to the underlying cancer or treatment of 
the underlying cancer do not meet criteria for targeted AE reporting, as defined in 
Section 9.4.2]; 2) meet criteria as a study outcome (see Section 3.1.4); or 3) an event of 
special interest (see Section 9.3).
All laboratory and vital sign values should be evaluated by the Investigator regarding 
clinical significance.  Isolated abnormal laboratory results or vital sign findings should be 
reported as AEs if they are clinically significant, and 1) meet seriousness criteria (see 
Section 9.4.2); or 2) result in interruption or discontinuation of study drug (edoxaban or 
dalteparin) unless related to underlying cancer or other pre-existing condition.  Clinically 
significant abnormal laboratory findings associated with the subject’s cancer or other pre-
existing conditions will not be reported as AEs or SAEs unless judged by the Investigator 
as more severe than expected for the subject’s condition and meet the criteria for targeted 
AE and SAE reporting.  Laboratory results that are defined as an AE of special interest 
(AESI) ie, combined elevations of aminotransferase and bilirubin should be reported 
regardless of causality as described in Section 9.3.1.  Medical conditions (including 
laboratory values/vital signs that are out of range) that were diagnosed or known to exist 
prior to informed consent will be recorded as part of medical history.  All SAEs are to be 
reported according to the procedures in Section 9.5 Serious Adverse Event Reporting-
Procedure for Investigators.  
All SAEs occurring after informed consent for general study participation is obtained are 
to be reported according to the procedures in Section 9.5.  Always report the diagnosis as 
an AE or SAE term.  When a diagnosis is unavailable, report the primary sign or 
symptom as the AE or SAE term with additional details included in the narrative until the 
diagnosis becomes available.  If the signs and symptoms are distinct and do not suggest a 
common diagnosis, report them as individual entries of AE or SAE.  For events that are 
serious due to hospitalization, the reason for hospitalization must be reported as the 
serious adverse event (diagnosis or symptom requiring hospitalization).  A procedure is 
not an AE or SAE, but the reason for the procedure may be an AE or SAE.  A pre-
planned (prior to signing the Informed Consent Form) procedure or treatment requiring 
hospitalization for pre-existing conditions which do not worsen in severity should not be 
reported as SAEs (see Section 9.4.2 for Definitions).  For deaths, the underlying or 
immediate cause of death should always be reported as an SAE. When a subject dies 
from disease progression of pre-existing cancer with no other immediate causes, “disease
progression” should be reported as an SAE.  In addition, any serious, untoward event that 
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may occur subsequent to the reporting period that the Investigator assesses as related to 
study drug should also be reported and managed as an SAE.
At each visit, the Investigator or appropriately qualified designee will determine whether 
any AEs have occurred by evaluating the subject.  Adverse events may be directly 
observed, reported spontaneously by the subject or by questioning the subject at each 
study visit.  Subjects should be questioned in a general way, without asking about the 
occurrence of any specific symptoms.  The Investigator must assess all AEs to determine 
seriousness, severity, and causality, in accordance with the definitions in Section 9.4. 
The Investigator’s assessment must be clearly documented in the site’s source 
documentation with the Investigator’s signature.  
Investigator should follow subjects with AEs until the event has resolved or the condition 
has stabilized.  In case of unresolved AEs including significant abnormal laboratory 
values at the end of study assessment, these events will be followed up until resolution or 
until they become clinically not relevant.
9.2. Safety Outcomes
9.2.1. Bleeding Outcomes
All suspected bleeding events, irrespective of the clinical relevance assessed by the 
Investigator, must be reported and will be reviewed and classified by the CEC as major, 
clinically relevant non major, nuisance or no bleeding event.  
Details regarding the classification of bleeding events and how these events will be 
assessed are provided in the CEC Charter.  The requirements for reporting bleeding 
events are provided in the Outcome Reporting Manual and will be provided to all study 
sites.  
9.3. Events of Special Interest
9.3.1. Combined Elevations of Aminotransferase and Bilirubin
There was no clinically concerning signal of drug-induced liver injury associated with 
edoxaban based on the extensive global Phase 3 experience involving over 34,100 
edoxaban subject-years exposure (with median drug exposure of ~2.5 years among 
~14,000 edoxaban subjects). However, there will be ongoing monitoring of hepatic 
events, including combined elevations of aminotransferases and bilirubin (ALT or AST >
3 x ULN with simultaneous TBL > 2 x ULN), particularly without evidence of 
cholestasis (ALP > 2 x ULN is considered evidence of possible cholestasis) and without 
alternative etiology for hepatocellular damage. 
Combined elevations of aminotransferases and bilirubin whether or not causally related, 
should always be reported to the Sponsor as soon as possible but within 24 hours of 
awareness if they meet the following criteria (see procedures outlined in Section 9.5 for 
SAE reporting):
 The event meets seriousness criteria;
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 The event (serious or non-serious) results in study drug interruption or 
discontinuation;
 The event is non-serious but there is no evidence of cholestasis (ALP > 2 x 
ULN) and without alternative etiology for hepatocellular damage.
In cases of liver laboratory abnormalities, or evidence of liver dysfunction, it is important 
to ensure that the nature and the extent of liver injury is identified and study subjects are 
monitored until the liver laboratory assessments are stabilized (Please refer to Section
4.2.2.1).
9.4. Definitions
9.4.1. Adverse Event (AE)
Any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product and which does not necessarily have to have a 
causal relationship with this treatment.  An AE can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding, for example), symptom, or 
disease temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product (ICH E2A Guideline.  Clinical Safety Data 
Management: Definitions and Standards for Expedited Reporting, Oct 1994).
It is the responsibility of Investigators, based on their knowledge and experience, to 
determine, those circumstances or abnormal laboratory findings which should be 
considered adverse events.
9.4.2. Serious Adverse Event (SAE)
Any untoward medical occurrence that at any dose:
 Results in death;
 Is life-threatening;
 Requires inpatient hospitalization or prolongation of existing hospitalization;
 Results in persistent or significant disability/incapacity;
 Is a congenital anomaly/birth defect; or
 Is an important medical event.
Note: The term “life-threatening” in the definition of “serious” refers to an event in 
which the subject was at risk of death at the time of the event; it does not refer to an event 
which hypothetically might have caused death if it were more severe (ICH E2A 
Guideline.  Clinical Safety Data Management: Definitions and Standards for Expedited 
Reporting, Oct 1994).
Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is appropriate in other situations, such as important medical events that may not 
be immediately life-threatening or result in death or hospitalization but may jeopardize 
the subject or may require intervention to prevent one of the other outcomes listed in the 
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definition above.  Examples include allergic bronchospasm, convulsions, and blood 
dyscrasias or development of drug dependency or drug abuse.
Note:
The following are not considered AEs or SAEs in the context of this study:
 Hospitalization for a pre-planned procedure or diagnostic tests (including for 
cancer staging, eg, CT scan, Magnetic Resonance Imaging, gastroscopy, 
cystoscopy, bronchoscopy, etc) or treatment for pre-existing conditions (eg, 
chemotherapy, radiation therapy) should NOT be reported as SAEs;
 Hospitalization and/or intervention for diagnostic work-up or treatment of 
worsening underlying cancer or complications of cancer treatment (eg, work-
up for febrile neutropenia, transfusion for anemia, MUGA scan to rule out 
cardiomyopathy) should NOT be reported as SAEs.
9.4.3. Adverse Event Severity
The following definitions should be used to assess intensity of AEs per the NCI CTCAE 
criteria:
 Grade 1 Mild AE
 Grade 2 Moderate AE
 Grade 3 Severe AE
 Grade 4 Life-threatening consequences; urgent intervention indicated
 Grade 5 Death related to AE
9.4.4. Causality Assessment
The Investigator should assess causal relationship between an adverse event and the study 
product LMWH/edoxaban on the basis or his/her clinical judgment and the following 
definitions.  The causality assessment should be made based on the available information 
and can be updated as new information becomes available.
 1 = Related:
 The AE follows a reasonable temporal sequence from study drug 
administration, and cannot be reasonably explained by the subject’s 
clinical state or other factors (eg, disease under study, concurrent diseases, 
and concomitant medications).
 The AE follows a reasonable temporal sequence from study drug 
administration, and is a known reaction to the drug under study or its 
chemical group, or is predicted by known pharmacology.
 2 = Not Related:
 The AE does not follow a reasonable sequence from study product 
administration, or can be reasonably explained by the subject’s clinical 
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state or other factors (eg, disease under study, concurrent diseases, and 
concomitant medications).
9.4.5. Action Taken Regarding the Study Product
 1 = Dose Not Changed: No change in study drug dosage was made.
 2 = Drug Withdrawn: The study product was permanently stopped.
 3 = Dose Reduced: The dosage of study product was reduced.
 4 = Drug Interrupted: The study product was temporarily stopped.
 5 = Dose Increased: The dosage of study product was increased.
9.4.6. Adverse Event Outcome
 1 = Recovered/Resolved
 The subject fully recovered from the adverse event with no residual effect 
observed.
 2 = Recovered/Resolved with Sequelae
 The residual effects of the adverse event are still present and observable.
 Include sequelae/residual effects.
 3 = Not Recovered/Not Resolved
 The adverse event itself is still present and observable.
 4 = Fatal
 5 = Unknown
9.4.7. Other Action Taken for Event
 1 = None.
 No treatment was required.
 2 = Medication required.
 Prescription and/or over-the-counter medication was required to treat the 
adverse event.
 3 = Other.
9.5. Serious Adverse Event Reporting–Procedure For Investigators
All AEs, SAEs, AESIs, and study outcomes that meet the criteria specified above will be 
captured in the eCRF. 
Study outcomes are clinically anticipated events and will be periodically reviewed by the 
DMC to ensure prompt identification of any clinically concerning safety issues. Study 
outcomes (suspected recurrent DVT or PE, bleeding, MI, stroke, SEE [see Appendix
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17.5.1], and thrombotic events at other locations [see Appendix 17.5.2]) will be exempted 
from expedited safety reports of suspected unexpected serious adverse reactions
(SUSARs) to regulatory authorities, Investigators, IECs, and IRBs.  All SAEs resulting in 
death, regardless of whether they are waived endpoint events, will be captured in the 
Sponsor’s global safety database.
The following types of events should be reported by the Investigator in eCRF within 
24 hours of awareness to support expedited safety reporting:
 SAEs (see Section 9.4.2 for definition)
 Liver enzyme abnormalities/liver dysfunction events [ALT or AST > 3x ULN 
with simultaneous TBL > 2 x ULN] meeting the following criteria:
 The event meets seriousness criteria;
 The event (serious or non-serious) results in study drug interruption or 
discontinuation;
 The event is non-serious but there is no evidence of cholestasis (ALP 
> 2 x ULN) and without alternative etiology for hepatocellular damage.
Call Quintiles (telephone number will be provided per country, per region; please refer to 
Study Manual for an appropriate phone number) for any questions on SAE reporting. 
Urgent safety queries must be followed up and addressed promptly.  Follow-up 
information and response to non-urgent safety queries should be combined for reporting 
to provide the most complete data possible within each follow-up.
In the event that eCRF is unavailable, report SAEs by faxing the paper Daiichi Sankyo 
Serious Adverse Event Report (SAVER) Form to Quintiles using the provided fax cover 
sheet and the appropriate fax number provided for your country (please refer to Study 
Manual for an appropriate fax number).  Once eCRF becomes available, please enter 
SAEs reported on the SAVER Form into eCRF as soon as possible.
9.5.1. Notifying Regulatory Authorities, Investigators, and IRB/IEC
Daiichi Sankyo and/or Quintiles will inform Investigators, IRBs (Institutional Review 
Board)/ECs, and regulatory authorities of any Suspected Unexpected Serious Adverse 
Event Reactions (SUSARs) occurring in other study centers or other Daiichi Sankyo 
studies of the investigational product (excluding waived study outcomes per Section 9.5), 
as appropriate per local reporting requirements.
In the US, upon receipt of the Sponsor’s notification of SUSARs that occurred with the 
investigational product, unless delegated to the Sponsor, it is the Investigator’s 
responsibility to inform the IRB per Sponsor’s instruction.
In the European Economic Area (EEA) states, it is the Sponsor’s responsibility to report
SUSARs to all ECs.
9.6. Exposure In Utero During Clinical Studies
Daiichi Sankyo must be notified of any subject who becomes pregnant while receiving 
investigational product and through Month 12 or the global EOT date, whichever occurs 
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first, or, within 30 days of last dose if it occurred less than 30 days of the global EOT 
date. 
Although pregnancy is not technically an adverse event, all pregnancies must be followed 
to conclusion to determine their outcome.  This information is important for both drug 
safety and public health concerns.  It is the responsibility of the Investigator, or designee, 
to report any pregnancy in a female subject using the Exposure In Utero (EIU) Reporting 
form.  Please contact your study monitor to receive the EIU Reporting form upon
learning of a pregnancy.  The Investigator should make every effort to follow the subject 
until completion of the pregnancy.  If the outcome of the pregnancy meets the criteria for 
immediate classification as a SAE (ie, post-partum complications, spontaneous abortion, 
stillbirth, neonatal death, or congenital anomaly, including that in an aborted fetus), the 
Investigator should follow the procedures for reporting SAEs outlined in Section 9.5.  
9.7. Clinical Laboratory Evaluations
Local laboratory results and reference ranges for the analytes outlined in Sections 6.2, 
6.3.1, 6.3.2, and 6.4 will be recorded in the eCRF.
9.8. Vital Signs
Vital sign data will consist of heart rate, BP, and height.  Weight will also be recorded in
order to make determinations regarding study drug dose adjustments.
9.9. Electrocardiograms
Routine ECGs are not required but will be recorded in the eCRF when appropriate.
9.10. Physical Findings
A physical examination, conducted prior to or at the time of randomization by the 
Investigator or other qualified health care provider designated by the Investigator, will 
consist of assessment of each of the relevant major body systems.
9.11. Other Safety Assessments
Other safety assessments will be conducted as necessary.
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11.1.1. Randomized Analysis Set
The randomized analysis set includes all subjects randomized to treatment.
11.1.2. Modified Intention-to-Treat Analysis Set




11.1.3. Per-Protocol Analysis Set
The Per-Protocol (PP) Analysis Set includes all randomized subjects who receive at least 
1 dose of study drug, who have not experienced treatment misallocation, and for whom 
the index DVT or PE event at baseline was confirmed by the CEC.  Treatment 
misallocation is defined as a subject taking incorrect treatment during the entire study 
period.
11.1.4. Safety Analysis Set
The Safety Analysis Set includes all randomized subjects who receive at least 1 dose of 
randomized study drug.  Analyses will be based on the randomized treatment, unless a 
subject inadvertently receives the incorrect drug during the entire study, in which case, 
the subject will be grouped according to the treatment actually received.
11.2. General Statistical Considerations
The efficacy analyses will be based on the mITT and PP Analysis sets.
The safety analyses will be based on the Safety Analysis Set.
The data analysis will be performed by a CRO under the guidance of the study 
biostatistician.  Data analyses will be performed using software SAS Version 8.0 or 
higher.
11.3. Study Population Data
The number of subjects in each analysis set will be presented by treatment group.  
Subjects excluded from the analysis sets will be listed and summarized by treatment 
group and reason for exclusion.  The number and percentage of randomized subjects who 
discontinued treatment prematurely will be tabulated by main reason for discontinuation 
and treatment group.  Demographic and baseline characteristics (including risk factors) 
will be summarized by treatment group using descriptive statistics.  No statistical tests 
will be performed.
                                                
1
Study drugs include the LMWH prescribed by the PI as the edoxaban lead-in, edoxaban, and dalteparin.
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11.4.1. Primary Outcome Analyses
The primary outcome analysis will be based on the mITT Analysis Set.  In this analysis,
the time to the first event of the composite primary outcome (recurrent VTE
[symptomatic recurrent DVT, non-fatal symptomatic recurrent PE, unsuspected PE, fatal-
PE] or major bleed) will be analyzed using a Cox’s proportional hazard model including 
treatment group, and the stratification factors as covariates.  The time to first event is 
defined as the time (days) from the day of randomization to the first event experienced by 
a subject during the 12-month study period.  Subjects who do not have a primary 
outcome during the 12-month study period will be censored at Day 365, or the last day 
the subject had a complete assessment for study outcomes, or the global EOT date, 
whichever comes first.  Subjects lost to follow-up, subjects who died because of reasons 
other than DVT/PE, or subjects who withdrew informed consent before the end of the 12-
month treatment period and who did not have a primary outcome, will be censored at the 
last day the subject had a complete assessment for study outcomes.  The 
LMWH/edoxaban-to-comparator Hazard Ratio will be computed with 95% CI (two-sided 
testing), based on this model.  LMWH/edoxaban will be considered non-inferior to 
comparator if the upper limit of the CI is < 1.5.
The assumption of proportional hazards will be checked using graphical methods as log
(log)-plots and plots of scaled Schoenfeld residuals for the primary analysis.  If the 
assumption is seriously violated, then a logistic model including treatment group and the 
stratification factors as covariates will be used.  The impact of selected baseline 
covariates on the primary outcome will be described by calculating adjusted Hazard 
Ratios and corresponding 95% CI of the treatment effect.  
The frequencies of the each components contributing to the primary outcome will be 
described.
The following sensitivity analyses will be performed for the Primary Outcome:
 On-Treatment events based on the PP Analysis Set will be analyzed using the 
counting process approach of the Cox proportional hazards regression model 
including treatment group, and the stratification factors as covariates.    An 
On-Treatment event is defined as the event occurring during the time period 
the subject is taking study drug up to 3 days after their last dose for that time 
period.  Only events occurring prior to or on Day 365 will be included into 
this analysis. Subjects who do not experience an On-Treatment event will be 
censored at Day 365, or the time study drug is permanently discontinued plus 
3 days or on the last day the subject had a complete assessment (in-person 
visit or by telephone) for study outcomes, or the day of global end of 
treatment, whichever comes first. 
 Events occurring during the first 6 months (180 days) based on the mITT
Analysis Set will be analyzed using the same statistical model as the primary 
analysis of the primary outcome. The time to event is defined as the time 
(days) from the randomization to the first event during the first 6 months after 
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randomization.  Subjects who do not experience an event until Day 180 will 
be censored at Day 180, or the time study drug is permanently discontinued or 
on the last day the subject had a complete assessment (in-person visit or by 
telephone) for study outcomes, whichever comes first.
11.4.2. Superiority Analysis of the Primary Outcome
If non-inferiority in the primary outcome is established, LMWH/edoxaban will be 
compared to dalteparin for superiority (α=0.05, two-sided) with regard to the time to an 
event in the composite clinical outcome of recurrent VTE (symptomatic recurrent DVT, 
non-fatal symptomatic recurrent PE, unsuspected PE, and fatal-PE) or major bleed during 
the 12-month study period.  This analysis will be based on the mITT Analysis Set using 
the same proportional hazard model as for the primary outcome.
11.4.3. Secondary Efficacy Outcome Analyses
Summary statistics will be provided for following efficacy outcomes:
 recurrent VTE;
 event-free survival, the proportion of subjects over time free of recurrent 
VTE, major bleeding events, and death;
 VTE -related death;
 recurrent DVT;
 recurrent PE.  
The impact of cancer status on the primary outcome will also be assessed.




All safety analyses will be performed on the Safety Analysis Set.
11.6.1. Analysis of the Primary Safety Outcome
The primary analysis of the primary safety outcome is based on an “On-Treatment” 
approach.  The “on-treatment” major bleeding events will be compared between 
treatment groups for superiority (α=0.05, two-sided) for subjects in the Safety Population, 
using the counting process approach of the Cox proportional hazards regression model 
including treatment group, and the stratification factors as covariates.  However, subjects 
will be censored 3 days after the day of permanent study medication discontinuation.
To control study-wise type I error, the testing for non-inferiority and superiority will 
follow the plan as described in Figure 11.1.  All tests will be two-sided.
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Figure 11.1: Non-Inferiority and Superiority Testing of LMWH/Edoxaban versus 
Dalteparin
11.6.2. Analysis of Secondary Safety Outcomes
Incidence and Hazard Ratio (with 95% CI) for the following outcomes will be calculated 
based on the Safety Analysis Set and On-Treatment-approach using the same counting 
process approach of the Cox proportional hazards regression model as for the primary 
safety outcome analysis:
 Major bleeding;
 Clinically relevant non-major bleeding;
 Major + clinically relevant non-major bleeding;
 All bleeding;
 Mortality from all causes.
Healthcare resource utilization for potential recurrent VTE and bleeding events will be 
analyzed separately.
11.6.3. Exploratory Analyses for Safety Outcomes
The incidence of cardiovascular events (myocardial infarction, stroke, SEE) and 
thrombotic events at other locations will be summarized by treatment.
The reason for permanent early discontinuation of study drug will be summarized by 
treatment group.
Details are specified in the SAP.
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11.6.4. Adverse Event Analyses
Adverse events will be coded according to the Medical Dictionary for Regulatory 
Activities (MedDRA).
Any AE that occurs during the study is a study AE.  Treatment-emergent adverse events 
(TEAEs) are defined as an event that emerges during treatment having been absent 
pre-treatment, or worsens relative to the pre-treatment state.  The incidence of TEAEs 
will be presented for the Safety Analysis Set by treatment group, by relationship to the 
study drug, and by severity.  Frequent TEAEs (reported by at least 5% of subjects in any 
treatment group) will be summarized by treatment group.  Adverse events that start or 
worsen after the third day following the calendar date of any “last dose” and before the 
date of the next “first dose” are defined as post-treatment AEs.  Because a subject can 
have study drug interruptions, it will be possible to have a post-treatment AE that occurs 
at an earlier calendar date than a TEAE.
The incidence of death, SAEs, drug-related SAEs, and AEs leading to discontinuation of 
study drug will be summarized by treatment group.  All AEs will be included in a data 
listing and a listing to display the coding of AEs will be prepared as well.
11.6.5. Clinical Laboratory Evaluation Analyses
The clinical laboratory evaluations at each scheduled visit and the change from baseline 
will be summarized for the Safety Analysis Set by treatment group.  Shift tables (low, 
normal, and high) will be provided for each treatment group for selected clinical
laboratory parameters.  The number and percentage of subjects with clinically relevant 
abnormal clinical laboratory values while on study drug will be calculated for each 
treatment group for selected clinical laboratory parameters.  All abnormal clinical
laboratory values will be presented in a listing.  
11.6.6. Vital Sign Analyses
Vital signs at each evaluation point and the change from baseline will be summarized for 
the Safety Analysis Set by treatment group.  The number and percentages of subjects 
with abnormal vital signs while on study drug will be summarized by treatment group.
11.6.7. Physical Finding Analyses
Abnormalities in physical examinations by body system will be listed.
11.7. Other Analyses
11.8. Interim Analyses
No formal interim analysis is planned.  Risk-benefit will be evaluated by the DMC, 
which will give recommendations on a regular basis to the Executive Committee.  Access 
to interim tabular risk-benefit data will be restricted.  The procedures of the DMC will be 
described in its charter.
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11.9. Data and Safety Monitoring Board
An independent DMC will be created to further protect the rights, safety, and well-being 
of subjects who will be participating in this study.  The DMC will be composed of 
qualified scientists, who are not Investigators in the study and not otherwise directly 
associated with the Sponsor.  The DMC will be described in detail in the DMC Charter.
Activities of the DMC will be documented.  This documentation will include data 
summaries and analyses provided to the committee as well as minutes of the meeting.  
The DMC can recommend study or treatment regimen/group termination to the Executive 
Committee based on pre-specified concerns described in the DMC Charter.
11.10. Subgroup Analyses for Efficacy and Safety
Exploratory subgroup analyses, relative to primary study outcomes and key safety 
outcomes may include, but are not limited to, treatment group comparisons within subject 
characteristics (age, gender, geographic region, dose adjustment) as described in the SAP.
11.11. Sample Size Determination
Assuming a hazard ratio of 1, a total of 191 overall primary events are projected to accrue 
in the mITT analysis set which will ensure at least 80% power for the primary analysis at 
a non- inferiority margin for the hazard ratio of 1.5 and a Type I error of 0.05 (two-
sided).
Assuming a primary combined outcome rate (recurrent VTE or major bleed) of 20.0%, a 
total of 1000 subjects are expected to be randomized to study treatment in order to accrue 
191 overall primary events in the mITT analysis set.
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12. DATA INTEGRITY AND QUALITY ASSURANCE
The Investigator/investigational site will permit study-related monitoring, audits, 
IEC/IRB review and regulatory inspections by providing direct access to source 
data/documents.  Direct access includes permission to examine, analyze, verify, and 
reproduce any records and reports that are important to the evaluation of a clinical study.
This study will utilize Quintiles Data-driven Trial Execution (DTE), which is Quintiles 
model for risk-based monitoring. 
Quintiles’ DTE and Daiichi Sankyo will begin with a risk assessment to evaluate the 
scientific and operational risks of the study. During this risk assessment key data points 
for the study will be identified and the optimum method for monitoring (eg, remote, 
on-site, and/or centralized monitoring processes) each key data point will be determined.  
Key data points are data items that are critical to study analysis, indicate if the objectives 
of the study have been met, support patient safety, and/or are deemed as a priority for 
monitoring.
12.1. Monitoring and Inspections
The Quintiles monitor and regulatory authority inspectors are responsible for contacting 
and visiting the Investigator for the purpose of inspecting the facilities and, upon request, 
inspecting the various records of the study (eg, eCRFs, source data, and other pertinent 
documents).
The monitor is responsible for conducting both onsite and remote monitoring visits 
throughout the study to verify adherence to the protocol; completeness, accuracy, and 
consistency of the data; and adherence to ICH GCP and local regulations on the conduct 
of clinical research.  The frequency of monitoring visits will be dependent on the 
activities at the site. At a minimum the monitor will visit active sites on an annual basis. 
The monitor is responsible for inspecting the eCRFs and ensuring completeness of the 
study essential documents.  The monitor is responsible for inspecting the eCRFs and 
ensuring completeness of the study essential documents.  The monitor should have access 
to subject medical records and other study-related records needed to verify the entries on 
the eCRFs.
Transcription-Based source data verification (SDV) is a strategic monitoring task that 
will be used to detect transcription errors between the source documents and the eCRF. 
SDV will be performed on 100% of data for a sample of enrolled subjects at each site. 
The sample size may be increased where issues are identified. 
Source data review (SDR) is an on-site monitoring process in which source 
documentation is reviewed to ensure that the site’s process for documenting source notes 
is appropriate and that the site is adhering to the requirements of the protocol. The SDR 
will be performed on the same subjects as SDV. The SDR may be performed on 
additional subjects where issues are identified.
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The monitor will communicate deviations from the protocol, SOPs, GCP and applicable 
regulations to the Investigator and will ensure that appropriate action designed to prevent 
recurrence of the detected deviations is taken and documented.
The Investigator agrees to cooperate with the monitor to ensure that any problems 
detected in the course of these monitoring visits are addressed and documented.
Monitoring triggers consisting of essential operational data elements will be used to 
assess site performance, data quality, and patient safety. Monitoring triggers may 
independently trigger a site contact or monitoring visit.
In accordance with ICH GCP and the Sponsor’s audit plans, this study may be selected 
for audit by representatives from Sponsor.  Inspection of site facilities (eg, pharmacy, 
drug storage areas, laboratories, etc) and review of study related records will occur in 
order to evaluate the study conduct and compliance with the protocol, ICH GCP, and 
applicable regulatory requirements.
12.2. Data Collection
The eCRF completion and query resolution should be kept current to enable the monitor 
to review the subject’s status throughout the course of the study and to enable review of 
the data by Clinical Data Management.
12.3. Data Management
Each subject will be identified in the database by a unique subject identifier as defined by 
the sponsor.
To ensure the quality of clinical data across all subjects and sites, two levels of review 
will be performed:
The first level review will comprise of traditional data management review. The second 
level review is a manual check for clinical congruency of the data.
Both the first and second levels of the Clinical Data Management review will be 
performed on subject data according to specifications agreed by Sponsor and CRO.  Data 
will be vetted both electronically and manually; eCRFs data will be electronically vetted 
by programmed data rules within the Electronic Data Capture (EDC).  Queries generated 
by rules and raised by reviewers will be generated and resolved within the EDC 
application.  During these reviews, subject data will be checked for consistency, 
omissions, and any apparent discrepancies.  To resolve any questions arising from the
Clinical/Data Management review process, eCRFs queries will be raised and resolved 
within the EDC application. 
Data received from external sources such as central laboratories will be reconciled to the 
clinical database.
Serious AEs in the clinical database will be reconciled with the safety database.
All Adverse Events and medical history entries will be coded using MedDRA. 
Concomitant medications, when necessary, will be coded using the World Health 
Organization Drug Reference (WHODRUG) List.  
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12.4. Study Documentation and Storage
The Investigator will maintain a Signature List of appropriately qualified persons to 
whom he/she has delegated study duties.  All persons authorized to make entries and/or 
corrections on eCRFs will be included on the Signature List.
Source documents are original documents, data, and records from which the subject’s 
eCRF data are obtained.  These include but are not limited to hospital records, clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, X-rays, and 
correspondence.
The Investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system (Trial Master File) of all study-related (essential) 
documentation, suitable for inspection at any time by representatives from the Sponsor
and/or applicable regulatory authorities.  Essential documents include:
 Subject files containing completed eCRFs, informed consents, and supporting 
copies of source documentation (if kept).
 Study files containing the protocol with all amendments, Investigator’s 
Brochure, copies of relevant essential documents required prior to 
commencing a clinical study, and all correspondence to and from the IEC/IRB 
and the Sponsor.
 Records related to the Investigational Product(s) including acknowledgment 
of receipt at site, accountability records and final reconciliation and applicable 
correspondence.
In addition, all original source documents supporting entries in the eCRFs must be 
maintained and be readily available.
12.5. Record Keeping
Records of subjects, source documents, monitoring visit logs, data correction forms, 
eCRFs, inventory of study product, regulatory documents (eg, protocol and amendments, 
IRB/EC correspondence and approvals, approved and signed informed consent forms, 
Investigator’s Agreement, clinical supplies receipts, distribution and return records), and 
other sponsor correspondence pertaining to the study must be kept in appropriate study 
files at the site.  Source documents include all recordings and observations or notations of 
clinical activities and all reports and records necessary for the evaluation and 
reconstruction of the clinical study.  These records will be retained in a secure file for the 
period required by the institution or site policy.  Prior to transfer or destruction of these 
records, the Sponsor must be notified in writing and be given the opportunity to further 
store such records.
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13. FINANCING AND INSURANCE
13.1. Finances
Prior to starting the study, the Principal Investigator and/or institution will sign a clinical 
study agreement with Quintiles. This agreement will include the financial information 
agreed upon by the parties.
13.2. Reimbursement, Indemnity, and Insurance
Reimbursement, indemnity and insurance shall be addressed in a separate agreement on 
terms agreed upon by the parties.
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A site may not publish results of a study until after a coordinated multicenter publication 
has been submitted for publication or until 1 year after the study has ended, whichever 
occurs first.  Therefore, the site will have the opportunity to publish the results of the 
study, provided that Daiichi Sankyo has had the opportunity to review and comment on 
the site’s proposed publication prior to its being submitted for publication with the prior 
advice of Daiichi Sankyo Legal Affairs (intellectual property council) and with proper 
regard to the protection of subjects’ identities.
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15. STUDY ADMINISTRATIVE INFORMATION
15.1. Protocol Amendments
Any amendments to the study protocol that seem to be appropriate as the study 
progresses will be communicated to the Investigator by the Sponsor.  All protocol 
amendments will undergo the same review and approval process as the original protocol.  
A protocol amendment may be implemented after it has been approved by the IRB/EC, 
unless immediate implementation of the change is necessary for subject safety.  In this 
case, the situation must be documented and reported to the IRB/EC within 5 working 
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17.1. Additional Information on Investigational Products
17.1.1. Fragmin Package Insert
The Fragmin (dalteparin) package insert can be accessed at the following link: 
http://www.medicines.org.uk/emc, then typing Fragmin in the search field.
17.2. Transition from Edoxaban to Other anticoagulants
17.2.1. Edoxaban to VKA
Discontinue edoxaban and administer a parenteral anticoagulant and VKA at the time of 
the next scheduled edoxaban dose.  Once a stable INR ≥ 2.0 is achieved, the parenteral 
anticoagulant must be discontinued and the VKA continued.
17.2.2. Edoxaban to non-VKA Oral Anticoagulants
Discontinue edoxaban and start the non-VKA anticoagulant at the time of the next 
scheduled dose of edoxaban.
17.2.3. Edoxaban to Parenteral Anticoagulants
Discontinue edoxaban and start the parenteral anticoagulant at the time of the next 
scheduled dose of edoxaban.
17.3. Prohibited Concomitant Medications
Specifically excluded concomitant medications and cautions regarding other concomitant 
medications are provided below.  The list in this appendix reflects exclusionary 
concomitant medications at the beginning of the study.  If there are changes to this list 
during the study, the changes will be provided as an update to this appendix, but will not 
be considered a protocol amendment.
17.3.1. Antiplatelet Drugs
Dual antiplatelet therapy (any 2 antiplatelet agents including aspirin plus any other oral or 
IV antiplatelet drug) is prohibited while on study drug.  If a clinical indication for dual 
antiplatelet therapy arises after randomization (eg, placement of an intracoronary stent), 
study drug should be interrupted and use of open-label LMWH/VKA is permitted at the 
physician’s discretion.
Use of any antiplatelet medication, including aspirin, as single agent antiplatelet therapy 
is allowed while on study drug.
It is strongly encouraged to restrict the dose of aspirin (if indicated) to ≤ 100 mg daily, 
although higher doses are permitted for a strong clinical indication (eg, development of 
an acute MI).
Examples of non-aspirin oral antiplatelet agents include the following: 




























IV antiplatelet agents include the following: 






 PGY12 Inhibitor: Cangrelor 
 Dextran 
17.3.2. Oral Anticoagulants Other Than Study Drug
Oral anticoagulants including vitamin K antagonists (eg, warfarin), Factor IIa inhibitors 
(eg, dabigatran), and FXa inhibitors (eg, rivaroxaban, apixaban) after randomization are 
prohibited (unless used to bridge a temporary study drug interruption). The only allowed 
oral antithrombotics are the study drugs.
17.3.3. Parenteral Anticoagulants
Parenteral anticoagulants such as heparin, LMWHs, direct thrombin inhibitors, and FXa 
inhibitors are prohibited except as specifically outlined in the protocol. For instance, 
LMWHs are allowed as lead-in therapy prior to edoxaban administration. Examples of 
prohibited parenteral anticoagulant medications, when used contrary to protocol 
specifications, include the following: 

































Examples of fibrinolytics include the following:
 Tissue plasminogen activator (alteplase, Activase
®
) 
 TNK (tenecteplase, TNKase
®
) 
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If a subject requires treatment with a fibrinolytic agent, then study drug must be 
interrupted while the subject is taking the fibrinolytic drug and at least 24 hours after 
administration of a fibrinolytic agent.
17.3.5. NSAIDs (Excluding Aspirin) 
While on study drug, NSAIDs cannot be taken for  4 days per week.  Less frequent use 
of NSAIDs is permitted while on study drug.  However, the Investigator should weigh the 
benefit/risk of NSAID use in combination with an oral anticoagulant for the individual 















Meclofenamate Mefanamic Acid Meloxicam
Morniflumate Nabumetone Naproxen





Tiaprofenac Acid Tolmetin Zomepirac
17.3.6. COX-2 Inhibitors 
While on study drug, COX-2 inhibitors cannot be taken for  4 days per week.  Less 
frequent use of COX-2 inhibitors is permitted while on study drug.  However, the 
Investigator should weigh the benefit/risk of COX-2 inhibitor use in combination with an 
oral anticoagulant for the individual subject.  Examples of COX-2 inhibitors include the 
following:
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Concomitant use of protease inhibitors (such as ritonavir, nelfinavir, indinavir, and
saquinavir) anticipated to continue during the course of the study is prohibited.  
Concomitant use of certain macrolide antibiotics (erythromycin, azithromycin, and 
clarithromycin) and azole antifungals (ketoconazole and itraconazole) are also prohibited 
at the time of randomization, but subsequent use of these agents is permitted after 
randomization with appropriate dose reduction of edoxaban to 30 mg QD.  Once 
treatment with these P-gp inhibitors is complete, the full 60 mg edoxaban dose should be 
resumed.  
The following common P-gp inhibitors that might be administered to study subjects 
require a reduction in the edoxaban dose to 30 mg QD:
 Tyrosine kinase inhibitors: imatinib, nilotinib, lapatinib, sunitinib, criozitinib,
vandetanib
 Hormonal agents: tamoxifen, enzalutamide, abiraterone,
 Immuno-modulating agents: cyclosporine, tracolimus
Once treatment with these P-gp inhibitors is complete, the full 60 mg edoxaban dose 
should be resumed.
Note:  Other agents in these classes may be administered concurrently without reducing 
the edoxaban dose.
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17.4. Precautions and Dose Modifications for Dalteparin 






47 to 56 10000
57 to 68 12500
69 to 82 15000
≥ 83 18000






57 to 68 10000
69 to 82 12500
83 to 98 15000
≥ 99 18000
Precautions and Dose Modifications
Month 1: 
In the case of chemotherapy-induced thrombocytopenia, the dalteparin dose should be 
adapted as follows: 
 In subjects receiving dalteparin who experience platelet counts between 
50,000 and 100,000/mm
3
, the daily dose of dalteparin should be reduced by 
2,500 IU until the platelet count recovers to ≥100,000/mm
3
. 
 In subjects receiving dalteparin who experience platelet counts < 50,000/mm
3
, 









In the case of chemotherapy-induced thrombocytopenia, the dalteparin dose should be 
adapted as follows: 
 With platelet counts < 50,000/mm
3
, dalteparin dosing should be interrupted 
until the platelet count recovers above 50,000/mm
3
. 
 For platelet counts between 50,000 and 100,000/mm
3
, dalteparin should be 
reduced as illustrated in the table below in accordance with the subject's 
weight.  Once the platelet count has recovered to > 100,000/mm
3
, dalteparin 
should be re-instituted at full dose.











57 to 68 10000 7500
69 to 82 12500 10000
83 to 98 15000 12500
≥99 18000 15000
17.5. Definitions of Cardiovascular and Thrombotic Events
17.5.1. Systemic Embolic Event (SEE)
A systemic embolic event is defined as an abrupt episode of arterial insufficiency 
associated with clinical or radiologic evidence of arterial occlusion in the absence of 
other likely mechanisms (eg, atherosclerosis, instrumentation).  Arterial embolic events 
involving the CNS (including the eye), coronary, and pulmonary arterial circulation are 
not considered SEEs, but will be classified respectively as stroke/TIA, myocardial 
infarction, and pulmonary embolism.  In the presence of atherosclerotic peripheral 
vascular disease, diagnosis of embolism to the lower extremities requires arteriographic 
demonstration of abrupt arterial occlusions.
17.5.2. Thrombotic Events at Other Locations
These include:
 Catheter-associated thrombosis
 Cerebral venous and sinus thrombosis
 Retinal vein occlusion
 Upper extremity venous thrombosis
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 axillary, subclavain and brachial vein thrombosis
 Jugular vein thrombosis
 Superior caval vein thrombosis
 Abdominal vein thrombosis
 Splanchnic vein thrombosis 
 Portal vein thrombosis
 Mesenteric vein thrombosis
 Splenic vein thrombosis
 Hepatic vein thrombosis
 Genito-urinary venous thrombosis
 Renal vein thrombosis
 Ovarian vein thrombosis
 Penile vein thrombosis
 Superficial vein thrombosis of the lower or upper limb
17.6. Eastern Cooperative Oncology Group (ECOG) Performance 
Status
These scales and criteria are used by doctors and researchers to assess how a patient's 
disease is progressing, assess how the disease affects the daily living abilities of the 
patient, and determine appropriate treatment and prognosis. They are included here for 




0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
or sedentary nature, e.g., light house work, office work
2 Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5 Dead
* As published in Am. J. Clin. Oncol.: 
Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity 
And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
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17.7. Schedule of Events


























Vital Signs/Weight X X
Cancer Status/Stage X X X
Clinical Assessments and ECOG 
Performance Status






Serum Creatinine/CrCL X X X X X




Prior and Concomitant Medication X X X X X X X X
AE Reporting
e
X X X X X X X
Outcome Events Reporting
e
X X X X X X X
Healthcare Resource Utilization X X X X X X
Study Drug Dispensing
f
X X X X X
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Study Drug Compliance X X X X X X
Contact IXRS for study drug 
assignment or to enter subject status 
changes
g
X X X X X
LFT-liver function test; VTE-venous thromboembolism; AE-adverse event(s); IXRS-Interactive web/voice response system; CrCL-creatinine clearance; 
ALT-alanine transferase; AST-aspartate transferase; EOT-end-of-treatment; ECOG-Eastern Cooperative Oncology Group.
a
Review inclusion/exclusion criteria and ensure that the subject qualifies with regard to the laboratory tests for exclusion criteria (CrCl , 30 mL/min; 




Physical examination at pre-randomization may be performed by an Investigator or other healthcare provider designated by the Investigator.  The 
physical examination includes vital signs (sitting blood pressure and heart rate), record height, and record body weight.
c
ALT/AST, total bilirubin, and alkaline phosphatase at randomization and subsequent assessments.
d
One serum sample will be collected at randomization for archiving.
e
AE reporting and Outcome Events Reporting should occur throughout the study and not be restricted to specific visits; capture healthcare resource 
utilization data for potential recurrent VTE and bleed events.
f
Study drug assigned by the IXRS will be dispensed as a 3-month supply.
g
All subjects should be seen by qualified medical personnel for the following procedures at Month 12 or whenever study treatment is permanently 
discontinued.  Subjects who discontinue study treatment before Month 12 will still be followed until Month 12, or until the global EOT date, whichever 
comes first.
h
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1. LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
1.1. Abbreviations 
 
AEs Adverse Events Kg  Kilogram 
ALP Alkaline Phosphatase Mg Milligram 
ALT Alanine Aminotransferase min Minute 
AST Aspartate Aminotransferase mITT Modified Intent-to-Treat 
ARO Academic Research Organization PE Pulmonary Embolism 
CEC Clinical Events Committee PK Pharmacokinetic 
CI Confidence Interval PROBE Prospective, randomized, open-
label, blind-evaluator (study 
design) 
CrCL Creatinine Clearance PT Preferred Term 
CRO Contract Research Organization qd Once daily 
CV Cardiovascular SAE Serious Adverse Event 
DMC Data Monitoring Committee SEE Systemic Embolic Event 
DSPD Daiichi Sankyo Pharma 
Development 
SI Standard International 
DVT Deep Vein Thrombosis SOC System Organ Class 
eCRF Electronic Case Report Form TEAE Treatment-emergent Adverse Event 
eDC Electronic Data Capture TESAE Treatment-emergent Serious 
Adverse Event 
IXRS Interactive Voice/Web Response 
System 
ULN Upper Limit of Normal 
LMW Low Molecular Weight VTE Venous Thromboembolic Event 
MI Myocardial Infarction WHO World Health Organization 
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1.2. Definition of Terms 
 
Study Drugs: initial Low Molecular Weight Heparin (LMWH) (dosed after 
randomization), edoxaban, and dalteparin. 
Treatment Groups: References within this Statistical Analysis Plan (SAP) to the 
“LMWH/edoxaban Group” represent those subjects receiving initial Low Molecular 
Weight Heparin followed by edoxaban.  References to the “dalteparin” represent those 
subjects receiving dalteparin. 
Overall Study Period: The time from the randomization date  to the last study follow up 
visit.   
Initial 6-Month Study Period: The time from the randomization date  to Day 180, or the 
last study follow up visit, whichever comes first.   
On-Treatment Period: The time period the subject is taking study drug up to 3 days after 
their last dose for that time period.  A subject may have multiple periods of drug use if 
they temporarily interrupt and resume study drug during the study.  
SAP Version 1.0 Daiichi Sankyo Pharma Development 








This Statistical Analysis Plan (SAP) document provides a more technical and detailed 
description of the statistical analyses as outlined and/or specified in the study protocol 
Version 3.0 (dated 20 January, 2016). 
3. STUDY OBJECTIVES 
3.1. Primary Objective 
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a 
short course of LMWH) compared with dalteparin for the prevention of the combined 
outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with 
VTE associated with cancer during a 12-month study period. The LMWH/edoxaban will 
be considered non-inferior to dalteparin if the upper limit of the two-sided 95% 
confidence interval (CI) for the hazard ratio is less than 1.5. If non-inferiority is 
established, LMWH/edoxaban will be compared with dalteparin for superiority. 
 
3.2. Secondary Objectives 
The secondary objectives are to compare LMWH/edoxaban to dalteparin with regard to 
rates of the following endpoints during the 12-month study period: 
 Recurrent VTE 
 Major Bleeding 
 Clinically relevant non-major (CRNM) bleeding; 
 Major + CRNM bleeding; 
 All Bleeding; 
 Event-free survival, defined as the proportion of subjects over time free of recurrent 
VTE, major bleeding events, and death; 
 VTE-related death; 
 Mortality from all causes;  
 Recurrent deep vein thrombosis (DVT); 
 Recurrent pulmonary embolism (PE); 
 Healthcare resource utilization for potential recurrent VTE and bleed events. 
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3.3. Exploratory Objectives 
Exploratory objectives include comparing LMWH/edoxaban to dalteparin with regards 
to: 
 Cardiovascular (CV) events (myocardial infarction (MI), stroke, systemic embolic 
event (SEE)); 
 Thrombotic events at other locations; 
 Reason for permanent early discontinuation of study drug. 
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4. STUDY DESIGN AND OVERALL STUDY PLAN 
4.1. Study Design 
This is a multinational, prospective, randomized, open-label, blind-evaluator (PROBE), 
non-inferiority study comparing edoxaban with dalteparin for prevention of the combined 
outcome of recurrent VTE or major bleeding in patients with VTE associated with 
cancer.  Adult subjects with VTE associated with cancer (other than basal-cell or 
squamous-cell carcinoma of the skin; cancer should be active or diagnosed within the 
previous 2 years), and who present with confirmed acute symptomatic or unsuspected 
lower extremity proximal DVT, confirmed symptomatic PE, or unsuspected PE in a 
segmental or larger pulmonary artery for whom long-term treatment (at least 6 months) 
with LMWH is indicated are eligible to participate in this study.   
 
After a subject’s eligibility is confirmed, the subject will be stratified by 1) bleeding risk, 
and 2) the need for dose adjustment: 
1. Bleeding risk (assessed at time of randomization) 
 surgery within 2 weeks prior to randomization  
 use of antiplatelet agents (eg, aspirin ≤ 100 mg/day) that will continue during 
the study 
 brain tumor or brain metastases present at the time of randomization 
 metastatic disease present at the time of randomization 
 regionally advanced cancer present at the time of randomization 
 gastrointestinal cancer at randomization or diagnosed within a 6-month period 
prior to randomization 
 urothelial cancer at randomization or diagnosed within a 6-month period prior 
to randomization 
 Avastin (bevacizumab) use at randomization or given within the 6-week 
period prior to randomization 
2. The need for dose adjustment: 
 body weight ≤ 60 kg, or 
 creatinine clearance (CrCL) between 30 and 50 mL/min inclusive 
 concomitant use of P-gp inhibitors  
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After stratification, subjects will be randomly assigned via interactive voice/web response 
system (IXRS) in a 1:1 ratio to one of the two treatment groups: LMWH/edoxaban and 
delteparin. 
After randomization, subjects will be assessed at Month 1, Month 3, and then quarterly 
thereafter for up to 12 months until they complete the study.  
The intention is to treat patients for 12 months with the allocated study treatment. Once 
1000 subjects are randomized in the study, a global end-of-treatment (EOT) date will be 
established that ensures a minimum of 6 months of study treatment and follow-up for the 
final subject(s) randomized.  All subjects will complete or permanently discontinue study 
treatment on or before the EOT date. Subjects requiring additional anti-coagulation 
therapy who complete their treatment and full 12-month post randomization follow-up or 
whose treatment is truncated due to the global EOT date will be managed according to 
local practice. 
Approximately 140 study sites in North America, Europe, and Australia/New Zealand are 
planned to enroll subjects in this study. 
 
4.2. Overall Study Plan 
Regardless of the total duration of study drug treatment actually received, efficacy and 
safety data will be collected on all subjects, including those who temporarily interrupt or 
permanently discontinue study drug, during the entire 12-month study period following 
randomization.  For all subjects, contacts (visits or phone calls) are scheduled at regular 
time points (Protocol Appendix 17.7, Schedule of Events).  During these contacts, the 
treatment and clinical course of the subject will be evaluated.  Subjects with suspected 
efficacy or safety endpoints will undergo confirmatory testing.  All subjects, including 
those who temporarily interrupt or permanently discontinue study drug, will be followed 
up until Month 12, or until the global EOT date, whichever comes first. 
 
4.3. Treatments 
Subjects will be randomized to one of two treatment groups: 
 LMWH/Edoxaban group: Therapeutic doses of LMWH (SC) will be 
administered for at least 5 days; this 5-day period may include the pre-
randomization LMWH (if applicable).  The choice of this parenteral LMWH is up 
to the treating physician.  Thereafter, edoxaban will be started orally at 60 mg QD 
(2 × 30 mg tablets; 30 mg QD for subjects requiring dose adjustment) for the 
remainder of the treatment period.  
 Dalteparin group: After randomization, dalteparin will be administered at a dose 
of 200 IU/kg SC (maximum daily dose 18,000 IU) for 30 days.  The 30 day 
period may include the pre-randomization anticoagulant treatment if dalteparin 
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was used in therapeutic doses.  Thereafter (approximately Day 31 forward), 
dalteparin will be administered at a dose of 150 IU/kg SC (~ 75% - 83% of the 
initial dose) for the remainder of the treatment period.   
 
The edoxaban daily dose should be decreased to 30 mg QD for: 
 body weight ≤ 60 kg; or 
 creatinine clearance [CrCL] between 30 and 50 mL/min inclusive; 
 concomitant use of P-gp inhibitors (eg, hormonal agents: tamoxifen, 
enzalutamide, abiraterone). 
 
Dose reduction of edoxaban to 30 mg QD is intended only during concomitant use of P-
gp inhibitors.  When use of these inhibitors is discontinued/intermittent (eg, between 
chemotherapy cycles) full 60 mg edoxaban dose should be used. 
After randomization, if the subject’s CrCL becomes ≤ 50 mL/min and ≥ 30 mL/min and 
the decrease in CrCL is > 20% from the subject’s baseline CrCL value, repeat the 
measurement preferably within 1 week.  If the repeat measurement confirms this 
decrease, the edoxaban dosage regimen will be reduced permanently, even if the subject 
subsequently experiences improved CrCL to > 50 mL/min at a later measurement. 
After randomization, if the subject’s body weight drops to ≤ 60 kg (confirmed by repeat 
measurement at least 1 week apart) and the body weight change is > 10% of the subject’s 
baseline body weight, the edoxaban dosage regimen will be reduced permanently, even if 
the subject subsequently re-gains weight to > 60 kg. 
 
4.4. Blinding 
This study has an open-label, blinded-evaluator design. The subjects, Investigators, 
Sponsor, Contract Research Organization (CRO), and Academic Research Organization 
(ARO) staff involved in the treatment or clinical evaluation of the subjects will be aware 
of the treatments received.  
An independent Clinical Events Committee (CEC) will adjudicate and categorize the 
presenting index diagnosis, VTE outcomes, cardiovascular events, bleeding events, 
selected hepatic events, and death.  Adjudicators will be blinded as to subject treatment 
allocation. 
There will be an independent Data Monitoring Committee (DMC) to periodically review 
and examine the safety and efficacy data (mortality and events, bleeding events, serious 
adverse events [SAEs], systemic embolic event [SEE]).  
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The specifications for generation of the randomization schedule will be prepared by the 
CRO in charge of the IXRS.  For this study, the randomization schedule refers to a list 
that includes the randomization number, randomization block number, and treatment. 
4.5. Determination of Sample Size 
Assuming a hazard ratio of 1, a total of 191 overall primary events are projected to accrue 
in the mITT analysis set which will ensure at least 80% power for the primary analysis at 
a non-inferiority margin for the hazard ratio of 1.5 and a Type I error of 0.05 (two-sided). 
Assuming a primary combined outcome rate (recurrent VTE or major bleed) of 20.0%, a 
total of 1000 subjects are expected to be randomized to study treatment in order to accrue 
191 overall primary events in the mITT analysis set. 
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5. EFFICACY AND SAFETY ENDPOINTS 
5.1. Primary Outcome Endpoint 
The primary outcome endpoint is the composite of recurrent VTE, or major bleeding.   
Recurrent VTE is either:  
 symptomatic confirmed (new) DVT or (new) PE;  
 unsuspected (new) proximal DVT, which is a DVT coincidentally detected during 
other investigations (eg, abdominal or pelvic CT for cancer staging).  This DVT will 
only be included as an outcome if it concerns a (new) clot located in the popliteal or 
more proximal leg veins.  A thrombus detected in the IVC or iliac veins on an 
abdominal or pelvic CT does not require additional confirmation.  A thrombus 
detected in the common femoral vein or more distal veins can only be confirmed if 
CUS (or venography) diagnostic criteria are also met. 
 unsuspected (new) PE, which is an embolism coincidentally detected during other 
investigations (eg, CT for cancer staging), that involves segmental or more proximal 
pulmonary arteries. 
 fatal PE (including unexplained death for which PE cannot be ruled out).  
 
Major bleeding is defined as overt bleeding and: 
 associated with a decrease in hemoglobin of ≥ 2 g/dL, or 
 leading to a transfusion of ≥ 2 units of packed red blood cells or whole blood, or  
 occurring in a critical site:  intracranial, intraspinal, intraocular, pericardial, intra-
articular, intramuscular with compartment syndrome, retroperitoneal, or 
 contributing to death. 
All suspected recurrent VTE and bleeding events will be adjudicated by the CEC.  
Adjudicated results will be the basis for the final analyses. 
 
5.2. Secondary Efficacy Endpoint 
The secondary endpoints include: 
 Recurrent VTE 
 Event-free survival, defined as the proportion of subjects over time free of recurrent 
VTE, major bleeding events, and death; 
 VTE-related death; 
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 Recurrent deep vein thrombosis (DVT); 
 Recurrent pulmonary embolism (PE); 
All suspected VTE events, deaths, and bleeding events will be adjudicated by the CEC.  
Adjudicated results will be the basis for the final analyses. 
 
5.3. Safety Endpoints 
The primary safety endpoint is major bleeding, and the secondary safety endpoints 
include the following:  
 Major + clinically relevant non-major bleeding;  
 Clinically relevant non-major bleeding;  
 All bleeding; 
 Mortality from all causes. 
CEC adjudication results will form the basis for the final analysis.  Healthcare resource 
utilization for potential recurrent VTE and bleed events will also be analyzed. 
 
5.4. Exploratory Safety Endpoint 
Exploratory endpoints include: 
 CV events (MI, stroke, SEE); 
 Thrombotic events at other locations; 
 Reason for permanent early discontinuation of study drug. 
All suspected CV events and other thrombotic events will be adjudicated by the CEC.  
Adjudicated results will be the basis for the final analyses. 
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6. STATISTICAL METHODS 
The data analysis will be performed by Quintiles under the guidance of the sponsor study 
biostatisticians.  SAS version 8.21,2,3 or newer will be used in the statistical analysis.   
All data will be organized and analyzed according to the scheduled times as outlined in 
the protocol and by visit as denoted on the Electronic Case Report Form (eCRF).   
The clinical database is the source for data used in analyses. The primary data source 
contains all data (including local laboratory data) reported in the Electronic Data Capture 
(eDC) database.  Other sources of data used in analyses are: 
 Event adjudication data from CEC 
 Randomization data collected from IXRS including the stratification information. 
 Post randomization dose adjustment information from IXRS. 
 
All suspected and reported primary, secondary and exploratory endpoint events are 
captured on the eCRF . All endpoint events reported on the event forms will be 
adjudicated in a blinded manner by the CEC. The CEC adjudicator’s results will be 
entered into the adjudication database separate from eDC database.  The final analyses 
will be performed based on the CEC’s adjudicated outcomes. Investigator reported events 
will also be summarized. 
 
6.1. General Procedures and Data Presentation  
Raw data will be presented with the exact precision (decimal points) with which it was 
collected.  The number of decimal places to display for calculated data will be 
determined by the scale of the measurement.  No decimal places will be displayed if the 
smallest calculated value is ≥ 100; 1 decimal place will be displayed when all calculated 
values are within the interval (10, 100), with 10 being inclusive; 2 decimal places will be 
displayed when all calculated values are within (1, 10), with 1 being inclusive; and so on 
for even smaller scales of measurement.  
For continuous variables, statistical summaries will include means, medians, standard 
deviations, maximums, and minimums.  Means and medians will be displayed to one  
more decimal places than the raw or calculated data; standard deviations and other 
dispersion statistics will have two more decimal places; and minimums and maximums 
will be displayed to the same number of decimal places as the raw or calculated data. 
For categorical variables, statistical summaries will include counts and percentages.  
Percentages will be reported with exactly one decimal place.  In general, percentages are 
based on the total number of subjects on whom information is available within the 
analysis set of interest and in that treatment group.  For AEs and incidence analyses, 
percentages are based on the total number of subjects in the analysis set of interest and in 
that treatment group. 
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Kaplan-Meier survival curves will be presented for all time to event analyses. 
All tests and CIs are 2-sided unless specified otherwise. 
All p-values will be displayed with four decimal places.  
All by visit summaries and analyses will use scheduled nominal visit; if two or more 
visits have same nominal visit, the first one will be used.  
 
6.2. Adjustments for Covariates 
For the primary outcome variable, the time to first event will be analyzed using the Cox 
proportional hazards model with model terms for treatment group and the following 
randomization stratification factors: 
 Bleeding Risk (Yes; No) 
 Need for dose adjustment (Yes; No) 
 
Secondary efficacy and key safety endpoints will be analyzed using the similar Cox 
proportional hazards model with model terms for treatment group and the same 
covariates. 
 
6.3. Handling of Dropouts or Missing Data 
All analyses will be performed on observed data only and no missing data will be 
imputed unless otherwise described in the analysis sections.  Right censoring will apply 
for all time to event analyses. 
 
6.3.1. Partial and Estimated Dates 
Partial and estimated dates are allowed for some of the date fields as collected on the 
eCRF.  Partial dates will be imputed differently depending on whether the date is, by 
nature, a baseline date (e.g., the diagnosis date of a medical history) or a post-baseline 
date (e.g., the onset date of an AE).  Estimated dates will be used as collected.  In general, 
a conservative imputation rule will be implemented for all partial dates that will either 
include more events or result in events being considered part of the On-Treatment Period 
(i.e., while on study drug or within three days of last dose of study drug).    
 
6.4. Interim Analyses  
No formal interim analysis is planned; however, risk-benefit will be evaluated by the 
DMC and the DMC chairman will alert the chairman of the Steering Management 
Coordinating Committee (SMCC) in the event of any clinically concerning safety issues.  
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Access to the DMC tabular risk benefit data will be restricted to DMC members.  The 
procedures of the DMC are described in its charter.  
 
6.5. Data Monitoring Committee (DMC) 
An independent DMC will monitor safety during the study and give recommendations to 
the SMCC.  This committee will be unblinded to subjects’ treatment groups.  The 
primary role for the DMC will be to examine the unblinded safety and efficacy data 
(VTE events, bleeding events, deaths, MIs, stroke, SEE, thrombotic events at other 
locations, liver enzyme and bilirubin abnormalities, SAEs) in an ongoing manner and 
alert the Chairman of the SMCC in the event of any clinically concerning safety issues. 
See the submitted DMC charter for details. 
 
6.6. Clinical Events Committee (CEC)  
A CEC will objectively (blinded) adjudicate and categorize the presenting index 
diagnosis, protocol specified VTE events, bleeding events, deaths, CV events (MI, stroke, 
SEE), thrombotic events at other locations, selected hepatic dysfunction / liver enzyme 
elevation.  Due to logistical constraints, adjudication of index events will be performed 
after randomization; hence, these adjudicated index events will not be used to qualify the 
subject for study, but rather to subsequently define the efficacy analyses sets.  Final 
adjudicated results from the CEC assessments will be recorded in the adjudication 
database separate from eDC database for final analysis. See the submitted CEC charter 
for details. 
 
6.7. Data Pooling 
No Data pooling is planned for this study.  





North America USA, Canada 
Central Europe Czech Republic, Hungary 
South Europe France, Italy, Spain 
Western Europe Austria, Belgium, Germany, The Netherlands 
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6.8. Multiple Comparisons/Multiplicity 
The following test plan will be followed in the efficacy and safety analyses: 
Step 1: Test the primary outcome endpoint (overall recurrent VTE or major bleeding) 
based on the Modified Intent-to-Treat (mITT) Analysis Set for non-inferiority at α=0.05. 
Step 2: If non-inferiority is achieved in step 1, then test the primary outcome endpoint 
(overall recurrent VTE or major bleeding) based on the mITT Analysis Set for superiority 
at α=0.05. 
Step 3: Test the primary safety endpoint (on-treatment major bleeding) based on the 
Safety Analysis Set for superiority at α=0.05. 
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7.  STATISTICAL ANALYSIS 
7.1. Analysis Sets 
Randomized Analysis Set: All subjects randomized to treatment. 
Modified Intent-to-Treat (mITT) Analysis Set: All randomized subjects who receive at 
least one dose of post-randomization study drug.     
Per Protocol (PP) Analysis Set: All randomized subjects who receive at least one dose of 
study drug, who have not experienced treatment misallocation, and for whom the index 
Deep Vein Thrombosis (DVT) or pulmonary embolism (PE) event at baseline was 
confirmed by the CEC. Treatment misallocation is defined as a patient taking incorrect 
treatment during the entire study period. 
Safety Analysis Set: All randomized subjects who receive at least one dose of study drug.     
Frequency for each analysis set will be summarized by treatment group for all subjects 
randomized. 
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7.2. Disposition of Subjects 
Enrollment summary will be presented by region, country and treatment group for all 
subjects randomized. 
Disposition of subjects will be summarized for each analysis set by treatment group for 
the Safety/mITT Analysis Set.  This summary includes the total number of subjects 
completing the study per protocol, completing treatment (all subjects who permanently 
stop study treatment at a protocol defined stopping point), discontinuing from treatment, 
and discontinuing from the study. Reasons for discontinuation from treatment and 
discontinuation from the study will be provided.    A comparison by the treatment group 
will also be performed for total number of subjects completing the study and for those 
discontinuing the study. 
A summary of study drug discontinuation/interruptions will include, but not be limited to, 
the following: number and percent of subjects permanently discontinuing study drug and 
reason, number and percent of subjects with at least one interruption and reason, and 
number and percent of occurrences of study drug interruptions (1, ≥2 occurrences) for the 
Safety/mITT Analysis Set.     
Overall study period duration will be summarized for the Safety/mITT Analysis Set. 
Time to premature discontinuation from study by treatment group will be displayed 
graphically for the Safety/mITT Analysis Set.     
Listings will be provided for reasons for study discontinuation and study drug 
discontinuation separately. 
 
7.3. Protocol Deviations 
A descriptive summary and listing of all subjects with major protocol deviations will be 
provided for the mITT Analysis Set.  Prior to database lock, review will occur to finalize 
the list of subjects who meet the criteria for major protocol deviations.  
Major protocol deviations are:  
 Unconfirmed cancer, unconfirmed history of cancer or basal-cell or squamous-cell 
carcinoma of the skin 
 Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the 
current (index) episode of DVT and/or PE; 
 More than 72 hours pre-treatment with therapeutic dosages of anticoagulant treatment 
(LMWH, unfractionated heparin, and fondaparinux per local labeling), oral direct 
anticoagulants or VKA prior to randomization to treat the current (index) episode; 
 Treatment with therapeutic doses of an anticoagulant other than that used for pre-
treatment of the current (index) VTE episode prior to randomization; 
 Treatment misallocation; 
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 Concomitant use of disallowed medications (e.g., concomitant anticoagulation 
therapy) that impact the evaluation of primary outcomes for efficacy and safety; 
 CrCL < 30 mL/min or Platelets < 50,000 cc3 at the time of randomization. 
Any site for which subject data authenticity is suspect and cannot be confirmed will be 
identified at a data review meeting and subsequently excluded from all efficacy and 
safety analyses.  Any such decisions will be finalized and recorded prior to database lock. 
A listing will also be provided to summarize subjects with major protocol deviations. 
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7.4. Demographic and Other Baseline Characteristics 
Demographic and baseline characteristics will be summarized by treatment group and by 
Dose Adjustment Status at Randomization for the Safety/mITT Analysis Set.  All 
categorical parameters will be summarized by frequency and percentage based on the 
number of subjects with available data for that parameter.  Variables such as age, body 
weight, BMI, and CrCL will also be summarized by descriptive statistics including 
means, medians, standard deviations, maximums, and minimums.  
The following categorical baseline characteristics derived from IXRS will be presented: 
 Bleeding risk (yes, no); 
 Body Weight (≤60.0 kg, >60.0 kg); 
 Creatinine clearance (≥30-≤50 mL/min, >50 mL/min); 
 P-gp use at randomization (yes, no);  
 Dose adjusted at randomization (yes, no). 
 
Other categorical baseline characteristics will include: 
 Age (<65, ≥65-<75, ≥75 years);  
 Gender 
 Race 
 Ethnicity (Hispanic/Latino vs Not) for USA subjects only 
 Presenting diagnosis of DVT or PE 
 ECOG performance status 
 Primary cancer history/ Active cancer (specified in protocol section 6.1) 
 Past medical history 
 Region/country 
 
7.5. Measurements of Treatment Compliance 
Study drug dosing compliance will be summarized for the Safety/mITT Analysis Sets and 
will be presented by the three categories: <80%, ≥80% and ≤ 120%, as well as >120% of 
doses taken.   
Edoxaban compliance over the whole treatment period will be calculated as  
(total number of edoxaban tablets taken)/ (total number of edoxaban tablets should be 
taken)*100 
Total number of edoxaban tablets taken will be calculated as: 
∑(amount of dispensed at previous visit – amount of returned at current visit) 
Total number of edoxaban tablets that should be taken will be calculated as: 
∑tablets * (days between two visits – planned interruption days)  
For 60 mg dose, 2 tablets are to be taken; 1 tablet to be taken for 30 mg dose.  
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Treatment compliance for dalteparin will be calculated using the same method but will be 
accounting for number of dalteparin syringes instead of number of edoxaban tablets.  
7.6. Extent of Exposure to Study Drug 
Subject exposure will be summarized for the Safety/mITT Analysis Sets and will be 
presented by total time on study drug at 3 months (>=85 days), 6 months (>=175 days) 
and 12 months (>=353 days) after the first study drug dose.  Descriptive statistics, 
including mean, median, standard deviation, maximum, and minimum, will also be 
provided for total time on study drug, duration of exposure.  
Total time on study drug (exposed to study drug) is defined as the total number of days 
the subject took study drug, with interruptions not included in the interval of time. For 
each subject, the total time on study drug may actually be a few days less than the total 
time in all On-Treatment Periods as it does not include the three days after last dose of  
study medication. 
Total treatment period is defined as the total number of days the subject took study drug, 
with interruptions included in the interval of time (date of last study dose – date of first 
study dose +1).    
Descriptive statistics by treatment group will also be provided for intended treatment 
duration as collected on the eCRF. 
Number of subjects exposed to anti-coagulation therapy prior to randomization will be 
summarized for the Safety/mITT Analysis Set by treatment groups as: [LMW] heparin or 
other anti-coagulation use within the 5 days prior to randomization: None, have been 
used for ≤ 5 days, and have been used for > 5 days. 
 
7.6.1. Targeted Cancer Therapy  
Targeted cancer therapy received on or after initial dose of study drug will be 
summarized by treatment group for the Overall Study Period and  the Safety/mITT 
Analysis Set.    
 
7.6.2. Concomitant Medications  
Targeted and non-targeted concomitant medications taken on or after initial dose of study 
drug will be summarized separately by treatment group for the Overall Study Period.  
Medications will be coded using the World Health Organization (WHO) drug dictionary 
01June2010 Version or later.  Safety/mITT Analysis Set will be used for this analysis. 
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7.6.3. Non-Drug Therapies  
Non-drug therapies performed on or after the initial dose of study drug will be 
summarized by treatment group for the Overall Study Period. Safety/mITT Analysis Set 
will be used for this analysis.  
 
7.7. Analysis of Primary Outcome and Efficacy  
The following will be applied to all efficacy analyses where applicable. 
The mITT and Per Protocol Analysis Sets will be used in the analysis of primary outcome 
and all efficacy endpoints. Analyses for all efficacy endpoints will be based on the 
randomized treatment even if a subject inadvertently receives the incorrect study drug. 
Endpoints will be summarized by treatment group unless otherwise stated. 
The summary statistics for the primary outcome and efficacy endpoints and their 
individual components will be provided.  These statistics include the number of first 
events (i.e., the number of subjects with the event).  For primary outcome and secondary 
efficacy endpoints, the hazard ratios of the LMWH/edoxaban versus dalteparin with 95% 
CIs will be provided using the Cox proportional hazards model with model terms for 
treatment and the randomization stratification factors (bleeding risk, and need for dose 
adjustment) as covariates.  Kaplan-Meier plots4 of time to events for the endpoint will 
also be provided by treatment group.  CEC adjudication results will be the basis for the 
primary analysis.  
The reference date for efficacy analysis during Overall Study Period will be the 
randomization date. The reference date analysis during On-Treatment Period will be the 
first dose date. 
Incidence rates of subjects with ≥ 1 events, ≥ 2 events, etc will be analyzed for each of 
the key efficacy endpoints.   
 
7.7.1. Adjudicated Efficacy Endpoint Derivations 
The detailed definition for each endpoint event is described in the submitted CEC 
Charter.   
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7.7.2. Analyses of Primary Outcome and Efficacy Endpoints  
7.7.2.1. Analyses of the Primary Outcome Endpoint  
7.7.2.1.1. Primary Analysis of the Primary Outcome Endpoint  
The primary analysis will compare treatment efficacy for the occurrence of adjudicated 
composite primary outcome endpoint (recurrent VTE [symptomatic recurrent DVT, non-
fatal symptomatic recurrent PE, unsuspected PE, fatal-PE] or major bleed) using the 
Overall Study Period for all subjects in the mITT Analysis Set.  The events that will be 
counted in this analysis are those events occur from the date of randomization through the 
end of the 12-month (Day 365) study period, the last available date that the subject had a 
complete assessment (in-person visit or by telephone) for study outcomes, or the day of 
global EOT, regardless of whether the subject was taking study drug, whichever comes 
first.  
For subjects who do not experience an event, the time to first event will be censored at 
Day 365, or the last day the subject had a complete assessment (in-person visit or by 
telephone) for study outcomes, or the day of global EOT, whichever comes first. Subjects 
lost to follow-up, subjects who died because of reasons other than DVT/PE, or subjects 
who withdrew informed consent before the end of the 12-month treatment period and 
who did not have a primary outcome, will be censored at the last day the subject had a 
complete assessment for study outcomes. 
The primary outcome analysis is designed to demonstrate that the LMWH/edoxaban 
Group is non-inferior to the dalteparin Group at a non-inferiority margin of 1.5 for hazard 
ratio, using a significance level of α=0.05.  The time to first event will be analyzed using 
a Cox proportional hazards model including model terms for treatment and the 
randomization stratification factors (bleeding risk and need for dose adjustment as binary 
variables) as covariates.  If the upper limit of the two-sided 95% CI of the hazard ratio is 
below 1.5, then non-inferiority to dalteparin Group will be considered established for the 
LMWH/edoxaban Group. 
The assumptions of proportional hazards will be investigated graphically (e.g., log (-log)-
plots and plots of scaled Schoenfeld residuals) for the primary analysis.  If serious 
violations occur, then a logistic model including model terms for treatment, and the 
randomization stratification factors as covariates will be used. The impact of selected 
baseline covariates on the primary outcome will be described by calculating adjusted 
Hazard Ratios and corresponding 95% CI of the treatment effect. 
The components of primary outcome endpoint (recurrent VTE [symptomatic recurrent 
DVT, non-fatal symptomatic recurrent PE, unsuspected PE, fatal-PE] or major bleed) for 
each treatment group will be summarized. 
A listing of suspected endpoints and their adjudicated results will be provided. 
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7.7.2.1.2. Sensitivity Analyses of the Primary Outcome Endpoint 
The following sensitivity analyses will be performed for the Primary Outcome Endpoint: 
 On-Treatment events based on the PP Analysis Set will be analyzed using the 
counting process approach of the Cox proportional hazards regression model 
including treatment group, and the stratification factors (bleeding risk and need for 
dose adjustment as binary variables) as covariates. An On-Treatment event is defined 
as the event occurring during the time period the subject is taking study drug up to 3 
days after their last dose for that time period.  Only events occurring prior to or on 
Day 365 will be included into this analysis.  Subjects who do not experience an On-
Treatment event will be censored at Day 365, or the time study drug is permanently 
discontinued plus 3 days or on the last day the subject had a complete assessment (in-
person visit or by telephone) for study outcomes, or the day of global EOT, 
whichever comes first.  
 Events occurring during the first 6 months (180 days) based on the mITT Analysis 
Set will be analyzed using the same statistical model as the analysis of primary 
outcome during the Overall Study Period.  The time to event is defined as the time 
(days) from the randomization to the first event during the first 6 months (until Day 
180) after randomization.  Subjects who do not experience an event until Day 180 
will be censored at Day 180, or on the last day the subject had a complete assessment 
(in-person visit or by telephone) for study outcomes, whichever comes first. 
 The same analyses for primary outcome endpoint based on the mITT Analysis Set 
during Overall Study Period, and the mITT Analysis Set during the first 6 months 
study period, will also be carried out by dose adjustment status at randomization. 
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7.7.2.1.3.  Superiority Analysis of the Primary Outcome Endpoint 
If non-inferiority in the primary outcome is established, LMWH/edoxaban will be 
compared to dalteparin for superiority (α=0.05, two-sided) with regard to the time to an 
event in the composite clinical outcome of recurrent VTE or major bleed during the 12-
month study period.  This analysis will be based on the mITT Analysis Set during the 
Overall Study Period using the same proportional hazard model as for the primary 
outcome. The same analysis will also be carried out using the same proportional hazard 
model with counting process for the On-Treatment Period for the Per Protocol Analysis 
Set. 
 
7.7.2.2. Analysis of the Secondary Efficacy Endpoint  
Analysis for the secondary efficacy endpoints will be performed using the Overall Study 
Period for the mITT Analysis Set using Cox proportional hazards model including model 
terms for treatment and the randomization stratification factors (bleeding risk and need 
for dose adjustment as binary variables) as covariates. Descriptive summaries will also be 
provided. Secondary efficacy endpoints include: 
 recurrent VTE; 
 event-free survival: the proportion of subjects over time free of recurrent VTE, major 
bleeding events, and death; 
 VTE -related death; 
 recurrent DVT; 
 recurrent PE.   
The same event inclusion and censoring method used in primary outcome endpoint will 
be applied to secondary efficacy endpoints. The LMWH/edoxaban will be compared to 
dalteparin for superiority (α=0.05, two-sided) with regard to the time to an event in 
recurrent VTE during the Overall Study Period. 
Same sensitivity analyses used in primary outcome analysis will also be applied to 
secondary efficacy endpoints, which include:  
 Events occurring during the first 6 months (180 days) based on the mITT Analysis 





SAP Version 1.0 Daiichi Sankyo Pharma Development 




Page 29 of 36  Version Date: February-29-2016 
 
 
7.7.2.3. Subgroup Analyses for the Primary Outcome and Secondary Efficacy 
Endpoints  
 
Subgroup analyses will be performed for the primary outcome and secondary efficacy 
endpoints using the Overall Study Period approach for the mITT Analysis Set, and the 
Initial 6-Month Study Period for the mITT Analysis Set. Descriptive summaries will be 
provided. The percentages will be based on the total number of subjects that make up the 
subgroup being summarized, regardless if an event occurred.  Forest plots will be 
generated for subgroup analyses.     
Subgroups will be based on characteristics including, but not limited to, the following: 
1. Presenting diagnosis of DVT or PE. Adjudicated results will form the basis for the 
subgroup analysis. In the instance the CEC is unable to confirm the diagnosis, the 
investigators’ diagnosis will be used).  
2. Age (<65 years vs. ≥65 years, <75 years vs. ≥75 years)  
3. Gender (male vs. female) 
4. Bleeding Risk at randomization (Yes/No) 
5. Dose adjustment at randomization, (dose adjusted: Yes/No)  
6. CrCL at randomization: 30-<60, 60-<90, >=90 mL/min  
7. Platelet at randomization: 50,000-100,000/mL vs > 100,000/mL  
8. P-gp use at randomization (Yes, No) 
9. Race  
10. Baseline ECOG Performance Status 
11. Initial heparin treatment duration on or after randomization (for example, <5 days, 
5-7 days, 8-10 days, >10 days; ≤median, >median; ≤25th percentile, >25th-50th 
percentile, >50th-75th percentile, >75th percentile). The categorical groups will be 
determined based on subjects in each category prior to database lock.   
12. Heparin use prior to randomization (Yes/No) 
13. Active cancer at randomization (Yes/No) 
The incidence of VTE based on each subgroup will be estimated and a 95% CI for the 
LMWH /edoxaban: dalteparin hazard ratio will be constructed. 
 
7.7.2.4. Exploratory Efficacy Analyses 
The impact of baseline covariates on the primary outcome will also be described by 
calculating adjusted hazard ratios and corresponding 95% CIs for the treatment effect. 
The investigator reported events for primary and secondary endpoints will be 
summarized using Overall Study Period approach for the mITT analysis set. 
Summary of agreement between investigator and adjudicator for investigator suspected, 
confirmed and CEC confirmed primary and secondary efficacy endpoints will be 
provided by treatment group for the mITT Analysis Set. 
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7.8.  Analysis of Safety 
The following procedures will be applied to all safety endpoints unless otherwise stated 
in the individual sections. 
Safety analyses will be summarized for all subjects included in the Safety Analysis Set by 
treatment group. Analyses for all safety endpoints will be based on randomized treatment, 
unless a subject inadvertently receives the incorrect study drug during the entire study, in 
which case, the subject will be grouped according to the treatment actually received. The 
time periods used for analyses are described for each safety parameter.  Adjudicated 
safety events along with select key investigator reported safety events will be analyzed.  
All remaining safety results will be summarized descriptively.  
 
7.8.1. Safety Event Derivations 
Detailed definitions for bleeding categories are described in the submitted CEC Charter.   
 
7.8.1.1. Analysis of the Primary and Secondary Safety Endpoints  
The primary safety endpoint is major bleeding events that occur during On-Treatment 
Period (on study drug or up to 3 days after the last dose for that time period.) 
The time from date of initial study dose to first major bleeding will be compared between 
treatment groups for superiority (α=0.05 two-sided) for subjects in the Safety Analysis 
Set, using a Cox’s proportional hazard regression model with counting process using the 
model terms for treatment and the randomization stratification factors (bleeding risk and 
need for dose adjustment as binary variables) as covariates.   
For subjects did not experience any event, they will be censored 3 days after the day of 
permanent study medication discontinuation, the last day the subject had a complete 
assessment for study outcomes, or the day of global EOT, whichever comes first.   
Subjects who experience multiple major bleeding events will be summarized by 
treatment groups. 
Incidence and Hazard Ratio (with 95% CI) for the following secondary safety outcomes  
will be calculated based on the Safety Analysis Set and On-Treatment-approach using the 
Cox proportional hazards regression model with counting process approach with the  
model terms for treatment and the randomization stratification factors (bleeding risk and 
need for dose adjustment as binary variables) as covariates: 
 Clinically relevant non-major bleeding 
 Major  + clinically relevant non-major bleeding 
 All bleeding 
Adjudicated bleeding events will also be summarized by category, location, 
characteristics, and circumstance as recorded in the CRF for major bleeding, clinically 
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relevant non-major bleeds, and major plus clinically relevant non-major bleeds. All 
investigators reported bleeds will be summarized separately from adjudicated bleeds. 
Adjudicated death events occurred during Overall Study Period described above will also 
be analyzed  using a Cox’s proportional hazard regression model with the treatment and 
the randomization stratification factors (bleeding risk and need for dose adjustment as 
binary variables) as covariates for subjects in the Safety Analysis Set. Subjects will be 
censored after the last day the subject had complete assessment (in-person visit or by 
telephone) for study outcomes, or the day of global EOT, whichever comes first.  
A listing of suspected endpoints and their adjudicated results will be provided. 
 
7.8.1.2. Healthcare Resources Utilization  
The incidence of hospital admission related to recurrent VTE or bleeding events will be 
summarized by treatment group for the Safety Analysis Set using the Overall Study 
Period. Total number of days in hospital, intensive care unit, step-down ward and general 
hospital ward will be descriptively summarized.  
 
7.8.1.3. Exploratory Safety Endpoints  
Incidence and Hazard Ratio (with 95% CI) will be calculated based on the Safety 
Analysis Set  and On-Treatment-approach using the Cox proportional hazards regression 
model with counting process and with the  model terms for treatment and the 
randomization stratification factors (bleeding risk and need for dose adjustment as binary 
variables) as covariates.  
The exploratory safety endpoints include: 
 CV events (MI, stroke, SEE) 
 Thrombotic events at other locations. 
Exploratory safety endpoints occurred during the Overall Study Period described above 
will also be analyzed for subjects in the Safety Analysis Set.  
The investigator reported endpoints will be summarized separately for the On-Treatment 
Period and Overall Study Period. 
Summary of agreement between investigator and adjudicator for investigator suspected, 
confirmed and CEC confirmed safety endpoints will be provided by treatment group for 
the Safety Analysis Set. 
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7.8.1.4. Subgroup Analyses for the Primary and Secondary Safety  Endpoint  
 
Subgroup analyses will be performed for the adjudicated major bleeding, major or 
CRNM bleeding using the Safety Analysis Set for the On-Treatment Period.  Descriptive 
summaries will be provided. Percentages will be based on the total number of subjects 
that make up the subgroup being summarized, regardless if an event occurred.  Forest 
plots will be generated for subgroup analyses.  No inferential analysis will be conducted 
unless specified otherwise. Subgroups to be used for safety analysis will be the same as 
those for efficacy analysis.   
 
7.8.2. Liver Enzyme and Bilirubin Abnormalities 
Liver enzyme and bilirubin abnormalities will be summarized by treatment group using 
the On-Treatment Period for the Safety Analysis Set. These summaries will be for based 
on the adjudicated data, the investigator reported data, and the local laboratory data.  In 
addition, subject listings will be presented for those subjects with reported abnormalities 
whose cases are sent to adjudicators.      
Based on the adjudication information completed by the adjudicators, the nature, clinical 
severity, and causality of an event and whether Hy’s law was satisfied will be presented.   
The number of subjects adjudicated as having hepatocellular injury will be summarized.  
Furthermore, regardless of the investigator reports, all local laboratory results will be 
evaluated by treatment group for the incidence of elevated liver enzymes for the Safety 
Analysis set during the On-Treatment Period.  The number and percentage of subjects 
with elevation of liver enzymes according to various multiples of Upper Limit of Normal 
(ULN) (Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) 
3xULN, 5xULN, 8xULN, 10xULN, 20xULN; total bilirubin ≥1.5xULN, 2xULN, 
3xULN, 5xULN) will be summarized by treatment group. A combination of ALT 
and/or AST  3xULN accompanied by concurrent (within 37 days after the maximum 
AST/ALT) total bilirubin  2xULN will be summarized. Incidence of Alkaline 
Phosphatase (ALP) will be summarized using cutoffs of 1.5xULN,  2xULN, 3xULN, as 
well as confirmed elevation using these same boundaries. Additional combinations of 
(ALT and/or AST  3xULN accompanied by concurrent total bilirubin  2xULN and 
ALP  2xULN) and (ALT and/or AST  3xULN accompanied by concurrent total 
bilirubin  2xULN and concurrent ALP < 2x ULN) will be presented and analyzed.  For 
laboratory data, the assessments performed prior to or on the first dose date will be 
excluded. A listing with clinically significant abnormal values for these tests will be 
provided. 
Scatter plots of Peak AST/ALT vs. Peak Total Bilirubin will be displayed for the Overall 
Study Period. A separated scatter plot of Peak AST/ALT  vs. Peak Total Bilirubin after 
starting Edoxaban will be displayed (i.e., AT and TBL values obtained 1 day after 
starting edoxaban). 
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7.8.3. Adverse Events  
Two sets of AE summaries will be presented:  
1. All AEs excluding investigator confirmed VTE, bleeding, MI, Stroke, SEE, and 
thrombotic  events.  
2.  For all investigator confirmed VTE, bleeding, MI, Stroke, SEE, and thrombotic 
events. 
All adverse event (AE) summaries will be presented by System Organ Class (SOC) and 
by Preferred Term (PT) within each SOC as classified by the Medical Dictionary for 
Regulatory Activities (MedDRA) coding dictionary5 Version 12.0 or newer. 
The primary Treatment-emergent Adverse Event (TEAE) analyses will be presented 
using the On-Treatment Period for the Safety Analysis Set.  TEAEs are defined as an 
event that emerge during treatment having been absent pre-treatment, or worsens relative 
to the pre-treatment state. 
An overall incidence summary of AEs with corresponding 95% CIs for incidence rates 
will be provided, which includes the following:  
 Number and percent of subjects with at least one Treatment-emergent Serious 
Adverse Event (TESAE). 
 Number and percent of subjects with at least one TEAE. 
 Number and percent of subjects with at least one drug-related TEAE. 
 Number and percent of subjects with at least one TEAE with fatal outcome. 
 Number and percent of subjects with at least one TEAE that caused study drug 
permanent discontinuation. 
This summary will also be presented for all AEs including investigator confirmed VTE, 
bleeding, MI, Stroke, SEE, and thrombotic events. 
Incidence rates by SOC and PT will be presented by treatment group for the following: 
 TEAEs/ TESAEs 
 Drug-related TEAEs (only for AEs excluding investigator confirmed events) 
 TEAEs by maximum severity (only for AEs excluding investigator confirmed events) 
 TEAEs with fatal outcome 
 TEAEs/TESAEs that caused study drug permanent discontinuation 
SAEs that occurred prior to the initial dose of study drug will be presented in a subject 
listing.  Any AEs leading to death or permanent discontinuation of study drug will also be 
presented in a subject listing. Investigator confirmed major bleeding AEs, deaths, and 
special interest AEs will be presented in subject listings separately as well.  
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7.8.4. Clinical Laboratory Evaluations  
 
The clinical laboratory evaluations at each scheduled visit and the change from baseline 
will be summarized for the Safety Analysis Set by treatment group. Shift from baseline 
with specific clinically meaningful ranges for select clinical local laboratory evaluations 
will be summarized by treatment group. This will be summarized at each scheduled visit, 
last assessment and at the worst assessment.  If a laboratory retest occurs within a day, 
then the later value will be used for summarization.   
The number and percentage of subjects with clinically relevant abnormal laboratory 
values will be calculated for each treatment group for selected laboratory parameters.  
Percentages for these summaries will be based on the available data, rather than the total 
number of subjects.   
 
7.8.5. Vital Signs and Physical Exam  
Observed values of vital signs including systolic and diastolic blood pressure (mmHg), 
pulse (bpm), weight (kg) and height (cm) collected at randomization will be summarized.  
Observed and changed from baseline in weight collected at each scheduled visit will also 
be summarized.  
Clinically significant physical examination findings will be listed by treatment group for 
each body system. 
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1. LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 
1.1. Abbreviations 
 
AEs Adverse Events Kg  Kilogram 
ALP Alkaline Phosphatase Mg Milligram 
ALT Alanine Aminotransferase min Minute 
AST Aspartate Aminotransferase mITT Modified Intent-to-Treat 
ARO Academic Research Organization PE Pulmonary Embolism 
CEC Clinical Events Committee PK Pharmacokinetic 
CI Confidence Interval PROBE Prospective, randomized, open-
label, blind-evaluator (study 
design) 
CrCL Creatinine Clearance PT Preferred Term 
CRO Contract Research Organization qd Once daily 
CV Cardiovascular SAE Serious Adverse Event 
DMC Data Monitoring Committee SEE Systemic Embolic Event 
DSPD Daiichi Sankyo Pharma 
Development 
SI Standard International 
DVT Deep Vein Thrombosis SOC System Organ Class 
eCRF Electronic Case Report Form TEAE Treatment-emergent Adverse Event 
eDC Electronic Data Capture TESAE Treatment-emergent Serious 
Adverse Event 
IXRS Interactive Voice/Web Response 
System 
ULN Upper Limit of Normal 
LMW Low Molecular Weight VTE Venous Thromboembolic Event 
MI Myocardial Infarction WHO World Health Organization 
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1.2. Definition of Terms 
 
Study Drugs: initial Low Molecular Weight Heparin (LMWH) (dosed after 
randomization), edoxaban, and dalteparin. 
Treatment Groups: References within this Statistical Analysis Plan (SAP) to the 
“LMWH/edoxaban Group” represent those subjects receiving initial Low Molecular 
Weight Heparin followed by edoxaban.  References to the “dalteparin” represent those 
subjects receiving dalteparin. 
Overall Study Period: The time from the randomization date to the last study follow up 
visit.   
Initial 6-Month Study Period: The time from the randomization date to Day 180, or the 
last study follow up visit, whichever comes first.   
On-Treatment Period: The time period the subject is taking study drug up to 3 days after 
their last dose for that time period.  A subject may have multiple periods of drug use if 
they temporarily interrupt and resume study drug during the study.  
Initial 6-Month On-Treatment Period: The time period the subject is taking study drug up 
to 3 days after their last dose or up to Day 180, whichever comes first.   
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This Statistical Analysis Plan (SAP) document provides a more technical and detailed 
description of the statistical analyses as outlined and/or specified in the study protocol 
Version 3.0 (dated 20 January, 2016). 
3. STUDY OBJECTIVES 
3.1. Primary Objective 
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a 
short course of LMWH) compared with dalteparin for the prevention of the combined 
outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with 
VTE associated with cancer during a 12-month study period. The LMWH/edoxaban will 
be considered non-inferior to dalteparin if the upper limit of the two-sided 95% 
confidence interval (CI) for the hazard ratio is less than 1.5. If non-inferiority is 
established, LMWH/edoxaban will be compared with dalteparin for superiority. 
3.2. Secondary Objectives 
The secondary objectives are to compare LMWH/edoxaban to dalteparin with regard to 
rates of the following endpoints during the 12-month study period: 
• Recurrent VTE 
• Major Bleeding 
• Clinically relevant non-major (CRNM) bleeding; 
• Major + CRNM bleeding; 
• All Bleeding; 
• Event-free survival, defined as the proportion of subjects over time free of recurrent 
VTE, major bleeding events, and death; 
• VTE-related death; 
• Mortality from all causes;  
• Recurrent deep vein thrombosis (DVT); 
• Recurrent pulmonary embolism (PE); 
• Healthcare resource utilization for potential recurrent VTE and bleed events. 
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3.3. Exploratory Objectives 
Exploratory objectives include comparing LMWH/edoxaban to dalteparin with regards 
to: 
• Cardiovascular (CV) events (myocardial infarction (MI), stroke, systemic embolic 
event (SEE)); 
• Thrombotic events at other locations; 
• Reason for permanent early discontinuation of study drug. 
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4. STUDY DESIGN AND OVERALL STUDY PLAN 
4.1. Study Design 
This is a multinational, prospective, randomized, open-label, blind-evaluator (PROBE), 
non-inferiority study comparing edoxaban with dalteparin for prevention of the combined 
outcome of recurrent VTE or major bleeding in patients with VTE associated with 
cancer.  Adult subjects with VTE associated with cancer (other than basal-cell or 
squamous-cell carcinoma of the skin; cancer should be active or diagnosed within the 
previous 2 years), and who present with confirmed acute symptomatic or unsuspected 
lower extremity proximal DVT, confirmed symptomatic PE, or unsuspected PE in a 
segmental or larger pulmonary artery for whom long-term treatment (at least 6 months) 
with LMWH is indicated are eligible to participate in this study.   
 
After a subject’s eligibility is confirmed, the subject will be stratified by 1) bleeding risk, 
and 2) the need for dose adjustment: 
1. Bleeding risk (assessed at time of randomization) 
• surgery within 2 weeks prior to randomization  
• use of antiplatelet agents (eg, aspirin ≤ 100 mg/day) that will continue during 
the study 
• brain tumor or brain metastases present at the time of randomization 
• metastatic disease present at the time of randomization 
• regionally advanced cancer present at the time of randomization 
• gastrointestinal cancer at randomization or diagnosed within a 6-month period 
prior to randomization 
• urothelial cancer at randomization or diagnosed within a 6-month period prior 
to randomization 
• Avastin (bevacizumab) use at randomization or given within the 6-week 
period prior to randomization 
2. The need for dose adjustment: 
• body weight ≤ 60 kg, or 
• creatinine clearance (CrCL) between 30 and 50 mL/min inclusive 
• concomitant use of P-gp inhibitors  
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After stratification, subjects will be randomly assigned via interactive voice/web response 
system (IXRS) in a 1:1 ratio to one of the two treatment groups: LMWH/edoxaban and 
delteparin. 
After randomization, subjects will be assessed at Month 1, Month 3, and then quarterly 
thereafter for up to 12 months until they complete the study.  
The intention is to treat patients for 12 months with the allocated study treatment. Once 
1000 subjects are randomized in the study, a global end-of-treatment (EOT) date will be 
established that ensures a minimum of 6 months of study treatment and follow-up for the 
final subject(s) randomized.  All subjects will complete or permanently discontinue study 
treatment on or before the EOT date. Subjects requiring additional anti-coagulation 
therapy who complete their treatment and full 12-month post randomization follow-up or 
whose treatment is truncated due to the global EOT date will be managed according to 
local practice. 
Approximately 140 study sites in North America, Europe, and Australia/New Zealand are 
planned to enroll subjects in this study. 
 
4.2. Overall Study Plan 
Regardless of the total duration of study drug treatment actually received, efficacy and 
safety data will be collected on all subjects, including those who temporarily interrupt or 
permanently discontinue study drug, during the entire 12-month study period following 
randomization.  For all subjects, contacts (visits or phone calls) are scheduled at regular 
time points (Protocol Appendix 17.7, Schedule of Events).  During these contacts, the 
treatment and clinical course of the subject will be evaluated.  Subjects with suspected 
efficacy or safety endpoints will undergo confirmatory testing.  All subjects, including 
those who temporarily interrupt or permanently discontinue study drug, will be followed 
up until Month 12, or until the global EOT date, whichever comes first. 
 
4.3. Treatments 
Subjects will be randomized to one of two treatment groups: 
• LMWH/Edoxaban group: Therapeutic doses of LMWH (SC) will be 
administered for at least 5 days; this 5-day period may include the pre-
randomization LMWH (if applicable).  The choice of this parenteral LMWH is up 
to the treating physician.  Thereafter, edoxaban will be started orally at 60 mg QD 
(2 × 30 mg tablets; 30 mg QD for subjects requiring dose adjustment) for the 
remainder of the treatment period.  
• Dalteparin group: After randomization, dalteparin will be administered at a dose 
of 200 IU/kg SC (maximum daily dose 18,000 IU) for 30 days.  The 30 day 
period may include the pre-randomization anticoagulant treatment if dalteparin 
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was used in therapeutic doses.  Thereafter (approximately Day 31 forward), 
dalteparin will be administered at a dose of 150 IU/kg SC (~ 75% - 83% of the 
initial dose) for the remainder of the treatment period.   
 
The edoxaban daily dose should be decreased to 30 mg QD for: 
• body weight ≤ 60 kg; or 
• creatinine clearance [CrCL] between 30 and 50 mL/min inclusive; 
• concomitant use of P-gp inhibitors (eg, hormonal agents: tamoxifen, 
enzalutamide, abiraterone). 
 
Dose reduction of edoxaban to 30 mg QD is intended only during concomitant use of P-
gp inhibitors.  When use of these inhibitors is discontinued/intermittent (eg, between 
chemotherapy cycles) full 60 mg edoxaban dose should be used. 
After randomization, if the subject’s CrCL becomes ≤ 50 mL/min and ≥ 30 mL/min and 
the decrease in CrCL is > 20% from the subject’s baseline CrCL value, repeat the 
measurement preferably within 1 week.  If the repeat measurement confirms this 
decrease, the edoxaban dosage regimen will be reduced permanently, even if the subject 
subsequently experiences improved CrCL to > 50 mL/min at a later measurement. 
After randomization, if the subject’s body weight drops to ≤ 60 kg (confirmed by repeat 
measurement at least 1 week apart) and the body weight change is > 10% of the subject’s 
baseline body weight, the edoxaban dosage regimen will be reduced permanently, even if 
the subject subsequently re-gains weight to > 60 kg. 
 
4.4. Blinding 
This study has an open-label, blinded-evaluator design. The subjects, Investigators, 
Sponsor, Contract Research Organization (CRO), and Academic Research Organization 
(ARO) staff involved in the treatment or clinical evaluation of the subjects will be aware 
of the treatments received.  
An independent Clinical Events Committee (CEC) will adjudicate and categorize the 
presenting index diagnosis, VTE outcomes, cardiovascular events, bleeding events, 
selected hepatic events, and death.  Adjudicators will be blinded as to subject treatment 
allocation. 
There will be an independent Data Monitoring Committee (DMC) to periodically review 
and examine the safety and efficacy data (mortality and events, bleeding events, serious 
adverse events [SAEs], systemic embolic event [SEE]).  
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The specifications for generation of the randomization schedule will be prepared by the 
CRO in charge of the IXRS.  For this study, the randomization schedule refers to a list 
that includes the randomization number, randomization block number, and treatment. 
4.5. Determination of Sample Size 
Assuming a hazard ratio of 1, a total of 191 overall primary events are projected to accrue 
in the mITT analysis set which will ensure at least 80% power for the primary analysis at 
a non-inferiority margin for the hazard ratio of 1.5 and a Type I error of 0.05 (two-sided). 
Assuming a primary combined outcome rate (recurrent VTE or major bleed) of 20.0%, a 
total of 1000 subjects are expected to be randomized to study treatment in order to accrue 
191 overall primary events in the mITT analysis set. 
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5. EFFICACY AND SAFETY ENDPOINTS 
5.1. Primary Outcome Endpoint 
The primary outcome endpoint is the composite of recurrent VTE, or major bleeding.   
Recurrent VTE is either:  
• symptomatic confirmed (new) DVT or (new) PE;  
• unsuspected (new) proximal DVT, which is a DVT coincidentally detected during 
other investigations (eg, abdominal or pelvic CT for cancer staging).  This DVT will 
only be included as an outcome if it concerns a (new) clot located in the popliteal or 
more proximal leg veins.  A thrombus detected in the IVC or iliac veins on an 
abdominal or pelvic CT does not require additional confirmation.  A thrombus 
detected in the common femoral vein or more distal veins can only be confirmed if 
CUS (or venography) diagnostic criteria are also met. 
• unsuspected (new) PE, which is an embolism coincidentally detected during other 
investigations (eg, CT for cancer staging), that involves segmental or more proximal 
pulmonary arteries. 
• fatal PE (including unexplained death for which PE cannot be ruled out).  
 
Major bleeding is defined as overt bleeding and: 
• associated with a decrease in hemoglobin of ≥ 2 g/dL, or 
• leading to a transfusion of ≥ 2 units of packed red blood cells or whole blood, or  
• occurring in a critical site:  intracranial, intraspinal, intraocular, pericardial, intra-
articular, intramuscular with compartment syndrome, retroperitoneal, or 
• contributing to death. 
All suspected recurrent VTE and bleeding events will be adjudicated by the CEC.  
Adjudicated results will be the basis for the final analyses. 
 
5.2. Secondary Efficacy Endpoint 
The secondary endpoints include: 
• Recurrent VTE 
• Event-free survival, defined as the proportion of subjects over time free of recurrent 
VTE, major bleeding events, and death; 
• VTE-related death; 
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• Recurrent deep vein thrombosis (DVT); 
• Recurrent pulmonary embolism (PE); 
All investigator reported VTE events, deaths, and bleeding events will be adjudicated by 
the CEC.  Adjudicated results will be the basis for the final analyses. 
 
5.3. Safety Endpoints 
The primary safety endpoint is major bleeding, and the secondary safety endpoints 
include the following:  
• Major + clinically relevant non-major bleeding;  
• Clinically relevant non-major bleeding;  
• All bleeding; 
• Mortality from all causes. 
CEC adjudication results will form the basis for the final analysis.  Healthcare resource 
utilization for potential recurrent VTE and bleed events will also be analyzed. 
 
5.4. Exploratory Safety Endpoint 
Exploratory endpoints include: 
• CV events (MI, stroke, SEE); 
• Thrombotic events at other locations; 
• Reason for permanent early discontinuation of study drug. 
All investigator reported CV events and other thrombotic events will be adjudicated by 
the CEC.  Adjudicated results will be the basis for the final analyses. 
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6. STATISTICAL METHODS 
The data analysis will be performed by Quintiles under the guidance of the sponsor study 
biostatisticians.  SAS version 8.21,2,3 or newer will be used in the statistical analysis.   
All data will be organized and analyzed according to the scheduled times as outlined in 
the protocol and by visit as denoted on the Electronic Case Report Form (eCRF).   
The clinical database is the source for data used in analyses. The primary data source 
contains all data (including local laboratory data) reported in the Electronic Data Capture 
(eDC) database.  Other sources of data used in analyses are: 
• Event adjudication data from CEC 
• Randomization data collected from IXRS including the stratification information. 
• Post randomization dose adjustment information from IXRS. 
 
All investigator reported primary, secondary and exploratory endpoint events are 
captured on the eCRF . All endpoint events reported on the event forms will be 
adjudicated in a blinded manner by the CEC. The CEC adjudicator’s results will be 
entered into the adjudication database separate from eDC database.  The final analyses 
will be performed based on the CEC’s adjudicated outcomes. Investigator reported events 
will also be summarized. 
 
6.1. General Procedures and Data Presentation  
Raw data will be presented with the exact precision (decimal points) with which it was 
collected.  The number of decimal places to display for calculated data will be 
determined by the scale of the measurement.  No decimal places will be displayed if the 
smallest calculated value is ≥ 100; 1 decimal place will be displayed when all calculated 
values are within the interval (10, 100), with 10 being inclusive; 2 decimal places will be 
displayed when all calculated values are within (1, 10), with 1 being inclusive; and so on 
for even smaller scales of measurement.  
For continuous variables, statistical summaries will include means, medians, standard 
deviations, maximums, and minimums.  Means and medians will be displayed to one  
more decimal places than the raw or calculated data; standard deviations and other 
dispersion statistics will have two more decimal places; and minimums and maximums 
will be displayed to the same number of decimal places as the raw or calculated data. 
For categorical variables, statistical summaries will include counts and percentages.  
Percentages will be reported with exactly one decimal place.  In general, percentages are 
based on the total number of subjects on whom information is available within the 
analysis set of interest and in that treatment group.  For AEs and incidence analyses, 
percentages are based on the total number of subjects in the analysis set of interest and in 
that treatment group. 
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Kaplan-Meier survival curves will be presented for all time to event analyses. 
All tests and CIs are 2-sided unless specified otherwise. 
All p-values will be displayed with four decimal places.  
When the number of events in at least one of the treatment groups is <3, hazard ratios, 
CIs and p-values will not be presented. 
All by visit summaries and analyses will use scheduled nominal visit; if two or more 
visits have same nominal visit, the first one will be used.  
 
6.2. Adjustments for Covariates 
For the primary outcome variable, the time to first event will be analyzed using the Cox 
proportional hazards model with model terms for treatment group and the following 
randomization stratification factors: 
• Bleeding Risk (Yes; No) 
• Need for dose adjustment (Yes; No) 
 
Secondary efficacy and key safety endpoints will be analyzed using the similar Cox 
proportional hazards model with model terms for treatment group and the same 
covariates. 
 
6.3. Handling of Dropouts or Missing Data 
All analyses will be performed on observed data only and no missing data will be 
imputed unless otherwise described in the analysis sections.  Right censoring will apply 
for all time to event analyses. 
 
6.3.1. Partial and Estimated Dates 
Partial and estimated dates are allowed for some of the date fields as collected on the 
eCRF.  Partial dates will be imputed differently depending on whether the date is, by 
nature, a baseline date (e.g., the diagnosis date of a medical history) or a post-baseline 
date (e.g., the onset date of an AE).  Estimated dates will be used as collected.  In general, 
a conservative imputation rule will be implemented for all partial dates that will either 
include more events or result in events being considered part of the On-Treatment Period 
(i.e., while on study drug or within three days of last dose of study drug).    
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6.4. Interim Analyses  
No formal interim analysis is planned; however, risk-benefit will be evaluated by the 
DMC and the DMC chairman will alert the chairman of the Joint Steering Committee 
(JSC) in the event of any clinically concerning safety issues.  Access to the DMC tabular 
risk benefit data will be restricted to DMC members.  The procedures of the DMC are 
described in its charter.  
 
6.5. Data Monitoring Committee (DMC) 
An independent DMC will monitor safety during the study and give recommendations to 
the JSC.  This committee will be unblinded to subjects’ treatment groups.  The primary 
role for the DMC will be to examine the unblinded safety and efficacy data (VTE events, 
bleeding events, deaths, MIs, stroke, SEE, thrombotic events at other locations, liver 
enzyme and bilirubin abnormalities, SAEs) in an ongoing manner and alert the Chairman 
of the JSC in the event of any clinically concerning safety issues. See the submitted DMC 
charter for details. 
 
6.6. Clinical Events Committee (CEC)  
A CEC will objectively (blinded) adjudicate and categorize the presenting index 
diagnosis, protocol specified VTE events, bleeding events, deaths, CV events (MI, stroke, 
SEE), thrombotic events at other locations, selected hepatic dysfunction / liver enzyme 
elevation.  Due to logistical constraints, adjudication of index events will be performed 
after randomization; hence, these adjudicated index events will not be used to qualify the 
subject for study, but rather to subsequently define the efficacy analyses sets.  Final 
adjudicated results from the CEC assessments will be recorded in the adjudication 
database separate from eDC database for final analysis. See the submitted CEC charter 
for details. 
 
6.7. Data Pooling 
No Data pooling is planned for this study.  




North America USA, Canada 
Central Europe Czech Republic, Hungary 
South Europe France, Italy, Spain 
Western Europe Austria, Belgium, Germany, The Netherlands 
Australia-New Zealand Australia, New Zealand 
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6.8. Multiple Comparisons/Multiplicity 
The following test plan will be followed in the efficacy and safety analyses: 
Step 1: Test the primary outcome endpoint (overall recurrent VTE or major bleeding) 
based on the Modified Intent-to-Treat (mITT) Analysis Set for non-inferiority at α=0.05. 
Step 2: If non-inferiority is achieved in step 1, then test the primary outcome endpoint 
(overall recurrent VTE or major bleeding) based on the mITT Analysis Set for superiority 
at α=0.05. 
Step 3: Test the primary safety endpoint (on-treatment major bleeding) based on the 
Safety Analysis Set for superiority at α=0.05. 
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7.  STATISTICAL ANALYSIS 
7.1. Analysis Sets 
Randomized Analysis Set: All subjects randomized to treatment. 
Modified Intent-to-Treat (mITT) Analysis Set: All randomized subjects who receive at 
least one dose of post-randomization study drug.     
Per Protocol (PP) Analysis Set: All randomized subjects who receive at least one dose of 
the full study drug regimen1, who have not experienced treatment misallocation, and for 
whom the index Deep Vein Thrombosis (DVT) or pulmonary embolism (PE) event at 
baseline was confirmed by the CEC, and who had at least one active cancer or history of 
cancer at randomization. Treatment misallocation is defined as a patient taking incorrect 
treatment during the entire study period. 
Safety Analysis Set: All randomized subjects who receive at least one dose of study drug.     
Frequency for each analysis set will be summarized by treatment group for all subjects 
randomized. 
7.2. Disposition of Subjects 
Enrollment summary will be presented by region, country and treatment group for all 
subjects randomized. 
Disposition of subjects will be summarized for each analysis set by treatment group for 
the Safety/mITT Analysis Set and the Per Protocol (PP) Analysis Set.  This summary 
includes the total number of subjects completing the study follow-up per protocol, 
completing treatment (all subjects who permanently stop study treatment at a protocol 
defined stopping point), discontinuing from treatment, and discontinuing from the study 
follow-up. Reasons for discontinuation from treatment and discontinuation from the 
study follow-up will be provided. Number of subjects survived in study (<3, ≥3 months) 
will be summarized.   A comparison by the treatment group will also be performed for 
total number of subjects completing the study follow-up and for those discontinuing the 
study follow-up. 
A summary of study drug discontinuation/interruptions will include, but not be limited to, 
the following: number and percent of subjects permanently discontinuing study drug and 
reason, number and percent of subjects with at least one interruption and reason, and 
number and percent of occurrences of study drug interruptions (1, ≥2 occurrences) for the 
Safety/mITT Analysis Set and the Per Protocol (PP) Analysis Set.     
Overall study period duration will be summarized for the Safety/mITT Analysis Set and 
the Per Protocol (PP) Analysis Set. Time to premature discontinuation from study by 
                                                 
1 This means at least one dose of post-randomization edoxaban for subjects assigned to the edoxaban 
group and at least one dose of post randomization dalteparin for subjects assigned to the dalteparin 
group 
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treatment group will be displayed graphically for the Safety/mITT Analysis Set and the 
Per Protocol (PP) Analysis Set.     
Listings will be provided for reasons for study discontinuation and study drug 
discontinuation separately. 
 
7.3. Protocol Deviations 
A descriptive summary and listing of all subjects with major protocol deviations will be 
provided for the mITT Analysis Set. A descriptive summary of all subjects with major 
protocol deviations will also be provided for the Per Protocol (PP) Analysis Set. Prior to 
database lock, review will occur to finalize the list of subjects who meet the criteria for 
major protocol deviations.  
Major protocol deviations are:  
• Unconfirmed active cancer, or unconfirmed cancer diagnosed within two years prior 
to randomization 
• Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the 
current (index) episode of DVT and/or PE; 
• More than 72 hours pre-treatment with therapeutic dosages of anticoagulant treatment 
(LMWH, unfractionated heparin, and fondaparinux per local labeling), oral direct 
anticoagulants or VKA prior to randomization to treat the current (index) episode; 
• Treatment with therapeutic doses of an anticoagulant other than that used for pre-
treatment of the current (index) VTE episode prior to randomization; 
• Treatment misallocation; 
• Concomitant use of disallowed medications (e.g., concomitant anticoagulation 
therapy) that impact the evaluation of primary outcomes for efficacy and safety; 
• CrCL < 30 mL/min or Platelets < 50,000 cc3 at the time of randomization. 
• Unconfirmed index events with Thrombosis in incorrect anatomic location. 
Any site for which subject data authenticity is suspect and cannot be confirmed will be 
identified at a data review meeting and subsequently excluded from all efficacy and 
safety analyses.  Any such decisions will be finalized and recorded prior to database lock. 
A listing will also be provided to summarize subjects with major protocol deviations. 
7.4. Demographic and Other Baseline Characteristics 
Demographic and baseline characteristics will be summarized by treatment group and by 
Dose Adjustment Status at Randomization for the Safety/mITT Analysis Set and the Per 
Protocol (PP) Analysis Set.  All categorical parameters will be summarized by frequency 
and percentage based on the number of subjects with available data for that parameter.  
Variables such as age, body weight, BMI, and CrCL will also be summarized by 
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descriptive statistics including means, medians, standard deviations, maximums, and 
minimums.  
The following categorical baseline characteristics derived from IXRS will be presented: 
• Dose Adjustment at Randomization (yes, no);  
• Bleeding risk (yes, no), and number of bleeding risk (0, 1, 2, 3, ≥4). Bleeding risk 
factors at randomization including:  
o Surgery within 2 weeks prior to randomization  
o Antiplatelet use  
o Brain tumor or brain metastases 
o Metastatic disease 
o Regionally advanced cancer 
o Gastrointestinal cancer at randomization or diagnosed within a 6-month period 
prior to randomization 
o Urothelial cancer at randomization or diagnosed within a 6-month period prior to 
randomization 
o Avastin (bevacizumab) use at randomization or given within the 6-week period 
prior to randomization 
• Combination of Dose Adjustment (yes, no) and Bleeding Risk (yes, no); 
• Body Weight (≤60.0 kg, >60.0 kg; ≤60.0 kg, 60<-90 kg, >90 kg); 
• Creatinine clearance (≥30-≤50 mL/min, >50 mL/min); 
• Platelet (50,000-100,000/mL, >100,000/mL); 
• P-gp use at randomization (yes, no). 
 
Other categorical baseline characteristics collected from eCRF will include: 
• Age (<65, ≥65-<75, ≥75 years);  
• Gender 
• Race 
• Ethnicity (Hispanic/Latino vs Not) for USA subjects only 
• Body Weight (≤60.0 kg, >60.0 kg; ≤60.0 kg, 60<-90 kg, >90 kg); 
• Body Mass Index; 
• Creatinine clearance (<30 mL/min, ≥30-≤50 mL/min, >50 mL/min); 
• Presenting diagnosis of DVT or PE 
• ECOG performance status 
• Past cancer and medical history 
• Region/country 
 
The following cancer diagnosis and presenting diagnosis at randomization, confirmed by 
adjudication, will be presented: 
• Type of cancer (Solid Tumor, Haematological Malignancy); 
• Active cancer (yes, no); 
• Distant metastasis (yes, no); 
• Receiving cancer treatment (yes, no); 
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• Recurrent cancer (yes, no); 
• Cancer cured (yes, no); 
• Symptomatic DVT, Unsuspected DVT, Symptomatic PE, Unsuspected PE; 
• Anatomical extent of qualifying event. 
 
 
7.5. Measurements of Treatment Compliance 
Study drug dosing compliance will be summarized for the Safety/mITT Analysis Sets and 
the Per Protocol (PP) Analysis Set and will be presented by the three categories: <80%, 
≥80% and ≤ 120%, as well as >120% of doses taken.   
Edoxaban compliance over the whole treatment period will be calculated as  
(total number of edoxaban tablets taken)/ (total number of edoxaban tablets should be 
taken)*100 
Total number of edoxaban tablets taken will be calculated as: 
∑(amount of dispensed at previous visit – amount of returned at current visit) 
Total number of edoxaban tablets that should be taken will be calculated as: 
∑tablets * (days between two visits – planned interruption days)  
For 60 mg dose, 2 tablets are to be taken; 1 tablet to be taken for 30 mg dose.  
Treatment compliance for dalteparin will be calculated using the same method but will be 
accounting for number of dalteparin syringes instead of number of edoxaban tablets.  
7.6. Extent of Exposure to Study Drug 
Subject exposure will be summarized for the Safety/mITT Analysis Sets and the Per 
Protocol (PP) Analysis Set and will be presented by total time on study drug at <3 
months (<90 days), 3-≤6 months (90-≤180 days) , 6-≤9 months (180-≤270 days), 9<-≤12 
months (270<-≤365 days), and >12 months (>365 days) after the first study drug dose.  
Descriptive statistics, including mean, median, standard deviation, maximum, and 
minimum, will also be provided for total time on study drug, duration of exposure.  
Total time on study drug (exposed to study drug) is defined as the total number of days 
the subject took study drug, with interruptions not included in the interval of time. For 
each subject, the total time on study drug may actually be a few days less than the total 
time in all On-Treatment Periods as it does not include the three days after last dose of  
study medication. 
Total treatment period is defined as the total number of days the subject took study drug, 
with interruptions included in the interval of time (date of last study dose – date of first 
study dose +1).    
Number of subjects exposed to anti-coagulation therapy prior to randomization will be 
summarized for the Safety/mITT Analysis Set and the Per Protocol (PP) Analysis Set by 
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treatment groups as: [LMW] heparin or other anti-coagulation use within the 5 days prior 
to randomization: None, have been used for ≤ 5 days, and have been used for > 5 days. 
 
7.6.1. Targeted Cancer Therapy  
Targeted cancer therapy received on or after initial dose of study drug will be 
summarized by treatment group for the Overall Study Period and the Safety/mITT 
Analysis Set and the Per Protocol (PP) Analysis Set.    
 
7.6.2. Concomitant Medications  
Targeted and non-targeted concomitant medications taken on or after initial dose of study 
drug will be summarized separately by treatment group for the Overall Study Period.  
Medications will be coded using the World Health Organization (WHO) drug dictionary 
01June2010 Version or later.  Safety/mITT Analysis Set and the Per Protocol (PP) 
Analysis Set will be used for this analysis. 
 
7.6.3. Non-Drug Therapies  
Non-drug therapies performed on or after the initial dose of study drug will be 
summarized by treatment group for the Overall Study Period. Safety/mITT Analysis Set 
and the Per Protocol (PP) Analysis Set will be used for this analysis.  
 
7.7. Analysis of Primary Outcome and Efficacy  
The following will be applied to all efficacy analyses where applicable. 
The mITT and the Per Protocol Analysis Sets will be used in the analysis of primary 
outcome and all efficacy endpoints. Analyses for all efficacy endpoints will be based on 
the randomized treatment even if a subject inadvertently receives the incorrect study 
drug. Endpoints will be summarized by treatment group unless otherwise stated. 
The summary statistics for the primary outcome and efficacy endpoints and their 
individual components will be provided.  These statistics include the number of first 
events (i.e., the number of subjects with the event).  For primary outcome and secondary 
efficacy endpoints, the hazard ratios of the LMWH/edoxaban versus dalteparin with 95% 
CIs will be provided using the Cox proportional hazards model with model terms for 
treatment and the randomization stratification factors (bleeding risk, and need for dose 
adjustment) as covariates.  Kaplan-Meier plots4 of time to events for the endpoint will 
also be provided by treatment group.  CEC adjudication results will be the basis for the 
primary analysis.  
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The reference date for efficacy analysis during Overall Study Period will be the 
randomization date. The reference date analysis during On-Treatment Period will be the 
first dose date. 
Incidence rates of subjects with only 1 event, only 2 events, and >= 3 events will be 
analyzed for each of the key efficacy endpoints.   
 
Sensitivity analyses will be performed for the all primary outcome and efficacy endpoints 
based on the Per Protocol Analysis Set. 
7.7.1. Adjudicated Efficacy Endpoint Derivations 
The detailed definition for each endpoint event is described in the submitted CEC 
Charter.   
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7.7.2. Analyses of Primary Outcome and Efficacy Endpoints  
7.7.2.1. Analyses of the Primary Outcome Endpoint  
7.7.2.1.1. Primary Analysis of the Primary Outcome Endpoint  
The primary analysis will compare treatment efficacy for the occurrence of adjudicated 
composite primary outcome endpoint (recurrent VTE [symptomatic recurrent DVT, 
unsuspected proximal DVT, non-fatal symptomatic recurrent PE, unsuspected PE, fatal-
PE] or major bleed) using the Overall Study Period for all subjects in the mITT Analysis 
Set.  The events that will be counted in this analysis are those events occur from the date 
of randomization through the end of the 12-month (Day 365) study period, the last 
available date that the subject had a complete assessment (in-person visit or by telephone) 
for study outcomes, or the day of global EOT, regardless of whether the subject was 
taking study drug, whichever comes first.  
For subjects who do not experience an event, the time to first event will be censored at 
Day 365, or the last day the subject had a complete assessment (in-person visit or by 
telephone) for study outcomes, or the day of global EOT, whichever comes first. Subjects 
lost to follow-up, subjects who died because of reasons other than DVT/PE, or subjects 
who withdrew informed consent before the end of the 12-month treatment period and 
who did not have a primary outcome, will be censored at the last day the subject had a 
complete assessment for study outcomes. 
The primary outcome analysis is designed to demonstrate that the LMWH/edoxaban 
Group is non-inferior to the dalteparin Group at a non-inferiority margin of 1.5 for hazard 
ratio, using a significance level of α=0.05.  The time to first event will be analyzed using 
a Cox proportional hazards model including model terms for treatment and the 
randomization stratification factors (bleeding risk and need for dose adjustment as binary 
variables) as covariates.  If the upper limit of the two-sided 95% CI of the hazard ratio is 
below 1.5, then non-inferiority to dalteparin Group will be considered established for the 
LMWH/edoxaban Group. 
The impact of selected baseline covariates on the primary outcome will be described by 
calculating adjusted Hazard Ratios and corresponding 95% CI of the treatment effect. 
The components of primary outcome endpoint (recurrent VTE [symptomatic recurrent 
DVT, non-fatal symptomatic recurrent PE, unsuspected PE, fatal-PE] or major bleed) for 
each treatment group will be summarized. 
A listing of investigator reported endpoints and their adjudicated results will be provided. 
A sensitivity analysis will be performed for the primary outcome endpoint based on the 
Per Protocol Analysis Set. 
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7.7.2.1.2. Sensitivity Analyses of the Primary Outcome Endpoint 
The following sensitivity analyses will be performed for the Primary Outcome Endpoint: 
• On-Treatment events based on the mITT and PP Analysis Set will be analyzed using 
the counting process approach of the Cox proportional hazards regression model 
including treatment group, and the stratification factors (bleeding risk and need for 
dose adjustment as binary variables) as covariates. An On-Treatment event is defined 
as the event occurring during the time period the subject is taking study drug up to 3 
days after their last dose for that time period.  Only events occurring prior to or on 
Day 365 will be included into this analysis.  Subjects who do not experience an On-
Treatment event will be censored at Day 365, or the time study drug is permanently 
discontinued plus 3 days or on the last day the subject had a complete assessment (in-
person visit or by telephone) for study outcomes, or the day of global EOT, 
whichever comes first.  
• Events occurring during the first 6 months (180 days) based on the mITT Analysis 
Set and the Per Protocol Analysis Set will be analyzed using the same statistical 
model as the analysis of primary outcome during the Overall Study Period.  The time 
to event is defined as the time (days) from the randomization to the first event during 
the first 6 months (until Day 180) after randomization.  Subjects who do not 
experience an event until Day 180 will be censored at Day 180, or on the last day the 
subject had a complete assessment (in-person visit or by telephone) for study 
outcomes, whichever comes first. 
• On-Treatment events during the first 6 months (180 days) based on the mITT and PP 
Analysis Set will also be analyzed using the same counting process approach with the 
Cox proportional hazards regression model including treatment group, and the 
stratification factors (bleeding risk and need for dose adjustment as binary variables) 
as covariates. Only On-Treatment events occurring during the first 6 months (until 
Day 180) will be included into this analysis. Subjects who do not experience an On-
Treatment event will be censored at Day 180 if they are still on study drug on Day 
180, or the time study drug is permanently discontinued plus 3 days if the 
discontinuation is before Day 180, or on the last day the subject had a complete 
assessment (in-person visit or by telephone) for study outcomes, or the day of global 
EOT, whichever comes first. 
• The same analyses for primary outcome endpoint based on the mITT Analysis Set 
and the Per Protocol Analysis Set during Overall Study Period, and the mITT 
Analysis Set and the Per Protocol Analysis Set during the first 6 months study period, 
will also be carried out by dose adjustment status at randomization. 
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7.7.2.1.3.  Superiority Analysis of the Primary Outcome Endpoint 
If non-inferiority in the primary outcome is established, LMWH/edoxaban will be 
compared to dalteparin for superiority (α=0.05, two-sided) with regard to the time to an 
event in the composite clinical outcome of recurrent VTE or major bleed during the 12-
month study period.  This analysis will be based on the mITT Analysis Set during the 
Overall Study Period using the same proportional hazard model as for the primary 
outcome. The same analysis will also be carried out using the same proportional hazard 
model with counting process for the On-Treatment Period for the mITT. The same 
analysis will also be carried out for the Per Protocol Analysis Set. 
 
7.7.2.2. Analysis of the Secondary Efficacy Endpoint  
Analysis for the secondary efficacy endpoints will be performed using the Overall Study 
Period for the mITT Analysis Set using Cox proportional hazards model including model 
terms for treatment and the randomization stratification factors (bleeding risk and need 
for dose adjustment as binary variables) as covariates. Descriptive summaries will also be 
provided. Secondary efficacy endpoints include: 
• recurrent VTE; 
• event-free survival: the proportion of subjects over time free of recurrent VTE, major 
bleeding events, and death; 
• VTE -related death; 
• recurrent DVT; 
• recurrent PE.   
The same event inclusion and censoring method used in primary outcome endpoint will 
be applied to secondary efficacy endpoints. The LMWH/edoxaban will be compared to 
dalteparin for superiority (α=0.05, two-sided) with regard to the time to an event in 
recurrent VTE during the Overall Study Period. 
Same sensitivity analyses used in primary outcome analysis will also be applied to 
secondary efficacy endpoints, which include:  
• Events occurring during the first 6 months (180 days) based on the mITT Analysis 
Set using the Initial 6-Month Study Period. 
 
The same analyses will also be carried out for the Per Protocol Analysis Set. 
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7.7.2.3. Subgroup Analyses for the Primary Outcome and Secondary Efficacy 
Endpoints  
 
Subgroup analyses will be performed for the primary outcome and secondary efficacy 
endpoints using the Overall Study Period approach for the mITT Analysis Set, and the 
Initial 6-Month Study Period for the mITT Analysis Set. Descriptive summaries will be 
provided. The percentages will be based on the total number of subjects that make up the 
subgroup being summarized, regardless if an event occurred.  Forest plots will be 
generated for subgroup analyses.     
Subgroups will be based on characteristics including, but not limited to, the following: 
1. Presenting diagnosis of DVT or PE (Symptomatic vs Unsuspected). Adjudicated 
results will form the basis for the subgroup analysis. In the instance the CEC is 
unable to confirm the diagnosis, the investigators’ diagnosis will be used).  
2. Presenting diagnosis of DVT only, vs PE with or without DVT 
3. Age (<65 years vs. ≥65 years, <75 years vs. ≥75 years)  
4. Gender (male vs. female) 
5. Race (White, Other than white) 
6. Weight (<60, 60-90, >90 kg) 
7. Prior VTE (yes, no) 
8. Dose adjustment at randomization (yes, no) 
9. CrCL at randomization (≥30-≤50 mL/min, >50 mL/min)  
10. Platelet at randomization (50,000-100,000/mL vs > 100,000/mL) 
11. P-gp use at randomization (yes, no) 
12. Bleeding Risk at randomization (yes, no), and bleeding risk factors including:  
o Surgery within 2 weeks prior to randomization  
o Antiplatelet use  
o Brain tumor or brain metastases 
o Metastatic disease 
o Regionally advanced cancer 
o Gastrointestinal cancer at randomization or diagnosed within a 6-month 
period prior to randomization 
o Urothelial cancer at randomization or diagnosed within a 6-month period prior 
to randomization 
o Avastin (bevacizumab) use at randomization or given within the 6-week 
period prior to randomization 
13. Combination of Dose Adjustment (yes, no) and Bleeding Risk (yes, no) 
14. Survival in study (<3 Months, >=3 Months) 
15. Cancer diagnosis at randomization confirmed by adjudication: 
o Type of cancer (Solid Tumor, Haematological Malignancy) 
o Active cancer (yes, no) 
o Distant metastasis (yes, no) 
o Receiving cancer treatment (yes, no) 
o Recurrent cancer (yes, no) 
o Cancer cured (yes, no) 
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16. Baseline ECOG Performance Status 
17. Initial heparin treatment duration on or after randomization (for example, <5 days, 
5-7 days, 8-10 days, >10 days; ≤median, >median; ≤25th percentile, >25th-50th 
percentile, >50th-75th percentile, >75th percentile). The categorical groups will be 
determined based on subjects in each category prior to database lock   
18. Heparin use prior to randomization (yes, no) 
19. Anatomical extent of qualifying event. 
The incidence of VTE based on each subgroup will be estimated and a 95% CI for the 
LMWH /edoxaban: dalteparin hazard ratio will be constructed. 
The same analyses will also be carried out for the Per Protocol Analysis Set. 
7.7.2.4. Exploratory Efficacy Analyses 
The impact of baseline covariates on the primary outcome will also be described by 
calculating adjusted hazard ratios and corresponding 95% CIs for the treatment effect. 
The investigator reported events for primary and secondary endpoints will be 
summarized using Overall Study Period approach for the mITT analysis set. 
Summary of agreement between investigator and adjudicator for investigator reported, 
confirmed and CEC confirmed primary and secondary efficacy endpoints will be 
provided by treatment group for the mITT Analysis Set. 
The same analyses will also be carried out for the Per Protocol Analysis Set. 
7.8.  Analysis of Safety 
The following procedures will be applied to all safety endpoints unless otherwise stated 
in the individual sections. 
Safety analyses will be summarized for all subjects included in the Safety Analysis Set by 
treatment group. Analyses for all safety endpoints will be based on randomized treatment, 
unless a subject inadvertently receives the incorrect study drug during the entire study, in 
which case, the subject will be grouped according to the treatment actually received. The 
time periods used for analyses are described for each safety parameter.  Adjudicated 
safety events along with select key investigator reported safety events will be analyzed.  
All remaining safety results will be summarized descriptively.  
 
The same analyses will also be carried out for the Per Protocol Analysis Set. 
7.8.1. Safety Event Derivations 
Detailed definitions for bleeding categories are described in the submitted CEC Charter.   
7.8.1.1. Analysis of the Primary and Secondary Safety Endpoints  
The primary safety endpoint is major bleeding events that occur during On-Treatment 
Period (on study drug or up to 3 days after the last dose for that time period.) 
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The time from date of initial study dose to first major bleeding will be compared between 
treatment groups for superiority (α=0.05 two-sided) for subjects in the Safety Analysis 
Set, using a Cox’s proportional hazard regression model with counting process using the 
model terms for treatment and the randomization stratification factors (bleeding risk and 
need for dose adjustment as binary variables) as covariates.   
For subjects did not experience any event, they will be censored 3 days after the day of 
permanent study medication discontinuation, the last day the subject had a complete 
assessment for study outcomes, or the day of global EOT, whichever comes first.   
Subjects who experience multiple major bleeding events will be summarized by 
treatment groups. 
Incidence and Hazard Ratio (with 95% CI) for the following secondary safety outcomes  
will be calculated based on the Safety Analysis Set and On-Treatment-approach using the 
Cox proportional hazards regression model with counting process approach with the  
model terms for treatment and the randomization stratification factors (bleeding risk and 
need for dose adjustment as binary variables) as covariates: 
• Clinically relevant non-major bleeding 
• Major  + clinically relevant non-major bleeding 
• All bleeding 
Both primary and secondary safety endpoints for bleedings will be analyzed using the 
following approaches for the Safety Analysis Set: 
• Events during Overall Study Period analyzing by Cox proportional hazard regression 
model with the treatment and the randomization stratification factors (bleeding risk 
and need for dose adjustment as binary variables) as covariates.  
• Events during the first 6 months On-Treatment Period (180 days) analyzing by Cox 
proportional hazards regression model with counting process including treatment 
group, and the stratification factors (bleeding risk and need for dose adjustment as 
binary variables) as covariates. 
Adjudicated bleeding events will also be summarized by category, location, 
characteristics, and circumstance as recorded in the CRF for major bleeding, clinically 
relevant non-major bleeds, and major plus clinically relevant non-major bleeds. All 
investigators reported bleeds will be summarized separately from adjudicated bleeds. 
Adjudicated death events occurred during Overall Study Period described above will also 
be analyzed  using a Cox’s proportional hazard regression model with the treatment and 
the randomization stratification factors (bleeding risk and need for dose adjustment as 
binary variables) as covariates for subjects in the Safety Analysis Set. Subjects will be 
censored after the last day the subject had complete assessment (in-person visit or by 
telephone) for study outcomes, or the day of global EOT, whichever comes first.  
A listing of investigator reported endpoints and their adjudicated results will be provided. 
Adjudicated events for subjects who did not expose to study drug Edoxaban will also be 
listed. 
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The same analyses will also be carried out for the Per Protocol Analysis Set. 
7.8.1.2. Healthcare Resources Utilization  
The incidence of hospital admission related to recurrent VTE or bleeding events will be 
summarized by treatment group for the Safety Analysis Set using the Overall Study 
Period. Total number of days in hospital, intensive care unit, step-down ward and general 
hospital ward will be descriptively summarized.  
The same analyses will also be carried out for the Per Protocol Analysis Set. 
7.8.1.3. Exploratory Safety Endpoints  
Incidence and Hazard Ratio (with 95% CI) will be calculated based on the Safety 
Analysis Set  and On-Treatment-approach using the Cox proportional hazards regression 
model with counting process and with the  model terms for treatment and the 
randomization stratification factors (bleeding risk and need for dose adjustment as binary 
variables) as covariates.  
The exploratory safety endpoints include: 
• CV events (MI, stroke, SEE) 
• Thrombotic events at other locations. 
Exploratory safety endpoints occurred during the Overall Study Period described above 
will also be analyzed for subjects in the Safety Analysis Set.  
The investigator reported endpoints will be summarized separately for the On-Treatment 
Period and Overall Study Period. 
Summary of agreement between investigator and adjudicator for investigator reported, 
confirmed and CEC confirmed safety endpoints will be provided by treatment group for 
the Safety Analysis Set. 
The same analyses will also be carried out for the Per Protocol Analysis Set. 
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7.8.1.4. Subgroup Analyses for the Primary and Secondary Safety  Endpoint  
 
Subgroup analyses will be performed for the adjudicated major bleeding, major or 
CRNM bleeding using the Safety Analysis Set for the On-Treatment Period, the Overall 
Study Period, and the Initial 6-Month On-Treatment Period.  Descriptive summaries will 
be provided. Percentages will be based on the total number of subjects that make up the 
subgroup being summarized, regardless if an event occurred.  Forest plots will be 
generated for subgroup analyses.  No inferential analysis will be conducted unless 
specified otherwise. Subgroups to be used for safety analysis will be the same as those for 
efficacy analysis.   
 
The same analyses will also be carried out for the Per Protocol Analysis Set. 
 
7.8.2. Liver Enzyme and Bilirubin Abnormalities 
Liver enzyme and bilirubin abnormalities will be summarized by treatment group using 
the On-Treatment Period and the Overall Study Period for the Safety Analysis Set. These 
summaries will be for based on the adjudicated data, the investigator reported data, and 
the local laboratory data.  In addition, subject listings will be presented for those subjects 
with reported abnormalities whose cases are sent to adjudicators.      
Based on the adjudication information completed by the adjudicators, the nature, clinical 
severity, and causality of an event and whether Hy’s law was satisfied will be presented.   
The number of subjects adjudicated as having hepatocellular injury will be summarized.  
Furthermore, regardless of the investigator reports, all local laboratory results will be 
evaluated by treatment group for the incidence of elevated liver enzymes for the Safety 
Analysis set during the On-Treatment Period and the Overall Study Period.  The number 
and percentage of subjects with elevation of liver enzymes according to various multiples 
of Upper Limit of Normal (ULN) (Alanine Aminotransferase (ALT) or Aspartate 
Aminotransferase (AST) ≥3xULN, ≥5xULN, ≥8xULN, ≥10xULN, ≥20xULN; total 
bilirubin ≥1.5xULN, ≥2xULN, ≥3xULN, ≥5xULN) will be summarized by treatment 
group. A combination of ALT and/or AST ≥ 3xULN accompanied by concurrent (within 
37 days after the maximum AST/ALT) total bilirubin ≥2xULN will be summarized. 
Incidence of Alkaline Phosphatase (ALP) will be summarized using cutoffs of 
≥1.5xULN, ≥2xULN, ≥3xULN, as well as confirmed elevation using these same 
boundaries. Additional combinations of (ALT and/or AST ≥ 3xULN accompanied by 
concurrent total bilirubin ≥ 2xULN and ALP ≥ 2xULN) and (ALT and/or AST ≥ 3xULN 
accompanied by concurrent total bilirubin ≥ 2xULN and concurrent ALP < 2x ULN) will 
be presented and analyzed.  For laboratory data, the assessments performed prior to or on 
the first dose date will be excluded.  
A listing with clinically significant abnormal values for these hepatic laboratory results 
will be provided. In addition, a listing for these hepatic laboratory results and cause of 
liver enzyme elevations for subjects who had at least one liver enzyme elevation will also 
be provided.  
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Scatter plots of Peak AST/ALT vs. Peak Total Bilirubin will be displayed for the Overall 
Study Period. A separated scatter plot of Peak AST/ALT vs. Peak Total Bilirubin after 
first study drug dose (i.e. excluding post-randomization LMWH exposures). 
The same analyses will also be carried out for the Per Protocol Analysis Set. 
 
7.8.3. Adverse Events  
Two sets of AE summaries will be presented:  
1. All AEs excluding investigator confirmed VTE, bleeding, MI, Stroke, SEE, and 
thrombotic events.  
2.  For all investigator confirmed VTE, bleeding, MI, Stroke, SEE, and thrombotic 
events. 
All adverse event (AE) summaries will be presented by System Organ Class (SOC) and 
by Preferred Term (PT) within each SOC as classified by the Medical Dictionary for 
Regulatory Activities (MedDRA) coding dictionary5 Version 12.0 or newer. 
The primary Treatment-emergent Adverse Event (TEAE) analyses will be presented 
using the On-Treatment Period and the Overall Study Period for the Safety Analysis Set.  
TEAEs are defined as an event that emerge during treatment having been absent pre-
treatment, or worsens relative to the pre-treatment state. 
An overall incidence summary of AEs with corresponding 95% CIs for incidence rates 
will be provided, which includes the following:  
• Number and percent of subjects with at least one Treatment-emergent Serious 
Adverse Event (TESAE). 
• Number and percent of subjects with at least one TEAE. 
• Number and percent of subjects with at least one drug-related TEAE. 
• Number and percent of subjects with at least one TEAE with fatal outcome. 
• Number and percent of subjects with at least one TEAE that caused study drug 
permanent discontinuation. 
This summary will also be presented for all AEs including investigator confirmed VTE, 
bleeding, MI, Stroke, SEE, and thrombotic events. 
Incidence rates by SOC and PT will be presented by treatment group for the following: 
• TEAEs/ TESAEs 
• Drug-related TEAEs  
• TEAEs by maximum severity (only for AEs excluding investigator confirmed events) 
• TEAEs with fatal outcome 
Incidence rates by PT in descending order of frequency will be presented by treatment 
group for the following: 
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• TEAEs that caused study drug permanent discontinuation 
All AEs will be presented in a subject listing.  Any AEs leading to permanent 
discontinuation of study drug will also be presented in a subject listing. AEs for subjects 
who had at least one adjudicated major bleeding event will be presented in listing 
separately.  
The same analyses will also be carried out for the Per Protocol Analysis Set. 
7.8.4. Clinical Laboratory Evaluations  
 
The clinical laboratory evaluations at each scheduled visit and the change from baseline 
will be summarized for the Safety Analysis Set by treatment group. Shift from baseline 
with specific clinically meaningful ranges for select clinical local laboratory evaluations 
will be summarized by treatment group. This will be summarized at each scheduled visit, 
last assessment and at the worst assessment.  If a laboratory retest occurs within a day, 
then the later value will be used for summarization.   
The number and percentage of subjects with clinically relevant abnormal laboratory 
values will be calculated for each treatment group for selected laboratory parameters.  
Percentages for these summaries will be based on the available data, rather than the total 
number of subjects.  
The same analyses will also be carried out for the Per Protocol Analysis Set.  
 
7.8.5. Vital Signs and Physical Exam  
Observed values of vital signs including systolic and diastolic blood pressure (mmHg), 
pulse (bpm), weight (kg) and height (cm) collected at randomization will be summarized.  
Observed and changed from baseline in weight collected at each scheduled visit will also 
be summarized.  
Clinically significant physical examination findings will be listed by treatment group for 
each body system. 
The same analyses will also be carried out for the Per Protocol Analysis Set. 
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III Trigger Terms 
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Summary of Main Changes in Statistical Analysis Plan from  
Version 1.0 Dated 29 February 2016 through Version 3.0 Dated 02 October 2017 
 
1. Initial 6-Month On-Treatment Period was defined and added: The time period the subject is taking study 
drug up to 3 days after their last dose or up to Day 180, whichever comes first. 
2. Analysis of Adjudicated Recurrent Venous Thromboembolism (VTE)  or Major Bleeding Event, Analysis 
of Adjudicated Bleeding Events, Subgroup Analysis of Adjudicated Major Bleeding Events, and Subgroup 
Analysis of Adjudicated Major or Clinically Relevant Non-Major Bleeding Events were added for Initial 
6-Month On-Treatment Period. 
3. Section 6.1, New sentence was added: When the number of events in at least one of the treatment groups is 
<3, hazard ratios, CIs and p-values will not be presented. 
4. New summary for Demographic and Other Baseline Characteristics were added: 
a. number of bleeding risk (0, 1, 2, 3, ≥4); 
b. Combination of Dose Adjustment (yes, no) and Bleeding Risk (yes, no); 
c. New Body Weight (≤60.0 kg, 60<-90 kg, >90 kg); 
d. Platelet (50,000-100,000/mL, >100,000/mL); 
e. Creatinine clearance (<30 mL/min, ≥30-≤50 mL/min, >50 mL/min); 
f. Type of cancer (Solid Tumor, Haematological Malignancy); 
g. Active cancer (yes, no); 
h. Distant metastasis (yes, no); 
i. Receiving cancer treatment (yes, no); 
j. Recurrent cancer (yes, no); 
k. Cancer cured (yes, no); 
l. Symptomatic DVT, Unsuspected DVT, Symptomatic PE, Unsuspected PE. 
5. Section 7.6, Exposure to study drug was revised as: <3 months (<90 days), 3-≤6 months (90-≤180 days) , 
6-≤9 months (180-≤270 days), 9<-≤12 months (270<-≤365 days), and >12 months (>365 days). 
From 
3 months (>=85 days), 6 months (>=175 days) and 12 months (>=353 days). 
6. Following subgroup analyses were added: 
a. Presenting diagnosis of DVT or PE (Symptomatic vs Unsuspected); 
b. Weight (<60, 60-90, >90 kg); 
c. Prior VTE (yes, no); 
d. CrCL at randomization (≥30-≤50 mL/min, >50 mL/min);  
e. Combination of Dose Adjustment (yes, no) and Bleeding Risk (yes, no); 
f. Survival in study (<3 Months, >=3 Months); 
g. Cancer diagnosis at randomization confirmed by adjudication; 
Subgroup analysis, CrCL at randomization: 30-<60, 60-<90, >=90 mL/min, was removed. 
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7. Per Protocol (PP) Analysis Set was defined:  All randomized subjects who receive at least one dose of the 
full study drug regimen1, who have not experienced treatment misallocation, and for whom the index Deep 
Vein Thrombosis (DVT) or pulmonary embolism (PE) event at baseline was confirmed by the CEC. 
Treatment misallocation is defined as a patient taking incorrect treatment during the entire study period 
 
                                                          
1 This means at least one dose of post-randomization edoxaban for subjects assigned to the edoxaban group and at 
least one dose of post randomization dalteparin for subjects assigned to the dalteparin group 
